WO2011088027A1 - Compounds and methods - Google Patents

Compounds and methods Download PDF

Info

Publication number
WO2011088027A1
WO2011088027A1 PCT/US2011/020798 US2011020798W WO2011088027A1 WO 2011088027 A1 WO2011088027 A1 WO 2011088027A1 US 2011020798 W US2011020798 W US 2011020798W WO 2011088027 A1 WO2011088027 A1 WO 2011088027A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
pyrimidinyl
benzenesulfonamide
alkyl
Prior art date
Application number
PCT/US2011/020798
Other languages
French (fr)
Other versions
WO2011088027A8 (en
Inventor
Lara S. Kallander
Brian Griffin Lawhorn
Joanne Philip
Yongdong Zhao
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2012549000A priority Critical patent/JP2013517273A/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Priority to SG2012049409A priority patent/SG182351A1/en
Priority to MX2012008141A priority patent/MX2012008141A/en
Priority to CA2786999A priority patent/CA2786999A1/en
Priority to EA201290642A priority patent/EA201290642A1/en
Priority to AU2011205485A priority patent/AU2011205485B2/en
Priority to EP11733258.5A priority patent/EP2523559A4/en
Priority to US13/520,861 priority patent/US20120329784A1/en
Priority to BR112012017277A priority patent/BR112012017277A2/en
Priority to CN2011800138247A priority patent/CN102791131A/en
Publication of WO2011088027A1 publication Critical patent/WO2011088027A1/en
Priority to IL220812A priority patent/IL220812A0/en
Publication of WO2011088027A8 publication Critical patent/WO2011088027A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds that inhibit TNNI3K and methods of making and using the same. Specifically, the present invention relates to
  • Cardiac troponin l-interacting kinase (TNNI3K), also known as CARK (for cardiac ankyrin repeat kinase), is a protein kinase that exhibits highly selective expression for cardiac tissues and has been shown to interact with components of the sarcomere, including troponin I (Zhao, Y. et al., J. Mol. Med., 2003, 81, 297-304; Feng, Y. et al., Gen. Physiol. Biophys., 2007, 26, 104-109; Wang, H. et al., J. Cell. Mol. Med., 2008, 12, 304- 315).
  • TNNI3K a cardiac-specific kinase, promotes cardiac hypertrophy in vivo
  • Inhibition of the kinase activity of TNNI3K may disrupt these signaling pathways, and enable the mitigation and/or reversal of cardiac hypertrophy seen in patients with progressively worsening heart failure.
  • the heart In response to mechanical, neurohormonal, and genetic stimuli, the heart will undergo hypertrophy, or muscle growth and remodeling, in order to maintain sufficient cardiac output to meet tissue oxygen demands. While these structural changes are initially seen as compensatory, sustained dysregulation of hypertrophic signaling can lead to heart failure, the pathophysiological state in which the heart can no longer adequately function as a pump (Mudd, J. O. and Kass, D. A., Nature, 2008, 451, 919-928).
  • Heart failure is responsible for a reduced quality of life and premature death in a significant proportion of sufferers, and is characterized by impaired cardiac function either due to reduced pump function (systolic dysfunction) or reduced filling (diastolic dysfunction).
  • Congestive heart failure is characterized by impaired left ventricular function, increased peripheral and pulmonary vascular resistance and reduced exercise tolerance and dyspnea. The prevalence of heart failure is anticipated to increase with ageing populations, prompting a need for new and improved methods of treating heart failure.
  • the invention is directed to novel diaminopyrimidines. Specifically, the invention is directed to compounds according to Formula I:
  • R 1 is (C C 4 )alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen, halogen, (CrC 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 3 -C 6 )cycloalkyl, aryl, hydroxyl, hydroxy(C 1 -C 4 )alkyl-, (d-C 4 )alkoxy, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl-,
  • R 4 is hydrogen, halogen, (CrC 8 )alkyl, (Ci-C 8 )haloalkyl, (C 3 -C 8 )cycloalkyl, hydroxyl, hydroxy(CrC 8 )alkyl-, (Ci-C 8 )alkoxy, (Ci-C 4 )alkoxy(CrC 8 )alkyl-, (Ci-C 8 )haloalkoxy, (C 3 -C 8 )cycloalkyloxy, (Ci-C 8 )alkylthio-, (Ci-C 8 )haloalkylthio-, -S0 2 (CrC 4 )alkyl, amino, -NHR 7 , or -NR 7 R 8 ;
  • R 5 is hydrogen
  • R 4 and R 5 taken together with atoms through which they are connected form a 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (Ci-C 4 )alkyl, (Ci-C 4 )haloalkyl, hydroxy(CrC 4 )alkyl-, oxo, hydroxyl, (Ci-C 4 )alkoxy, (Ci-C 4 )haloalkoxy, and (Ci-C 4 )alkylthio-;
  • R 6 is (CrCe)alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, aryl, or heteroaryl, wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (d-C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl,
  • R 7 is (CrC 4 )alkyl, aryl, heterocycloalkyl, or heterocycloalkyl(Ci-C 2 )alkyl, wherein said (CrC 4 )alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl, (Ci-C 4 )alkoxy, amino, (Ci-C 4 )alkylamino, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino, -C0 2 H, -C0 2 (CrC 4 )alkyl, -CONH 2 , -CONH(C C 4 )alkyl, or
  • R 8 is (Ci-C 4 )alkyl
  • R 7 and R 8 taken together with the nitrogen to which they are attached represent a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted one or two times, independently, by halogen, (Ci-C 4 )alkyl, (Ci-C 4 )haloalkyl, amino,
  • the compounds of the invention are inhibitors of TNNI3K and can be useful for the treatment of cardiac diseases and disorders, particularly heart failure. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting TNNI3K and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
  • alkyl represents a saturated, straight or branched hydrocarbon moiety, which may be unsubstituted or substituted by one or more of the substituents defined herein.
  • exemplary alkyls include, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, f-butyl, pentyl, and hexyl.
  • C1-C4" refers to an alkyl containing from 1 to 4 carbon atoms.
  • alkyl When the term “alkyl” is used in combination with other substituent groups, such as “haloalkyl”, “hydroxyalkyl”, or “alkoxyalkyl”, the term “alkyl” is intended to encompass a divalent straight or branched-chain hydrocarbon radical.
  • alkenyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and at least 1 and up to 3 carbon-carbon double bonds. Examples include ethenyl and propenyl.
  • alkynyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and at least 1 and up to 3 carbon-carbon triple bonds. Examples include ethynyl and propynyl.
  • cycloalkyl refers to a non-aromatic, saturated, cyclic hydrocarbon ring.
  • (C 3 -C 8 )cycloalkyl refers to a non-aromatic cyclic
  • hydrocarbon ring having from three to eight ring carbon atoms.
  • (C 3 -C 8 )cycloalkyl groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Alkoxy refers to a group containing an alkyl radical attached through an oxygen linking atom.
  • (CrC 4 )alkoxy refers to a straight- or branched-chain
  • hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom.
  • exemplary "(d-C 4 )alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, and f-butoxy.
  • Alkylthio- refers to a group containing an alkyl radical attached through a sulfur linking atom.
  • the term "(C 1 -C 4 )alkylthio-” refers to a straight- or branched-chain hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through a sulfur linking atom.
  • Exemplary "(C 1 -C 4 )alkylthio-” groups useful in the present invention include, but are not limited to, methylthio-, ethylthio-, n-propylthio-, isopropylthio-, n-butylthio-, s-butylthio-, and f-butylthio-.
  • Cycloalkyloxy refers to a group containing a saturated carbocyclic ring attached through an oxygen linking atom.
  • Examples of “cycloalkyloxy” moieties include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • Aryl represents a group or moiety comprising an aromatic, monovalent monocyclic or bicyclic hydrocarbon radical containing from 6 to 10 carbon ring atoms, which may be unsubstituted or substituted by one or more of the substituents defined herein, and to which may be fused to one or more cycloalkyl rings, which may be unsubstituted or substituted by one or more substituents defined herein.
  • aryl is phenyl
  • Heterocyclic groups may be heteroaryl or heterocycloalkyl groups.
  • Heterocycloalkyl represents a group or moiety comprising a non-aromatic, monovalent monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, which includes 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents defined herein.
  • heterocycloalkyls include, but are not limited to, azetidinyl, pyrrolidinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl, imidazolinyl, oxazolinyl, thiazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1 ,3-dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3-oxathianyl, 1 ,3-dithianyl, hexahydro-1 H-1 ,4-diazepinyl, azabicylo[3.2.1 ]o
  • heterocycloalkyl groups are 5-7 membered heterocycloalkyl groups, such as pyrrolidinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl, imidazolinyl, oxazolinyl, thiazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1 ,3-dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dihydropyranyl, and hexahydro-1 H-1 ,4-diazepinyl.
  • heterocycloalkyl groups are 5-7 membered heterocycloalkyl groups, such as pyrrolidinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl, imidazolinyl, oxazolinyl, thiazol
  • Heteroaryl represents a group or moiety comprising an aromatic monovalent monocyclic or bicyclic radical, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more of the substituents defined herein.
  • This term also encompasses bicyclic heterocyclic-aryl compounds containing an aryl ring moiety fused to a heterocycloalkyl ring moiety, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more of the substituents defined herein.
  • heteroaryls include, but are not limited to, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, benzofuranyl, isobenzofuryl, 2,3-dihydrobenzofuryl,
  • heteroaryl groups present in the compounds of this invention are 5-membered and/or 6-memebred monocyclic heteroaryl groups.
  • Selected 5-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, or 3 additional nitrogen ring atoms.
  • Selected 6-membered heteroaryl groups contain 1 , 2, or 3 nitrogen ring heteroatoms.
  • Selected 5- or 6-membered heteroaryl groups include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, and triazinyl.
  • halogen and halo represent chloro, fluoro, bromo, or iodo substituents.
  • the term "compound(s) of the invention” means a compound of Formula I (as defined above) in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a pharmaceutically acceptable salt thereof) and any physical form thereof (e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvates, including hydrates (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
  • any salt or non-salt form e.g., as a free acid or base form, or as a pharmaceutically acceptable salt thereof
  • any physical form thereof e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvates, including hydrates (
  • R 1 is (Ci-C 4 )alkyl. In a specific embodiment of this invention, R 1 is methyl.
  • R 2 is hydrogen or halogen.
  • R 2 is hydrogen or fluorine.
  • R 2 is hydrogen.
  • R 3 is hydrogen, halogen, (d-C 4 )alkyl, (CrC 4 )haloalkyl, (C 3 -C 6 )cycloalkyl, aryl, hydroxyl, hydroxy(CrC 4 )alkyl-, (CrC 4 )alkoxy, (Ci-C 4 )alkoxy(CrC 4 )alkyl-,
  • R 3 is hydrogen, halogen, (CrC 4 )alkyl, (CrC 4 )haloalkyl, phenyl, (Ci-C 4 )alkoxy, (CrC 4 )alkylthio-, or ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino.
  • R 3 is hydrogen, chlorine, or dimethylamino.
  • R 3 is hydrogen.
  • R 2 and R 3 are each hydrogen.
  • R 4 is hydrogen, halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, (C 3 -C 8 )cycloalkyl, hydroxyl, hydroxy(C 1 -C 8 )alkyl-, (C 1 -C 8 )alkoxy, (C 1 -C 4 )alkoxy(C 1 -C 8 )alkyl-,
  • R 4 is hydrogen, halogen, (Ci-C 8 )alkyl, (Ci-C 8 )haloalkyl, (C 3 -C 8 )cycloalkyl, hydroxyl, hydroxy(Ci-C 8 )alkyl-, (Ci-C 8 )alkoxy, (Ci-C 4 )alkoxy(CrC 8 )alkyl-, (Ci-C 8 )haloalkoxy, (C 3 -C 8 )cycloalkyloxy, (Ci-C 8 )alkylthio-, (Ci-C 8 )haloalkylthio-, -S0 2 (Ci-C 4 )alkyl, amino, (Ci-C 4 )alkylamino, (Ci-C 4 )haloalkyla
  • R 4 is hydrogen, halogen, (Ci-C 8 )alkyl, (Ci-C 8 )haloalkyl, (C 3 -C 8 )cycloalkyl, hydroxyl, hydroxy(Ci-C 8 )alkyl-, (Ci-C 8 )alkoxy, (Ci-C 4 )alkoxy(CrC 8 )alkyl-, (Ci-C 8 )haloalkoxy, (C 3 -C 8 )cycloalkyloxy, (Ci-C 8 )alkylthio-, -S0 2 (Ci-C 4 )alkyl, amino, (Ci-C 4 )alkylamino,
  • R 4 is hydrogen, fluorine, chlorine, hydroxyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, isobutyloxy, 3-methyl-2-butyloxy, 3-pentyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1 , 1 , 1-trifluoro-2-propyloxy, 3,3,3-trifluoro-1-propyloxy, 1 , 1 ,1 -trifluoro-2-methyl-2-propyloxy, 1 , 1 ,1 ,3,3,3-hexafluoro-2-methyl-2-propyloxy, cyclopentyloxy, cyclohexyloxy, methylthio-, ethylthio-, isobutylthio-, 2,2,2-trifluoroethylthio-, methylsulfone, ethylsulfone,
  • R 4 and R 5 taken together with atoms through which they are connected form a 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (d-C 4 )alkyl, (Ci-C 4 )haloalkyl, hydroxy(Ci-C 4 )alkyl-, oxo, hydroxyl, (Ci-C 4 )alkoxy, (Ci-C 4 )haloalkoxy, and (CrC 4 )alkylthio-.
  • R 4 and R 5 taken together with atoms through which they are connected form a partially saturated 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (Ci-C 4 )alkyl, (C 1 -C 4 )haloalkyl, hydroxy(C 1 -C 4 )alkyl-,
  • R 4 and R 5 taken together represent -CH 2 CH 2 -.
  • R 6 is (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, aryl, or heteroaryl, wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (CrC 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl,
  • R 6 is (C 1 -C 6 )alkyl, phenyl, dihydroindenyl, tetrahydronaphthalenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, indolyl, indazolyl, dihydroindolyl, dihydroisoindolyl, chromenyl, dihydrobenzimidazolyl,
  • dihydrobenzoxazolyl benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxolyl, or dihydrobenzodioxinyl, wherein said phenyl, dihydroindenyl, tetrahydronaphthalenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, indolyl, indazolyl, dihydroindolyl, dihydroisoindolyl, chromenyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, dihydr
  • R 6 is (CrC 6 )alkyl, phenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, indolyl, indazolyl, dihydroindolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, or dihydrobenzodioxinyl, wherein said phenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, indolyl, indazolyl, dihydroindolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzo
  • dihydrobenzodioxinyl group is optionally substituted one or two times, independently, by halogen, (C C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C C 4 )haloalkyl, cyano, -CO(C C 4 )alkyl, -C0 2 H, -C0 2 R 7 , -CONH 2 , -CONHR 7 , -CONR 7 R 8 , H0 2 C(C C 2 )alkyl-, R 7 0 2 C(Ci-C 2 )alkyl-, -SR 7 , -S0 2 (d-C 4 )alkyl, -S0 2 NH 2 , -S0 2 NHR 7 , -S0 2 NR 7 R 8 , nitro, amino, -NHR 7 , -NR 7 R 8 , amino(C C 2 )alkyl-, R 7 HN(C C 2 )alky
  • -NHS0 2 (d-C 4 )alkyl oxo, hydroxyl, -OR 7 , hydroxy(C C 2 )alkyl-, R 7 0(C C 2 )alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (C C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C C 4 )haloalkyl, cyano, -CO(C C 4 )alkyl, -C0 2 H, -C0 2 R 7 , -CONH 2 , -CONHR 7 , -CONR 7 R 8 , -SR 7 , -S0 2 (C C 4 )alkyl,
  • R 6 is phenyl optionally substituted one to three times, independently, by halogen, (d-C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 6 )cycloalkyl, (C C 4 )haloalkyl, cyano, -CO(C C 4 )alkyl, -C0 2 H, -C0 2 R 7 , -CONH 2 , -CONHR 7 , -CONR 7 R 8 , H0 2 C(C C 2 )alkyl-, R 7 0 2 C(C C 2 )alkyl-, cyano(Ci-C 2 )alkyl-, -SR 7 , -S0 2 (Ci-C 4 )alkyl, -S0 2 NH 2 , -S0 2 NHR 7 , -S0 2 NR 7 R
  • R 6 is phenyl optionally substituted one or two times, independently, by halogen, (CrC 6 )alkyl, (C 3 -C 6 )cycloalkyl,
  • R 7 R 8 N(Ci-C 2 )alkyl-, -NHCO(Ci-C 4 )alkyl, -NHS0 2 (C C 4 )alkyl, oxo, hydroxyl, -OR 7 , hydroxy(Ci-C 2 )alkyl-, R 7 0(CrC 2 )alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (CrC 6 )alkyl, (C 3 -C 6 )cycloalkyl, (CrC 4 )haloalkyl, cyano, -CO(C C 4 )alkyl, -C0 2 H, -C0 2 R 7 , -CONH 2
  • -S0 2 (Ci-C 4 )alkyl -S0 2 NH 2 , -S0 2 NHR 7 , -S0 2 NR 7 R 8 , nitro, amino, -NHR 7 , -NR 7 R 8 ,
  • R 6 is pyridinyl optionally substituted one or two times, independently, by halogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl,
  • R 7 R 8 N(Ci-C 2 )alkyl-, -NHCO(Ci-C 4 )alkyl, -NHS0 2 (C C 4 )alkyl, oxo, hydroxyl, -OR 7 , hydroxy(Ci-C 2 )alkyl-, or R 7 0(Ci-C 2 )alkyl-.
  • R 6 is pyridinyl optionally substituted one or two times, independently, by halogen
  • R 6 is methyl, ethyl, oxazol-2-yl, oxazol- 5-yl, 4-methyl-oxazol-2-yl, thiazol-2-yl, 4-trifluoromethyl-thiazol-2-yl, 4-isopropyl-thiazol-2- yl, 5-methyl-thiazol-2-yl, 4-carboxymethyl-thiazol-2-yl, 4-(methoxycarbonyl)methyl-thiazol- 2-yl, 5-carboxy-thiazol-2-yl, 1 ,3,4-thiadiazol-2-yl, pyridin-2-yl, 3-fluoro-pyridin-2-yl,
  • R 7 is (Ci-C 4 )alkyl, aryl, heterocycloalkyl, or heterocycloalkyl(Ci-C 2 )alkyl, wherein said (CrC 4 )alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl, (Ci-C 4 )alkoxy, amino, (Ci-C 4 )alkylamino,
  • R 7 is (CrC 4 )alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or
  • R 7 is methyl, difluoromethyl, trifluoromethyl, ethyl, 2,2,2-trifluoroethyl, isopropyl,
  • R 8 is (Ci-C 4 )alkyl.
  • R 8 is methyl or ethyl.
  • R 7 and R 8 taken together with the nitrogen to which they are attached represent a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted one or two times, independently, by halogen, (CrC 4 )alkyl, (d-C 4 )haloalkyl, amino, (Ci-C 4 )alkylamino, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino, hydroxyl, oxo, (C 1 -C 4 )alkoxy, or (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl.
  • R 7 and R 8 taken together with the nitrogen to which they are attached represent pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or hexahydro- 1 H-1 ,4-diazepinyl, each optionally substituted one or two times, independently, by halogen, (CrC 4 )alkyl, (CrC 4 )haloalkyl, amino, (Ci-C 4 )alkylamino,
  • R 7 and R 8 taken together with the nitrogen to which they are attached represent pyrrolidinyl
  • R 1 is (CrC 4 )alkyl
  • R 2 is hydrogen
  • R 3 is hydrogen, halogen, (CrC 4 )alkyl, (d-C 4 )haloalkyl, (C 3 -C 6 )cycloalkyl, aryl, hydroxyl, hydroxy(Ci-C 4 )alkyl-, (Ci-C 4 )alkoxy, (CrC 4 )alkoxy(Ci-C 4 )alkyl-,
  • R 4 is hydrogen, halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, (C 3 -C 8 )cycloalkyl, hydroxyl, hydroxy(C 1 -C 8 )alkyl-, (d-C ⁇ alkoxy, (C 1 -C 4 )alkoxy(C 1 -C 8 )alkyl-, (C 1 -C 8 )haloalkoxy, (C 3 -C 8 )cycloalkyloxy, (C C 8 )alkylthio-, -S0 2 (Ci-C 4 )alkyl, or -NR 7 R 8 ;
  • R 5 is hydrogen
  • R 4 and R 5 taken together with atoms through which they are connected form a partially saturated 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (CrC 4 )alkyl, (Ci-C 4 )haloalkyl, hydroxy(CrC 4 )alkyl-, (CrC 4 )alkoxy, (CrC 4 )haloalkoxy, and (Ci-C 4 )alkylthio-;
  • R 6 is (CrCe)alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, aryl, or heteroaryl, wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (CrC 6 )alkyl, (C 3 -C 6 )cycloalkyl, (CrC 4 )haloalkyl, cyano, -CO(Ci-C 4 )alkyl, -C0 2 H, -C0 2 R 7 , -CONH 2 , -CONHR 7 , -CONR 7 R 8 , H0 2 C(C C 2 )alkyl-, R 7 0 2 C(CrC 2 )alkyl-, -SR 7 , -S0 2 (C C 4 )alkyl, -S0 2 NH 2
  • R 7 is (CrC 4 )alkyl, aryl, heterocycloalkyl, or heterocycloalkyl(Ci-C 2 )alkyl, wherein said (CrC 4 )alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl, (CrC 4 )alkoxy, amino, (Ci-C 4 )alkylamino, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino, -CO2H, -C0 2 (Ci-C 4 )alkyl, -CON H 2 , -CON H(C C 4 )alkyl, or
  • R 8 is (Ci-C 4 )alkyl
  • R 7 and R 8 taken together with the nitrogen to which they are attached represent a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted one or two times, independently, by halogen, (d-C 4 )alkyl, (CrC 4 )haloalkyl, amino,
  • R 1 is methyl
  • R 2 is hydrogen or fluorine
  • R 3 is hydrogen, halogen, (CrC 4 )alkyl, (Ci-C 4 )haloalkyl, phenyl, (CrC 4 )alkoxy, (C C 4 )alkylthio-, or ((Ci-C 4 )alkyl)((C C 4 )alkyl)amino;
  • R 4 is hydrogen, halogen, (CrC 8 )alkyl, (Ci-C 8 )haloalkyl, (C 3 -C 8 )cycloalkyl, hydroxyl, hydroxy(CrC 8 )alkyl-, (Ci-C 8 )alkoxy, (Ci-C 4 )alkoxy(CrC 8 )alkyl-, (Ci-C 8 )haloalkoxy, (C 3 -C 8 )cycloalkyloxy, (Ci-C 8 )alkylthio-, (Ci-C 8 )haloalkylthio-, -S0 2 (Ci-C 4 )alkyl, amino, (Ci-C 4 )alkylamino, (Ci-C 4 )haloalkylamino, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino, ((Ci-C 4 )alky
  • R 5 is hydrogen
  • R 6 is phenyl optionally substituted one to three times, independently, by halogen, (C C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 6 )cycloalkyl, (C C 4 )haloalkyl, cyano, -CO(C C 4 )alkyl, -C0 2 H, -C0 2 R 7 , -CON H 2 , -CON H R 7 , -CON R 7 R 8 , H0 2 C(C C 2 )alkyl-, R 7 0 2 C(CrC 2 )alkyl-, cyano(Ci-C 2 )alkyl-, -SR 7 , -S0 2 (Ci-C 4 )alkyl, -S0 2 N H 2 , -S0 2 N H R 7 , -S0 2 N R 7 R 8 , nitro,
  • R 7 is (CrC 4 )alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or pyrrolidinyl(Ci-C 2 )alkyl, piperidinyl(Ci-C 2 )alkyl, morpholinyl(Ci-C 2 )alkyl, thiomorpholinyl(Ci-C 2 )alkyl, or piperazinyl(Ci-C 2 )alkyl, wherein said (Ci-C 4 )alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl,
  • (C 1 -C 4 )alkoxy amino, (C 1 -C 4 )alkylamino, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)amino, -C0 2 H, -C0 2 (C C 4 )alkyl, -CONH 2 , -CONH(C C 4 )alkyl, or -CON((d-d)alkylX(d-d)alkyl); and wherein any pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl is optionally substituted by (C 1 -C 4 )alkyl; and
  • R 8 is methyl or ethyl
  • R 7 and R 8 taken together with the nitrogen to which they are attached represent pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or hexahydro-1 H-1 ,4- diazepinyl, each optionally substituted one or two times, independently, by halogen, (CrC 4 )alkyl, (Ci-C 4 )haloalkyl, amino, (Ci-C 4 )alkylamino, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino, hydroxyl, oxo, (Ci-C 4 )alkoxy, or (Ci-C 4 )alkoxy(Ci-C 4 )alkyl.
  • R 1 is methyl
  • R 2 is hydrogen or fluorine
  • R 3 is hydrogen, halogen, (CrC 4 )alkyl, (Ci-C 4 )haloalkyl, phenyl, (CrC 4 )alkoxy, (C C 4 )alkylthio-, or ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino;
  • R 4 is hydrogen, halogen, (CrC 8 )alkyl, (Ci-C 8 )haloalkyl, (C 3 -C 8 )cycloalkyl, hydroxyl, hydroxy(CrC 8 )alkyl-, (Ci-C 8 )alkoxy, (Ci-C 4 )alkoxy(CrC 8 )alkyl-, (Ci-C 8 )haloalkoxy, (C 3 -C 8 )cycloalkyloxy, (C 1 -C 8 )alkylthio-, (C 1 -C 8 )haloalkylthio-, -S0 2 (C 1 -C 4 )alkyl, amino, (C 1 -C 4 )alkylamino, (C 1 -C 4 )haloalkylamino, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)amino,
  • R 6 is pyridinyl optionally substituted one or two times, independently, by halogen, (C C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (Ci-C 4 )haloalkyl, cyano, -CO(C C 4 )alkyl, -C0 2 H, -C0 2 R 7 , -CONH 2 , -CONHR 7 , -CONR 7 R 8 , H0 2 C(CrC 2 )alkyl-, R 7 0 2 C(Ci-C 2 )alkyl-, -SR 7 ,
  • -S0 2 (Ci-C 4 )alkyl -S0 2 NH 2 , -S0 2 NHR 7 , -S0 2 NR 7 R 8 , nitro, amino, -NHR 7 , -NR 7 R 8 , amino(Ci-C 2 )alkyl-, R 7 HN(C C 2 )alkyl-, R 7 R 8 N(C C 2 )alkyl-, -NHCO(Ci-C 4 )alkyl,
  • R 7 is (CrC 4 )alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or pyrrolidinyl(Ci-C 2 )alkyl, piperidinyl(Ci-C 2 )alkyl, morpholinyl(Ci-C 2 )alkyl, thiomorpholinyl(C 1 -C 2 )alkyl, or piperazinyl(C 1 -C 2 )alkyl, wherein said (C 1 -C 4 )alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl,
  • (C 1 -C 4 )alkoxy amino, (C 1 -C 4 )alkylamino, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)amino, -C0 2 H, -C0 2 (C C 4 )alkyl, -CONH 2 , -CONH(C C 4 )alkyl, or -CON((Ci-C 4 )alkyl)((Ci-C 4 )alkyl); and wherein any pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl is optionally substituted by (CrC 4 )alkyl; and
  • R 8 is methyl or ethyl
  • R 7 and R 8 taken together with the nitrogen to which they are attached represent pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or hexahydro-1 H-1 ,4- diazepinyl, each optionally substituted one or two times, independently, by halogen, (CrC 4 )alkyl, (d-C 4 )haloalkyl, amino, (Ci-C 4 )alkylamino, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino, hydroxyl, oxo, (Ci-C 4 )alkoxy, or (Ci-C 4 )alkoxy(Ci-C 4 )alkyl.
  • Representative compounds of this invention include the compounds of Examples
  • the compounds according to Formula I may contain one or more asymmetric centers (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof.
  • Chiral centers such as chiral carbon atoms, may also be present in a substituent such as an alkyl group.
  • the stereochemistry of a chiral center present in Formula I, or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof.
  • compounds according to Formula I containing one or more chiral center may be used as racemic mixtures, enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers.
  • diastereoisomeric salts, complexes or other derivatives (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • a stereoisomer-specific reagent for example by enzymatic oxidation or reduction
  • gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • specific stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • polymorphism i.e. the capacity to occur in different crystalline forms. These different crystalline forms are typically known as "polymorphs.” It is to be understood that when named or depicted by structure, the disclosed compound, or solvates (particularly, hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
  • solvates of the compounds of the invention, or salts thereof, that are in crystalline form may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice.
  • Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates.” Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes all such solvates.
  • the compounds of this invention are bases, wherein a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid, such as glucuronic acid or galacturonic acid, alpha-hydroxy acid, such as citric acid or tartaric acid, amino acid, such as aspartic acid or glutamic acid, aromatic acid, such as benzoic acid or cinnamic acid, sulfonic acid, such as p-toluenesul
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1 ,6- dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates,
  • hydroxybenzoates methoxybenzoates, phthalates, phenylacetates, phenylpropionates, phenylbutrates, citrates, lactates, ⁇ -hydroxybutyrates, glycolates, tartrates mandelates, and sulfonates, such as xylenesulfonates, methanesulfonates, propanesulfonates, naphthalene-1 -sulfonates and naphthalene-2-sulfonates.
  • Salts of the disclosed compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base.
  • a suitable base Such a
  • pharmaceutically acceptable salt may be made with a base which affords a
  • pharmaceutically acceptable cation which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, ⁇ /, ⁇ /'-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2- hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine,
  • alkali metal salts especially sodium and potassium
  • alkaline earth metal salts especially calcium and magnesium
  • aluminum salts and ammonium salts as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, ⁇ /, ⁇ /'-di
  • dehydroabietylamine /V,/V'-i)/sdehydroabietylamine, glucamine, /V-methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine.
  • the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pK a than the free base form of the compound.
  • the corresponding free acid form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic acid, suitably an inorganic or organic acid having a lower pK a than the free acid form of the compound.
  • the compounds of Formula I may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist.
  • the synthesis provided in these Schemes are applicable for producing compounds of the invention having a variety of different R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula I, they are illustrative of processes that may be used to make the compounds of the invention.
  • the compounds of Formula I can be prepared under a variety of conditions by sequential reaction of an R 6 -amine and an aryl amine (e.g., Ar- NH-R 5 ) with an activated pyrimidine.
  • the order of the synthetic steps may be varied to arrive at the targeted compound. Additional synthetic manipulation of the functionality present in the amine moieties, as shown in Schemes 2-6, allows for further analog generation.
  • the invention also includes various deuterated forms of the compounds of Formula I.
  • Each available hydrogen atom attached to a carbon atom may be
  • deuterated alkyl group amines may be prepared by conventional techniques (see for example: methyl-c/3-amine available from Aldrich Chemical Co., Milwaukee, Wl, Cat. No.489, 689-2). Employing such compounds according to Schemes 1 -3 will allow for the preparation of compounds of Formula I in which various hydrogen atoms are replaced with a deuterium atom.
  • the present invention is directed to a method of inhibiting TNNI3K which comprises contacting the kinase with a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
  • This invention is also directed to a method of treatment of a TNNI3K-mediated disease or disorder comprising administering an effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
  • patient refers to a human or other mammal.
  • this invention is directed to a method of inhibiting TNNI3K activity, comprising contacting the kinase with an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • TNNI3K activity may be inhibited in mammalian cardiac tissue by administering to a patient in need thereof, an effective amount a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the compounds of this invention may be particularly useful for treatment of TNNI3K-mediated diseases or disorders, specifically by inhibition of TNNI3K activity, where such diseases or disorders are selected from heart failure, particularly congestive heart failure; cardiac hypertrophy; and heart failure or congestive heart failure resulting from cardiac hypertrophy.
  • diseases or disorders are selected from heart failure, particularly congestive heart failure; cardiac hypertrophy; and heart failure or congestive heart failure resulting from cardiac hypertrophy.
  • the compounds of this invention may also be useful for the treatment of heart failure or congestive heart failure resulting from myocardial ischemia or myocardial infarction.
  • a therapeutically "effective amount” is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein.
  • a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to modulate or inhibit the activity of TNNI3K such that a disease condition which is mediated by that activity is reduced, alleviated or prevented.
  • the amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pXC 5 o), efficacy (EC 5 o), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • the particular compound e.g., the potency (pXC 5 o), efficacy (EC 5 o), and the biological half-life of the particular compound
  • disease condition and its severity e.g., the identity of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or condition and its severity and the specific composition and method being used, but can nevertheless be determined by one of skill in the art.
  • Treating is intended to mean at least the mitigation of a disease condition in a patient, where the disease condition is caused or mediated by TNNI3K.
  • the methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a disease.
  • the compounds of Formula I of this invention may be useful for the treatment of heart failure, particularly congestive heart failure.
  • the compounds of Formula I of this invention may be useful for the treatment of cardiac hypertrophy, and heart failure or congestive heart failure resulting from cardiac hypertrophy, myocardial ischemia or myocardial infarction.
  • the compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
  • Parenteral administration refers to routes of administration other than enteral
  • transdermal, or by inhalation and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • Topical administration includes application to the skin.
  • the compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
  • Treatment of TNNI3K-mediated disease conditions may be achieved using the compounds of this invention as a monotherapy, or in dual or multiple combination therapy, such as in combination with other cardiovascular agents, for example, in combination with one or more of the following agents: a beta-blocker, an ACE inhibitor, an angiotensin receptor blocker (ARB), a calcium channel blocker, a diuretic, a renin inhibitor, a centrally acting antihypertensive, a dual ACE/NEP inhibitor, an aldosterone synthase inhibitor, and an aldosterone-receptor antagonist, which are administered in effective amounts as is known in the art.
  • a beta-blocker an ACE inhibitor
  • ARB angiotensin receptor blocker
  • beta blockers examples include timolol (such as BLOCARDENTM), carteolol (such as CARTROLTM), carvedilol (such as COREGTM), nadolol (such as
  • CORGARDTM propanolol (such as INNOPRAN XLTM), betaxolol (such as KERLONETM), penbutolol (such as LEVATOLTM), metoprolol (such as LOPRESSORTM and TOPROL- XLTM), atenolol (such as TENORMINTM), pindolol (such as VISKENTM), bisoprolol, bucindolol, esmolol, acebutolol, labetalol, nebivolol, celiprolol, sotalol, and oxprenolol.
  • propanolol such as INNOPRAN XLTM
  • betaxolol such as KERLONETM
  • penbutolol such as LEVATOLTM
  • metoprolol such as LOPRESSORTM and TOPROL- XLTM
  • atenolol such
  • ACE inhibitors examples include alacepril, benazepril, benazaprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipiril, moveltopril, perindopril, quinapril, quinaprilat, ramipril, ramiprilat, spirapril, temocapril, trandolapril, and zofenopril.
  • Preferred ACE inhibitors are benazepril, enalpril, lisinopril, and ramipril.
  • angiotensin receptor blockers examples include candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan, and valsartan.
  • Suitable calcium channel blockers include dihydropyridines (DHPs) and non- DHPs.
  • DHPs include amlodipine, felodipine, ryosidine, isradipine, lacidipine, nicardipine, nifedipine, nigulpidine, niludipine, nimodiphine, nisoldipine, nitrendipine, and nivaldipine, and their pharmaceutically acceptable salts.
  • Suitable non-DHPs are flunarizine, prenylamine, diltiazem, fendiline, gallopamil, mibefradil, anipamil, tiapamil, and verampimil, and their pharmaceutically acceptable salts.
  • a suitable diuretic is a thiazide derivative selected from amiloride, chlorothiazide, hydrochlorothiazide,
  • a suitable renin inhibitor is aliskiren.
  • suitable centrally acting antiphypertensives include clonidine, guanabenz, guanfacine and methyldopa.
  • suitable dual ACE/NEP inhibitors include omapatrilat, fasidotril, and fasidotrilat.
  • suitable aldosterone synthase inhibitors include anastrozole, fadrozole, and exemestane.
  • suitable aldosterone-receptor antagonists include spironolactone and eplerenone.
  • the invention further includes the use of compounds of the invention as an active therapeutic substance, in particular in the treatment of diseases mediated by TNNI3K.
  • the invention includes the use of compounds of the invention in the treatment of heart failure, particularly congestive heart failure; cardiac hypertrophy; heart failure or congestive heart failure resulting from cardiac hypertrophy; and heart failure or congestive heart failure resulting from myocardial ischemia or myocardial infarction.
  • the invention includes the use of compounds of the invention in the manufacture of a medicament for use in the treatment of the above disorders.
  • the compounds of the invention will normally, but not necessarily, be formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically-acceptable excipient.
  • compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection.
  • the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form.
  • a dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula I or a salt, particularly a pharmaceutically acceptable salt, thereof).
  • the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
  • compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
  • pharmaceutically-acceptable excipient means a material, composition or vehicle involved in giving form or consistency to the composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically-acceptable are avoided.
  • each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
  • the compounds of the invention and the pharmaceutically-acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration.
  • Conventional dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically- acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants,
  • Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention.
  • resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically-acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
  • compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
  • Step 1 4-(ethylthio)-/V-methyl-3-nitrobenzenesulfonamide
  • Step 1 phenylmethyl [(4-fluoro-3-nitrophenyl)sulfonyl]methylcarbamate
  • Step 1 2-fluoro-/V-methyl-4-(methylthio)-5-nitrobenzenesulfonamide
  • the aqueous phase contained significant amount of target product, thus, it was concentrated and the residue was re-distributed in 200 mL EtOAc and then concentrated.
  • the resulting brown oil was combined with the above solid and purified by flash column chromatography (120 g silica column, 0-10% MeOH (w/ 0.1 % aq. NH 4 OH)/CH 2 CI 2 ) to afford 3-amino-/v-methyl-5- nitrobenzenesulfonamide (0.698 g, 39.8%) as a yellow-brown solid.
  • 3-amino-/ ⁇ /-methyl-5-nitrobenzenesulfonamide (0.698 g, 3.02 mmol) was added in one portion into a solution of HCI (cone.) (10 mL, 329 mmol) and 10 mL water and the mixture was cooled to -10 °C before a solution of sodium nitrite (0.208 g, 3.02 mmol) in 5 mL water was added dropwise. The resulting mixture was stirred at -10 °C for 30 min before being added slowly into a mixture of CuCI (0.075 g, 0.755 mmol) in 20 mL of concentrated HCI at 4 °C.
  • the solid was dissolved in 6 mL DMSO, treated with a solution of dimethylamine (1.5 mL, 2 M aq. solution) and heated at 1 10 °C for 20 h before being partitioned between 120 mL EtOAc and 20 mL brine.
  • the organic layer was dried over MgS0 4 , concentrated, and subjected to flash column chromatography (40 g silica column, 0-40% EtOAc/hexane) to afford 3-(dimethylamino)- A/-methyl-5-nitrobenzenesulfonamide (42 mg, 27.1 %) as a yellow solid.
  • Step 4 1 -acetyl-/V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide
  • Step 5 1 -acetyl-3,3-dimethyl-2,3-dihydro-1 H-indole-6-sulfonic acid
  • Step 6 1 -acetyl-3,3-dimethyl-2,3-dihydro-1 /-/-indole-6-sulfonyl chloride
  • Step 7 1 -acetyl-/V,3,3-trimethyl-2,3-dihydro-1 H-indole-6-sulfonamide
  • Step 8 A/,3,3-trimethyl-2,3-dihydro-1 /-/-indole-6-sulfonamide
  • Step 3 4-[(6-chloro-4-pyrimidinyl)amino]-/ ⁇ /-[2-(methyloxy)ethyl]benzamide
  • Step 1 phenylmethyl [(4-fluoro-3-nitrophenyl)sulfonyl]methylcarbamate
  • Step 2 phenylmethyl [(4-amino-3-nitrophenyl)sulfonyl]methylcarbamate
  • Step 4 phenylmethyl (1 H-benzimidazol-5-ylsulfonyl)methylcarbamate
  • Step 5 1 -(6-chloro-4-pyrimidinyl)-/ ⁇ /-methyl-1 H-benzimidazole-6-sulfonamide
  • Dioxan A mixture of 4,6-dichloropyrimidine (476 mg, 3.22 mmol, 6-bromo-4-methyl-2- pyridinamine (300 mg, 1.62 mmol, prepared according to procedures outlined in WO2005061496 and references therein), Pd 2 (dba) 3 (28 mg, 0.032 mmol), Xantphos (36 mg, 0.064 mmol) and potassium carbonate (670 mg, 4.89 mmol) in 1 ,4-dioxane (5 ml.) was heated in the microwave at 130 °C for 1 h.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are compounds having the formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined herein, and methods of making and using the same.

Description

COMPOUNDS AND METHODS
FIELD OF THE INVENTION
The present invention relates to compounds that inhibit TNNI3K and methods of making and using the same. Specifically, the present invention relates to
4,6-diaminopyrimidines as TNNI3K inhibitors.
BACKGROUND OF THE INVENTION
Cardiac troponin l-interacting kinase (TNNI3K), also known as CARK (for cardiac ankyrin repeat kinase), is a protein kinase that exhibits highly selective expression for cardiac tissues and has been shown to interact with components of the sarcomere, including troponin I (Zhao, Y. et al., J. Mol. Med., 2003, 81, 297-304; Feng, Y. et al., Gen. Physiol. Biophys., 2007, 26, 104-109; Wang, H. et al., J. Cell. Mol. Med., 2008, 12, 304- 315). Although substrates for TNNI3K have not been identified to date, recent reports suggest that this protein does play a role in the development of pressure-induced cardiomyocyte hypertrophy and contractile dysfunction (Wheeler, F. C. et al., Mamm. Genome, 2005, 16, 414-423; Wang, X. et al. "TNNI3K, a cardiac-specific kinase, promotes cardiac hypertrophy in vivo", Poster presentation at the 2006 Scientific Sessions of the American Heart Association, Chicago, IL, Wheeler, F. C. et al., PLos Genet, 2009, 5(9), e1000647; and Pu, W.T., PLos Genet, 2009, 5(9), e1000643). Inhibition of the kinase activity of TNNI3K may disrupt these signaling pathways, and enable the mitigation and/or reversal of cardiac hypertrophy seen in patients with progressively worsening heart failure.
In response to mechanical, neurohormonal, and genetic stimuli, the heart will undergo hypertrophy, or muscle growth and remodeling, in order to maintain sufficient cardiac output to meet tissue oxygen demands. While these structural changes are initially seen as compensatory, sustained dysregulation of hypertrophic signaling can lead to heart failure, the pathophysiological state in which the heart can no longer adequately function as a pump (Mudd, J. O. and Kass, D. A., Nature, 2008, 451, 919-928).
Prevention or reversal of pathological cardiac hypertrophy has the potential to delay or prevent the development of congestive heart failure (McKinsey, T. A. and Kass, D. A., Nat. Rev. Drug Discov., 2007, 6, 617-635; Kaye, D. M. and Krum, H., Nat. Rev. Drug Discov., 2007, 6, 127-139).
Heart failure is responsible for a reduced quality of life and premature death in a significant proportion of sufferers, and is characterized by impaired cardiac function either due to reduced pump function (systolic dysfunction) or reduced filling (diastolic dysfunction). Congestive heart failure (CHF) is characterized by impaired left ventricular function, increased peripheral and pulmonary vascular resistance and reduced exercise tolerance and dyspnea. The prevalence of heart failure is anticipated to increase with ageing populations, prompting a need for new and improved methods of treating heart failure.
SUMMARY OF THE INVENTION
The invention is directed to novel diaminopyrimidines. Specifically, the invention is directed to compounds according to Formula I:
Figure imgf000003_0001
H wherein:
R1 is (C C4)alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen, halogen, (CrC4)alkyl, (C1-C4)haloalkyl, (C3-C6)cycloalkyl, aryl, hydroxyl, hydroxy(C1-C4)alkyl-, (d-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl-,
(Ci-C4)haloalkoxy, (C3-C6)cycloalkyloxy, (Ci-C4)alkylthio-, amino, (Ci-C4)alkylamino, or ((Ci-C4)alkyl)((Ci-C4)alkyl)amino;
R4 is hydrogen, halogen, (CrC8)alkyl, (Ci-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(CrC8)alkyl-, (Ci-C8)alkoxy, (Ci-C4)alkoxy(CrC8)alkyl-, (Ci-C8)haloalkoxy, (C3-C8)cycloalkyloxy, (Ci-C8)alkylthio-, (Ci-C8)haloalkylthio-, -S02(CrC4)alkyl, amino, -NHR7, or -NR7R8;
R5 is hydrogen;
or R4 and R5 taken together with atoms through which they are connected form a 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (Ci-C4)alkyl, (Ci-C4)haloalkyl, hydroxy(CrC4)alkyl-, oxo, hydroxyl, (Ci-C4)alkoxy, (Ci-C4)haloalkoxy, and (Ci-C4)alkylthio-;
R6 is (CrCe)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, or heteroaryl, wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (d-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl,
(C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(C C2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(Ci-C2)alkyl-, R7R8N(C C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, R70(C C2)alkyl-, cyano(C C2)alkyl-, aryl, heteroaryl, or heteroaryl(C1-C2)alkyl-, wherein any said aryl or heteroaryl is optionally substituted one to three times, independently, by halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(CrC4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(Ci-C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(Ci-C2)alkyl-;
R7 is (CrC4)alkyl, aryl, heterocycloalkyl, or heterocycloalkyl(Ci-C2)alkyl, wherein said (CrC4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl, (Ci-C4)alkoxy, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, -C02H, -C02(CrC4)alkyl, -CONH2, -CONH(C C4)alkyl, or
-CON((Ci-C4)alkyl)((CrC4)alkyl); and wherein any heterocycloalkyl is optionally substituted by (Ci-C4)alkyl; and
R8 is (Ci-C4)alkyl;
or R7 and R8 taken together with the nitrogen to which they are attached represent a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted one or two times, independently, by halogen, (Ci-C4)alkyl, (Ci-C4)haloalkyl, amino,
(C1-C4)alkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino, hydroxyl, oxo, (CrC4)alkoxy, or (C1-C4)alkoxy(C1-C4)alkyl;
or a salt thereof.
The compounds of the invention are inhibitors of TNNI3K and can be useful for the treatment of cardiac diseases and disorders, particularly heart failure. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting TNNI3K and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "alkyl" represents a saturated, straight or branched hydrocarbon moiety, which may be unsubstituted or substituted by one or more of the substituents defined herein. Exemplary alkyls include, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, f-butyl, pentyl, and hexyl. The term "C1-C4" refers to an alkyl containing from 1 to 4 carbon atoms.
When the term "alkyl" is used in combination with other substituent groups, such as "haloalkyl", "hydroxyalkyl", or "alkoxyalkyl", the term "alkyl" is intended to encompass a divalent straight or branched-chain hydrocarbon radical.
As used herein, the term "alkenyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and at least 1 and up to 3 carbon-carbon double bonds. Examples include ethenyl and propenyl.
As used herein, the term "alkynyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and at least 1 and up to 3 carbon-carbon triple bonds. Examples include ethynyl and propynyl.
As used herein, the term "cycloalkyl" refers to a non-aromatic, saturated, cyclic hydrocarbon ring. The term "(C3-C8)cycloalkyl" refers to a non-aromatic cyclic
hydrocarbon ring having from three to eight ring carbon atoms. Exemplary
"(C3-C8)cycloalkyl" groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
"Alkoxy" refers to a group containing an alkyl radical attached through an oxygen linking atom. The term "(CrC4)alkoxy" refers to a straight- or branched-chain
hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom. Exemplary "(d-C4)alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, and f-butoxy.
"Alkylthio-" refers to a group containing an alkyl radical attached through a sulfur linking atom. The term "(C1-C4)alkylthio-" refers to a straight- or branched-chain hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through a sulfur linking atom. Exemplary "(C1-C4)alkylthio-" groups useful in the present invention include, but are not limited to, methylthio-, ethylthio-, n-propylthio-, isopropylthio-, n-butylthio-, s-butylthio-, and f-butylthio-.
"Cycloalkyloxy" refers to a group containing a saturated carbocyclic ring attached through an oxygen linking atom. Examples of "cycloalkyloxy" moieties include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. "Aryl" represents a group or moiety comprising an aromatic, monovalent monocyclic or bicyclic hydrocarbon radical containing from 6 to 10 carbon ring atoms, which may be unsubstituted or substituted by one or more of the substituents defined herein, and to which may be fused to one or more cycloalkyl rings, which may be unsubstituted or substituted by one or more substituents defined herein.
Generally, in the compounds of this invention, aryl is phenyl.
Heterocyclic groups may be heteroaryl or heterocycloalkyl groups.
"Heterocycloalkyl" represents a group or moiety comprising a non-aromatic, monovalent monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, which includes 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents defined herein. Illustrative examples of heterocycloalkyls include, but are not limited to, azetidinyl, pyrrolidinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl, imidazolinyl, oxazolinyl, thiazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1 ,3-dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3-oxathianyl, 1 ,3-dithianyl, hexahydro-1 H-1 ,4-diazepinyl, azabicylo[3.2.1 ]octyl, azabicylo[3.3.1 ]nonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1 ]heptyl and 1 ,5,9-triazacyclododecyl.
Generally, in the compounds of this invention, heterocycloalkyl groups are 5-7 membered heterocycloalkyl groups, such as pyrrolidinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl, imidazolinyl, oxazolinyl, thiazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1 ,3-dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dihydropyranyl, and hexahydro-1 H-1 ,4-diazepinyl.
"Heteroaryl" represents a group or moiety comprising an aromatic monovalent monocyclic or bicyclic radical, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more of the substituents defined herein. This term also encompasses bicyclic heterocyclic-aryl compounds containing an aryl ring moiety fused to a heterocycloalkyl ring moiety, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more of the substituents defined herein. Illustrative examples of heteroaryls include, but are not limited to, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, benzofuranyl, isobenzofuryl, 2,3-dihydrobenzofuryl,
1 ,3-benzodioxolyl, dihydrobenzodioxinyl, benzothienyl, indolizinyl, indolyl, isoindolyl, dihydroindolyl, dihydroisoindolyl, chromenyl, benzimidazolyl, dihydrobenzimidazolyl, benzoxazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzothiazolyl, benzoisothiazolyl, dihydrobenzoisothiazolyl, indazolyl, imidazopyridinyl, pyrazolopyridinyl, benzotriazolyl, triazolopyridinyl, purinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl, 1 ,5-naphthyridinyl, 1 ,6-naphthyridinyl, 1 ,7-naphthyridinyl, 1 ,8-naphthyridinyl, and pteridinyl.
Generally, the heteroaryl groups present in the compounds of this invention are 5-membered and/or 6-memebred monocyclic heteroaryl groups. Selected 5-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, or 3 additional nitrogen ring atoms. Selected 6-membered heteroaryl groups contain 1 , 2, or 3 nitrogen ring heteroatoms. Selected 5- or 6-membered heteroaryl groups include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, and triazinyl.
Όχο" represents a double-bonded oxygen moiety; for example, if attached directly to a carbon atom forms a carbonyl moiety (C=0).
The terms "halogen" and "halo" represent chloro, fluoro, bromo, or iodo substituents. "Hydroxy" or "hydroxyl" is intended to mean the radical -OH.
As used herein, the term "compound(s) of the invention" means a compound of Formula I (as defined above) in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a pharmaceutically acceptable salt thereof) and any physical form thereof (e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvates, including hydrates (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
As used herein, the term "optionally substituted" means that the groups may be either unsubstituted or substituted with one or more of the specified substituents.
The alternative definitions for the various groups and substituent groups of Formula I provided throughout the specification are intended to particularly describe each compound species disclosed herein, individually, as well as groups of one or more compound species. The scope of this invention includes any combination of these group and substituent group definitions.
Suitably, R1 is (Ci-C4)alkyl. In a specific embodiment of this invention, R1 is methyl.
Suitably, R2 is hydrogen or halogen. In a specific embodiment of this invention, R2 is hydrogen or fluorine. In a further specific embodiment of this invention, R2 is hydrogen. Suitably, R3 is hydrogen, halogen, (d-C4)alkyl, (CrC4)haloalkyl, (C3-C6)cycloalkyl, aryl, hydroxyl, hydroxy(CrC4)alkyl-, (CrC4)alkoxy, (Ci-C4)alkoxy(CrC4)alkyl-,
(CrC4)haloalkoxy, (C3-C6)cycloalkyloxy, (Ci-C4)alkylthio-, amino, (Ci-C4)alkylamino, or ((Ci-C4)alkyl)((Ci-C4)alkyl)amino. In another embodiment of this invention, R3 is hydrogen, halogen, (CrC4)alkyl, (CrC4)haloalkyl, phenyl, (Ci-C4)alkoxy, (CrC4)alkylthio-, or ((Ci-C4)alkyl)((Ci-C4)alkyl)amino. In a specific embodiment of this invention, R3 is hydrogen, chlorine, or dimethylamino. In a further specific embodiment of this invention, R3 is hydrogen. In yet a further specific embodiment of this invention, R2 and R3 are each hydrogen.
Suitably, R4 is hydrogen, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(C1-C8)alkyl-, (C1-C8)alkoxy, (C1-C4)alkoxy(C1-C8)alkyl-,
(C1-C8)haloalkoxy, (C3-C8)cycloalkyloxy, (C1-C8)alkylthio-, (C1-C8)haloalkylthio-,
-S02(C1-C4)alkyl, amino, -NHR7, or -NR7R8. In another embodiment of this invention, R4 is hydrogen, halogen, (Ci-C8)alkyl, (Ci-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(Ci-C8)alkyl-, (Ci-C8)alkoxy, (Ci-C4)alkoxy(CrC8)alkyl-, (Ci-C8)haloalkoxy, (C3-C8)cycloalkyloxy, (Ci-C8)alkylthio-, (Ci-C8)haloalkylthio-, -S02(Ci-C4)alkyl, amino, (Ci-C4)alkylamino, (Ci-C4)haloalkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino,
((Ci-C4)alkyl)((Ci-C4)haloalkyl)amino, ((Ci-C4)haloalkyl)((Ci-C4)haloalkyl)amino, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, wherein said pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl is optionally substituted one or two times, independently, by halogen, (Ci-C4)alkyl, (CrC4)haloalkyl, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (CrC4)alkoxy, or
(Ci-C4)alkoxy(Ci-C4)alkyl. In a further embodiment of this invention, R4 is hydrogen, halogen, (Ci-C8)alkyl, (Ci-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(Ci-C8)alkyl-, (Ci-C8)alkoxy, (Ci-C4)alkoxy(CrC8)alkyl-, (Ci-C8)haloalkoxy, (C3-C8)cycloalkyloxy, (Ci-C8)alkylthio-, -S02(Ci-C4)alkyl, amino, (Ci-C4)alkylamino,
((C1-C4)alkyl)((C1-C4)alkyl)amino, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl. In specific embodiments of this invention, R4 is hydrogen, fluorine, chlorine, hydroxyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, isobutyloxy, 3-methyl-2-butyloxy, 3-pentyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1 , 1 , 1-trifluoro-2-propyloxy, 3,3,3-trifluoro-1-propyloxy, 1 , 1 ,1 -trifluoro-2-methyl-2-propyloxy, 1 , 1 , 1 ,3,3,3-hexafluoro-2-methyl-2-propyloxy, cyclopentyloxy, cyclohexyloxy, methylthio-, ethylthio-, isobutylthio-, 2,2,2-trifluoroethylthio-, methylsulfone, ethylsulfone,
isopropylsulfone, isobutylsulfone, ferf-butylsulfone, amino, dimethylamino,
ethylmethylamino, diethylamino, methyl-2,2,2-trifluoroethylamino, 2-methylpyrrolidin-1 -yl, (R)-2-trifluoromethylpyrrolidin-1-yl, 2,5-dimethylpyrrolidin-1 -yl, 3 , 3-d if I uoropy rrol id i n- 1 -y I , 3,3-difluoropiperidin-1 -yl, or morpholin-4-yl.
In a further embodiment of the invention, R4 and R5 taken together with atoms through which they are connected form a 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (d-C4)alkyl, (Ci-C4)haloalkyl, hydroxy(Ci-C4)alkyl-, oxo, hydroxyl, (Ci-C4)alkoxy, (Ci-C4)haloalkoxy, and (CrC4)alkylthio-. In yet a further embodiment of the invention, R4 and R5 taken together with atoms through which they are connected form a partially saturated 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (Ci-C4)alkyl, (C1-C4)haloalkyl, hydroxy(C1-C4)alkyl-,
(C1-C4)alkoxy, (C1-C4)haloalkoxy, and (C1-C4)alkylthio-. In a specific embodiment of this invention, R4 and R5 taken together represent -CH2CH2-, -C(CH3)2CH2-, -CH=CH- -NH(C=0)-, or -N=CH-. In a further specific embodiment of this invention, R4 and R5 taken together represent -CH2CH2-.
Suitably, R6 is (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, or heteroaryl, wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl,
(C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(C C2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(Ci-C2)alkyl-, R7R8N(C C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, R70(C C2)alkyl-, cyano(C C2)alkyl-, aryl, heteroaryl, or heteroaryl(Ci-C2)alkyl-, wherein any said aryl or heteroaryl is optionally substituted one to three times, independently, by halogen, (CrC6)alkyl, (C3-C6)cycloalkyl, (Ci-C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(C1-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(C C2)alkyl-.
In another embodiment of this invention, R6 is (C1-C6)alkyl, phenyl, dihydroindenyl, tetrahydronaphthalenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, indolyl, indazolyl, dihydroindolyl, dihydroisoindolyl, chromenyl, dihydrobenzimidazolyl,
dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxolyl, or dihydrobenzodioxinyl, wherein said phenyl, dihydroindenyl, tetrahydronaphthalenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, indolyl, indazolyl, dihydroindolyl, dihydroisoindolyl, chromenyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxolyl, or dihydrobenzodioxinyl group is optionally substituted one to three times, independently, by halogen, (d-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(Ci-C2)alkyl-, cyano(Ci-C2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(C C2)alkyl-, R7R8N(C C2)alkyl-, triazolyl(C1-C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(d-C2)alkyl-, R70(C1-C2)alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (C C6)alkyl, (C3-C6)cycloalkyl, (Ci-C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(Ci-C2)alkyl-, or R70(C C2)alkyl-.
In yet another embodiment of this invention, R6 is (CrC6)alkyl, phenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, indolyl, indazolyl, dihydroindolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, or dihydrobenzodioxinyl, wherein said phenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, indolyl, indazolyl, dihydroindolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, or
dihydrobenzodioxinyl group is optionally substituted one or two times, independently, by halogen, (C C6)alkyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(Ci-C2)alkyl-, -SR7, -S02(d-C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(C C2)alkyl-, R7R8N(C C2)alkyl-, -NHCO(d-C4)alkyl,
-NHS02(d-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, R70(C C2)alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (C C6)alkyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(C C2)alkyl-. In a further embodiment of this invention, R6 is phenyl optionally substituted one to three times, independently, by halogen, (d-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(C C2)alkyl-, cyano(Ci-C2)alkyl-, -SR7, -S02(Ci-C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(Ci-C2)alkyl-, R7HN(C C2)alkyl-, R7R8N(C C2)alkyl-, triazolyl(C C2)alkyl-,
-NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, R70(CrC2)alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (C1-C6)alkyl,
(C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(d-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(Ci-C2)alkyl-, or R70(Ci-C2)alkyk
In yet a further embodiment of this invention, R6 is phenyl optionally substituted one or two times, independently, by halogen, (CrC6)alkyl, (C3-C6)cycloalkyl,
(Ci-C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(CrC2)alkyl-, R702C(C C2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(Ci-C2)alkyl-, R7HN(Ci-C2)alkyl-,
R7R8N(Ci-C2)alkyl-, -NHCO(Ci-C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(Ci-C2)alkyl-, R70(CrC2)alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (CrC6)alkyl, (C3-C6)cycloalkyl, (CrC4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7,
-S02(Ci-C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8,
-NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(Ci-C2)alkyk
In still a further embodiment of this invention, R6 is pyridinyl optionally substituted one or two times, independently, by halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl,
(C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(C C2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(Ci-C2)alkyl-, R7HN(Ci-C2)alkyl-,
R7R8N(Ci-C2)alkyl-, -NHCO(Ci-C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(Ci-C2)alkyl-, or R70(Ci-C2)alkyl-. In still a further embodiment of this invention, R6 is pyridinyl optionally substituted one or two times, independently, by halogen,
(CrC4)alkyl, (Ci-C4)haloalkyl, or cyano. In a specific embodiment of this invention, R6 is methyl, ethyl, oxazol-2-yl, oxazol- 5-yl, 4-methyl-oxazol-2-yl, thiazol-2-yl, 4-trifluoromethyl-thiazol-2-yl, 4-isopropyl-thiazol-2- yl, 5-methyl-thiazol-2-yl, 4-carboxymethyl-thiazol-2-yl, 4-(methoxycarbonyl)methyl-thiazol- 2-yl, 5-carboxy-thiazol-2-yl, 1 ,3,4-thiadiazol-2-yl, pyridin-2-yl, 3-fluoro-pyridin-2-yl,
5-fluoro-pyridin-2-yl, 5-chloro-pyridin-2-yl, 5-isopropyl-pyridin-2-yl, 5-trifluoromethyl- pyridin-2-yl, 5-cyano-pyridin-2-yl, 5-chloro-3-fluoro-pyridin-2-yl, 3,5-dichloro-pyridin-2-yl, 4,5-dichloro-pyridin-2-yl, 5-chloro-4-methyl-pyridin-2-yl, 5-chloro-6-methyl-pyridin-2-yl, 5-bromo-6-methyl-pyridin-2-yl, 6-bromo-4-methyl-pyridin-2-yl, pyridin-3-yl, 5-methyl- pyridin-3-yl, 6-trifluoromethyl-pyridin-3-yl, 5-methylsulfonamide-pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, 2,3-dihydro-1 H-inden-5-yl, 5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl, 1 H-indol-5-yl, 1 H-indol-6-yl, 1-acetyl-2,3-dihydro-1 H-indol-6-yl, 2-methyl-1 ,3-dioxo-2,3- dihydro-1 -/-isoindol-5-yl, 1 H-indazol-5-yl, 1 H-indazol-6-yl, 3-methyl-1 H-indazol-6-yl, 2-0X0-2, 3-dihydro-1 H-indol-5-yl, 2-oxo-2,3-dihydro-1 H-indol-6-yl, 2-methyl-4-oxo-4H- chromen-7-yl, 4-methyl-2-oxo-2H-chromen-7-yl, 2-oxo-2,3-dihydro-1 H-benzimidazol-5-yl,
2- 0X0-2, 3-d ihydro-1 ,3-benzoxazol-6-yl, 2-methyl-1 ,3-benzothiazol-5-yl, 1 ,3-benzothiazol- 5-yl, 1 ,3-benzothiazol-6-yl, 1 , 1-dioxido-2,3-dihydro-1 ,2-benzisothiazol-6-yl, quinolin-2-yl, quinolin-6-yl, isoquinolin-3-yl, 4-methyl-2-oxo-1 ,2-dihydroquinolin-7-yl, 2-methyl-1 ,2,3,4- tetrahydroisoquinolin-7-yl, 2-oxo-1 ,2,3,4-tetrahydroquinolin-7-yl, 1 ,3-benzodioxol-5-yl,
2.3- dihydro-1 ,4-benzodioxin-6-yl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl,
3- chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-difluorophenyl,
3.4- dichlorophenyl, 3,5-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-bromo-4-chlorophenyl, 3-bromo-5-chlorophenyl, 3,4,5-trifluorophenyl, 3-methylphenyl, 4-methylphenyl,
3- isopropylphenyl, 4-isopropylphenyl, 4-sec-butylphenyl, 3-ferf-butylphenyl,
4- ferf-butylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 3-fluoro-4- methylphenyl, 4-fluoro-3-methylphenyl, 4-chloro-3-methylphenyl, 3-bromo-5-methylphenyl,
3- ethynylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-fluoro-4- trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-methyl-3-trifluoromethylphenyl,
4- cyclopropylphenyl, 4-(2,2,2-trifluoroethyl)phenyl, 4-(thien-2-yl)phenyl, 4-(1 H-pyrazol-1- yl)phenyl, 4-(3,5-dimethyl-1 H-pyrazol-1 -yl)phenyl, 4-(2-methyl-1 H-imidazol-1-yl)phenyl, 4-(oxazol-5-yl)phenyl, 3-(2-methyl-thiazol-4-yl)phenyl, 3-biphenylyl, 3'-aminocarbonyl-3- biphenylyl, 4'-aminocarbonyl-3-biphenylyl, 3'-dimethylamino-3-biphenylyl,
4'-dimethylamino-3-biphenylyl, 4'-morpholin-4-yl-3-biphenylyl, 3'-acetylamino-3-biphenylyl, 4'-acetylamino-3-biphenylyl, 3'-[(methylsulfonyl)amino]-3-biphenylyl,
4'-[(methylsulfonyl)amino]-3-biphenylyl, 3'-[(methylamino)sulfonyl]-3-biphenylyl,
4'-[(methylamino)sulfonyl]-3-biphenylyl, 5-methyl-3-biphenylyl, 4-chloro-3'-morpholin-4-yl- 3-biphenylyl, 4-chloro-3'-aminocarbonyl-3-biphenylyl, 3-(4-methoxy-pyridin-3-yl)phenyl, 3- (5-methoxy-pyridin-3-yl)phenyl, 3-(6-methoxy-pyridin-3-yl)phenyl, 3-(6-oxo-pyridin-3- yl)phenyl, 3-(6-dimethylamino-pyridin-3-yl)phenyl, 5-methyl-3-(pyridin-3-yl)phenyl,
4- chloro-3-(pyridin-3-yl)phenyl, 4-(cyanomethyl)phenyl, 3-(1 -pyrrolidinylmethyl)phenyl,
3- [(4-methyl-1 -piperazinyl)methyl]phenyl, 4-(1 H-1 ,2,4-triazol-1-ylmethyl)phenyl, 4-(4H- 1 ,2,4-triazol-4-ylmethyl)phenyl, 3-acetylphenyl, 4-acetylphenyl, 4-carboxyphenyl,
4- [(methoxy)carbonyl]phenyl, 4-[(isopropoxy)carbonyl]phenyl, 3-aminocarbonylphenyl, 4-aminocarbonylphenyl, 4-(methylamino)carbonylphenyl,
4-(dimethylaminoethylamino)carbonylphenyl, 4-(hydroxyethylamino)carbonylphenyl, 4-(methoxyethylamino)carbonylphenyl, 4-(methoxypropylamino)carbonylphenyl,
4-(carboxymethylamino)carbonylphenyl, 4-[(1-methyl-piperidin-4-yl)amino]carbonylphenyl,
3- (phenylamino)carbonylphenyl, 4-(phenylamino)carbonylphenyl,
4- (dimethylamino)carbonylphenyl, 4-(diethylamino)carbonylphenyl, 4-[/V-methyl-/\/-(/\/',/\/ - dimethylaminoethyl)amino]carbonylphenyl, 4-(pyrrolidin-1-yl)carbonylphenyl, 4-[(3S)-3- (dimethylamino)pyrrolidin-1-yl]carbonylphenyl, 4-[(3R)-3-(dimethylamino)pyrrolidin-1- yl]carbonylphenyl, 4-(4,4-difluoropiperidin-1-yl)carbonylphenyl, 4-(morpholin-4- yl)carbonylphenyl, 4-(thiomorpholin-4-yl)carbonylphenyl, 4-(piperazin-1-yl)carbonylphenyl, 4-(4-methyl-piperazin-1-yl)carbonylphenyl, 4-(4-methoxyethyl-piperazin-1 - yl)carbonylphenyl, 4-(4-methyl-hexahydro-1 /-/-1 ,4-diazepin-1-yl)carbonylphenyl,
4-cyanophenyl, 3-chloro-4-cyanophenyl, 3-nitrophenyl, 3-dimethylaminophenyl,
4-dimethylaminophenyl, 3-(pyrrolidin-1 -yl)phenyl, 4-(piperidin-1-yl)phenyl, 4-(piperazin-1- yl)phenyl, 3-(morpholin-4-yl)phenyl, 4-(morpholin-4-yl)phenyl, 3-(4-methyl-piperazin-1- yl)phenyl, 3-(acetylamino)phenyl, 4-(acetylamino)phenyl, 3-(propionylamino)phenyl, 4-(2-oxo-pyrrolidin-1-yl)phenyl, 3-[(methylsulfonyl)amino]phenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-difluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-ethoxyphenyl, 3-(2,2,2-trifluoroethoxy)phenyl, 4-isopropoxyphenyl,
3-(carboxymethyloxy)phenyl, 3-[(isopropoxycarbonyl)methyloxy]phenyl,
3- [(dimethylaminocarbonyl)methyloxy]phenyl, 4-(methoxyethyloxy)phenyl,
4- (dimethylaminoethyloxy)phenyl, 4-(diethylaminoethyloxy)phenyl, 4-[(morpholin-4- yl)ethyloxy]phenyl, 3-fluoro-4-methoxyphenyl, 3-chloro-4-hydroxyphenyl, 3-chloro-4- methoxyphenyl, 4-chloro-3-methoxyphenyl, 3-methoxy-5-trifluoromethylphenyl,
4-methoxy-3-trifluoromethylphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl,
3,5-dichloro-4-hydroxyphenyl, 2,3,4-trimethoxyphenyl, 3,4,5-trimethoxyphenyl,
4-(methylthio)phenyl, 4-(trifluoromethylthio)phenyl, 3-methylsulfonylphenyl,
4-methylsulfonylphenyl, 3-aminosulfonylphenyl, 3-(methylamino)sulfonylphenyl,
4-(methylamino)sulfonylphenyl, 3-(ethylamino)sulfonylphenyl, 3-(isopropylamino)sulfonylphenyl, 3-(dimethylamino)sulfonylphenyl, or 3-(morpholin-4- yl)sulfonylphenyl.
Suitably, R7 is (Ci-C4)alkyl, aryl, heterocycloalkyl, or heterocycloalkyl(Ci-C2)alkyl, wherein said (CrC4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl, (Ci-C4)alkoxy, amino, (Ci-C4)alkylamino,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino, -C02H, -C02(Ci-C4)alkyl, -CONH2, -CONH(C C4)alkyl, or -CON((Ci-C4)alkyl)((Ci-C4)alkyl); and wherein any heterocycloalkyl is optionally substituted by (Ci-C4)alkyl. In another embodiment of this invention, R7 is (CrC4)alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or
pyrrolidinyl(C1-C2)alkyl, piperidinyl(C1-C2)alkyl, morpholinyl(C1-C2)alkyl,
thiomorpholinyl(C1-C2)alkyl, or piperazinyl(C1-C2)alkyl, wherein said (C1-C4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl,
(C1-C4)alkoxy, amino, (C1-C4)alkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino, -C02H, -C02(CrC4)alkyl, -CONH2, -CONH(C C4)alkyl, or -CON((Ci-C4)alkyl)((C C4)alkyl); and wherein any pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl is optionally substituted by (CrC4)alkyl. In a specific embodiment of this invention, R7 is methyl, difluoromethyl, trifluoromethyl, ethyl, 2,2,2-trifluoroethyl, isopropyl,
dimethylaminoethyl, diethylaminoethyl, hydroxyethyl, methoxyethyl, methoxypropyl, carboxymethyl, (isopropoxycarbonyl)methyl, (dimethylaminocarbonyl)methyl, phenyl, 1 -methyl-piperidin-4-yl, or (morpholin-4-yl)ethyl.
Suitably, R8 is (Ci-C4)alkyl. In a specific embodiment of this invention, R8 is methyl or ethyl.
In another embodiment of this invention, R7 and R8 taken together with the nitrogen to which they are attached represent a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted one or two times, independently, by halogen, (CrC4)alkyl, (d-C4)haloalkyl, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (C1-C4)alkoxy, or (C1-C4)alkoxy(C1-C4)alkyl. In yet another embodiment of this invention, R7 and R8 taken together with the nitrogen to which they are attached represent pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or hexahydro- 1 H-1 ,4-diazepinyl, each optionally substituted one or two times, independently, by halogen, (CrC4)alkyl, (CrC4)haloalkyl, amino, (Ci-C4)alkylamino,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (CrC4)alkoxy, or
(Ci-C4)alkoxy(Ci-C4)alkyl. In a specific embodiment of this invention, R7 and R8 taken together with the nitrogen to which they are attached represent pyrrolidinyl,
2-methylpyrrolidinyl, 2-trifluoromethylpyrrolidinyl, 3-(dimethylamino)pyrrolidinyl, 2-oxo-pyrrolidinyl, 2,5-dimethylpyrrolidinyl, 3,3-difluoropyrrolidinyl, piperidinyl,
3,3-difluoropiperidinyl, 4,4-difluoropiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 4-methylpiperazinyl, 4-methoxyethylpiperazinyl, or 4-methyl-hexahydro-1 H-1 ,4-diazepinyl.
One particular embodiment of the invention is a compound of Formula I or a salt thereof wherein:
R1 is (CrC4)alkyl;
R2 is hydrogen;
R3 is hydrogen, halogen, (CrC4)alkyl, (d-C4)haloalkyl, (C3-C6)cycloalkyl, aryl, hydroxyl, hydroxy(Ci-C4)alkyl-, (Ci-C4)alkoxy, (CrC4)alkoxy(Ci-C4)alkyl-,
(C1-C4)haloalkoxy, (C3-C6)cycloalkyloxy, (C1-C4)alkylthio-, amino, (C1-C4)alkylamino, or ((Ci-C4)alkyl)((Ci-C4)alkyl)amino;
R4 is hydrogen, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(C1-C8)alkyl-, (d-C^alkoxy, (C1-C4)alkoxy(C1-C8)alkyl-, (C1-C8)haloalkoxy, (C3-C8)cycloalkyloxy, (C C8)alkylthio-, -S02(Ci-C4)alkyl, or -NR7R8;
R5 is hydrogen;
or R4 and R5 taken together with atoms through which they are connected form a partially saturated 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (CrC4)alkyl, (Ci-C4)haloalkyl, hydroxy(CrC4)alkyl-, (CrC4)alkoxy, (CrC4)haloalkoxy, and (Ci-C4)alkylthio-;
R6 is (CrCe)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, or heteroaryl, wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (CrC6)alkyl, (C3-C6)cycloalkyl, (CrC4)haloalkyl, cyano, -CO(Ci-C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(CrC2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(C C2)alkyl-, R7R8N(C C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, R70(C1-C2)alkyl-, aryl, or heteroaryl, wherein said aryl or heteroaryl is optionally substituted one to three times, independently, by halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(Ci-C2)alkyl-;
R7 is (CrC4)alkyl, aryl, heterocycloalkyl, or heterocycloalkyl(Ci-C2)alkyl, wherein said (CrC4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl, (CrC4)alkoxy, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, -CO2H, -C02(Ci-C4)alkyl, -CON H2, -CON H(C C4)alkyl, or
-CON((Ci-C4)alkyl)((Ci-C4)alkyl); and wherein any heterocycloalkyl is optionally substituted by (Ci-C4)alkyl; and
R8 is (Ci-C4)alkyl;
or R7 and R8 taken together with the nitrogen to which they are attached represent a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted one or two times, independently, by halogen, (d-C4)alkyl, (CrC4)haloalkyl, amino,
(Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (CrC4)alkoxy, or (Ci-C4)alkoxy(Ci-C4)alkyl.
Another particular embodiment of the invention is a compound of Formula I or a salt thereof wherein:
R1 is methyl;
R2 is hydrogen or fluorine;
R3 is hydrogen, halogen, (CrC4)alkyl, (Ci-C4)haloalkyl, phenyl, (CrC4)alkoxy, (C C4)alkylthio-, or ((Ci-C4)alkyl)((C C4)alkyl)amino;
R4 is hydrogen, halogen, (CrC8)alkyl, (Ci-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(CrC8)alkyl-, (Ci-C8)alkoxy, (Ci-C4)alkoxy(CrC8)alkyl-, (Ci-C8)haloalkoxy, (C3-C8)cycloalkyloxy, (Ci-C8)alkylthio-, (Ci-C8)haloalkylthio-, -S02(Ci-C4)alkyl, amino, (Ci-C4)alkylamino, (Ci-C4)haloalkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, ((Ci-C4)alkyl)((Ci-C4)haloalkyl)amino, ((Ci-C4)haloalkyl)((Ci-C4)haloalkyl)amino, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, wherein said pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl is optionally substituted one or two times, independently, by halogen, (Ci-C4)alkyl, (Ci-C4)haloalkyl, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (CrC4)alkoxy, or
(Ci-C4)alkoxy(CrC4)alkyl;
R5 is hydrogen;
R6 is phenyl optionally substituted one to three times, independently, by halogen, (C C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CON H2, -CON H R7, -CON R7R8, H02C(C C2)alkyl-, R702C(CrC2)alkyl-, cyano(Ci-C2)alkyl-, -SR7, -S02(Ci-C4)alkyl, -S02N H2, -S02N H R7, -S02N R7R8, nitro, amino, -N H R7, -N R7R8, amino(Ci-C2)alkyl-, R7H N(Ci-C2)alkyl-, R7R8N(Ci-C2)alkyl-, triazolyl(C C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(Ci-C2)alkyl-, R70(CrC2)alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (d-C6)alkyl, (C3-C6)cycloalkyl, (CrC4)haloalkyl, cyano, -CO(Ci-C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(Ci-C2)alkyl-;
R7 is (CrC4)alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or pyrrolidinyl(Ci-C2)alkyl, piperidinyl(Ci-C2)alkyl, morpholinyl(Ci-C2)alkyl, thiomorpholinyl(Ci-C2)alkyl, or piperazinyl(Ci-C2)alkyl, wherein said (Ci-C4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl,
(C1-C4)alkoxy, amino, (C1-C4)alkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino, -C02H, -C02(C C4)alkyl, -CONH2, -CONH(C C4)alkyl, or -CON((d-d)alkylX(d-d)alkyl); and wherein any pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl is optionally substituted by (C1-C4)alkyl; and
R8 is methyl or ethyl;
or R7 and R8 taken together with the nitrogen to which they are attached represent pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or hexahydro-1 H-1 ,4- diazepinyl, each optionally substituted one or two times, independently, by halogen, (CrC4)alkyl, (Ci-C4)haloalkyl, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (Ci-C4)alkoxy, or (Ci-C4)alkoxy(Ci-C4)alkyl.
Another particular embodiment of the invention is a compound of Formula I or a salt thereof wherein:
R1 is methyl;
R2 is hydrogen or fluorine;
R3 is hydrogen, halogen, (CrC4)alkyl, (Ci-C4)haloalkyl, phenyl, (CrC4)alkoxy, (C C4)alkylthio-, or ((Ci-C4)alkyl)((Ci-C4)alkyl)amino;
R4 is hydrogen, halogen, (CrC8)alkyl, (Ci-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(CrC8)alkyl-, (Ci-C8)alkoxy, (Ci-C4)alkoxy(CrC8)alkyl-, (Ci-C8)haloalkoxy, (C3-C8)cycloalkyloxy, (C1-C8)alkylthio-, (C1-C8)haloalkylthio-, -S02(C1-C4)alkyl, amino, (C1-C4)alkylamino, (C1-C4)haloalkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino,
((d-d)alkylX(d-d)haloalkyl)amino, ((d-d)haloalkylX(d-d)haloalkyl)amino, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, wherein said pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl is optionally substituted one or two times, independently, by halogen, (d-d)alkyl, (d-d)haloalkyl, amino, (d-d)alkylamino, ((d-d)alkyl)((Ci-d)alkyl)amino, hydroxyl, oxo, (d-d)alkoxy, or
(d-C4)alkoxy(d-C4)alkyl; R5 is hydrogen;
R6 is pyridinyl optionally substituted one or two times, independently, by halogen, (C C6)alkyl, (C3-C6)cycloalkyl, (Ci-C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(CrC2)alkyl-, R702C(Ci-C2)alkyl-, -SR7,
-S02(Ci-C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(Ci-C2)alkyl-, R7HN(C C2)alkyl-, R7R8N(C C2)alkyl-, -NHCO(Ci-C4)alkyl,
-NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(Ci-C2)alkyl-;
R7 is (CrC4)alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or pyrrolidinyl(Ci-C2)alkyl, piperidinyl(Ci-C2)alkyl, morpholinyl(Ci-C2)alkyl, thiomorpholinyl(C1-C2)alkyl, or piperazinyl(C1-C2)alkyl, wherein said (C1-C4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl,
(C1-C4)alkoxy, amino, (C1-C4)alkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino, -C02H, -C02(C C4)alkyl, -CONH2, -CONH(C C4)alkyl, or -CON((Ci-C4)alkyl)((Ci-C4)alkyl); and wherein any pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl is optionally substituted by (CrC4)alkyl; and
R8 is methyl or ethyl;
or R7 and R8 taken together with the nitrogen to which they are attached represent pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or hexahydro-1 H-1 ,4- diazepinyl, each optionally substituted one or two times, independently, by halogen, (CrC4)alkyl, (d-C4)haloalkyl, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (Ci-C4)alkoxy, or (Ci-C4)alkoxy(Ci-C4)alkyl.
Specific compounds of this invention include:
A/-methyl-3-({6-[(3-methylphenyl)amino]-4-pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(3-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methylbenzenesulfonamide;
A/-methyl-3-{[6-(methylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
3-{[6-(ethylamino)-4-pyrimidinyl]amino}-/\/-methylbenzenesulfonamide;
3,3'-(4,6-pyrimidinediyldiimino)bis(/\/-methylbenzenesulfonamide);
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-5-(dimethylamino)-/\/- methylbenzenesulfonamide;
3-chloro-5-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (propyloxy)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(ethyloxy)-/\/- methylbenzenesulfonamide; 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2- methylpropyl)oxy]benzenesulfonamide;
3- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-[(1 ,2-dimethylpropyl)oxy]-A/- methylbenzenesulfonamide;
4- chloro-3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]-benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(cyclohexyloxy)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-[(1 -ethylpropyl)oxy]-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(3,3,3- trifluoropropyl)oxy]-benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(cyclopentyloxy)-/\/- methylbenzenesulfonamide;
5- (6-(4-chlorophenylamino)pyrimidin-4-ylamino)-2-fluoro-4-methoxy-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[methyl(2,2,2- trifluoroethyl)amino]benzenesulfonamide;
1-[6-(4-chloro-phenylamino)-pyrimidin-4-yl]-3,3-dimethyl-2,3-dihydro-1 /-/-indole-6- sulfonic acid methylamide;
3- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifluoro-1 - methylethyl)oxy]benzenesulfonamide;
5-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-2-fluoro-/\/-methyl-4-(2,2,2- trifluoroethoxy)benzenesulfonamide;
4- amino-3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
5- [6-(4-chloro-phenylamino)-pyrimidin-4-ylamino]-4-dimethylamino-2-fluoro-/\/- methyl-benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(3,3-difluoro-1 -piperidinyl)-/V^ methylbenzenesulfonamide;
3- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-{[2,2,2-trifluoro-1 - (trifluoromethyl)ethyl]oxy}benzenesulfonamide;
4- (dimethylamino)-3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide; 3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-(4- morpholinyl)benzenesulfonamide;
1-{6-[(3-fluorophenyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 /-/-indole-6- sulfonamide;
3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methyloxy)benzenesulfonamide;
/V-methyl-3-[(6-{[4-(1-methylethyl)phenyl]amino}-4-pyrimidinyl)amino]-4- (methylthio)benzenesulfonamide;
3-[(6-{[3-chloro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3- [(6-{[3-chloro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/-methyl-4- (methyloxy)benzenesulfonamide;
/V-methyl-4-(methyloxy)-3-({6-[(4-{[2-(methyloxy)ethyl]oxy}phenyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-3-({6-[(4-{[2-(methyloxy)ethyl]oxy}phenyl)amino]-4-pyrimidinyl}amino)-4- [(2,2,2-trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-4-(methyloxy)-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4-pyrimidinyl)amino]-4-[(2,2,2 trifluoroethyl)thio]benzenesulfonamide;
4- [(6-{[5-[(methylamino)sulfonyl]-2-(methylthio)phenyl]amino}-4-pyrimidinyl)ami A/-[2-(methyloxy)ethyl]benzamide;
A/-methyl-4-(methyloxy)-3-[(6-{[4-(1 /-/-pyrazol-1-yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-[(6-{[4-(1 H-pyrazol-1-yl)phenyl]amino}-4-pyrimidinyl)amino]-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
A/-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-{[6-({4-[(2,2,2- trifluoroethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-4-fluoro-/\/- methylbenzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifl methylethyl)oxy]benzenesulfonamide; 1-{6-[(3,4-difluorophenyl)amino]-4-pyrimi
6-sulfonamide;
3-[6-(6-bromo-4-methyl-pyridin-2-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-(2,2,2- trifluoro-ethoxy)-benzenesulfonamide;
3-({6-[(3,5-dichloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-{[6-(3-biphenylylamino)-4-pyrimidinyl]amino}-/V-methylbenzenesulfonamide;
/V-methyl-3-({6-[(4-methylphenyl)amino]-4-pyrimidinyl}amino)benzenesulfonami
3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzamide;
3- ({6-[(3-acetylphenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide; A/-methyl-3-[(6-{[3-(methyloxy)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/\/-(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)acetamide;
/V-methyl-3-{[6-(phenylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
4- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzamide; 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide; A/-methyl-3-[(6-{[3-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-({6-[(2-methyl-1 ,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(2-fluorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
A/-methyl-3-[(6-{[3-(4-morpholinylsulfonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-{[6-({3-[(ethylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[3-(methylsulfonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[6-(1 H-indazol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide;
3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- phenylbenzamide;
3-{[6-({3-[(dimethylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- methylbenzenesulfonamide;
3-[(6-{[3-(aminosulfonyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide; 3-{[6-({3-[(methylamino)sulfonyl]phenyl}am
methylethyl)benzenesulfonamide;
3- ({6-[(4-acetylphenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide; A/-methyl-3-[(6-{[4-(methylsulfonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/\/-(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)acetamide;
/\/-(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)propanamide;
4- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- phenylbenzamide;
3-({6-[(1 ,1 -dioxido-2,3-dihydro-1 ,2-benzisothiazol-6-yl)amino]-4-pyrimidinyl}amino)- /V-methylbenzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-2,3-dihydro-1 H-indol-6-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-3-[6-(2-methyl-benzothiazol-5-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
/V-methyl-3-({6-[(3-nitrophenyl)amino]-4-pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-[(6-{[4-(4-morpholinylcarbonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
3-[6-(2,3-dihydro-benzo[1 ,4]dioxin-6-ylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
A/-methyl-3-[(6-{[4-(methyloxy)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[4-(4-morpholinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[4-(1 , 1-dimethylethyl)phenyl]amino}-4-pyrimidinyl)amino]-A/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[3-(4-morpholinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3-bromo-5-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-[(6-{[4-(dimethylamino)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide; 3-[(6-{[3-(dimethylamino)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
methyl 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoate;
1-methylethyl 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoate;
3-({6-[(4-chloro-3-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-fluoro-3-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-{[6-(1 H-indol-6-ylamino)-4-pyrimidinyl]amino}-/V-methylbenzenesulfonamide;
/V-methyl-3-{[6-({3-[(methylsulfonyl)amino]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-({6-[(3-methyl-1 H-indazol-6-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(4-{[2-(diethylamino)ethyl]oxy}phenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
1-methylethyl [(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)oxy]acetate;
3-[6-(benzothiazol-6-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-benzenesulfonamide;
3-[6-(1 /-/-indol-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-benzenesulfonamide;
3-{[6-(1 ,3-benzothiazol-5-ylamino)-4-pyrimidinyl]amino}-A/- methylbenzenesulfonamide;
3-({6-[(3-fluoro-4-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide ;
3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methylbenzenesulfonamide;
3-[(6-{[3-fluoro-4-(trifluoromethyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(methyloxy)-3-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-chloro-3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-[(6-{[3-fluoro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-methyl-3-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide; 3- [(6-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-(methylthio)-3-({6-[(2-oxo-1 ,2,3,4-tetrahydro-7-quinolinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
4- [(6-{[5-[(methylamino)sulfonyl]-2-(methylthio)phenyl]amino}-4- pyrimidinyl)amino]benzoic acid;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(diethylamino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino^
methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-(2-methyl-1 - pyrrolidinyl)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/,4- dimethylbenzenesulfonamide;
3- (6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(isobutylthio)-/\/- methylbenzenesulfonamide;
4- (isobutylthio)-/V-methyl-3-(6-(4-(trifluoromethyl)phenylamino)pyrimidin-4- ylamino)benzenesulfonamide;
4-(isobutylthio)-3-(6-(4-isopropylphenylamino)pyrimidin-4-ylamino)-/\/- methylbenzenesulfonamide;
3-{[6-({4-[(difluoromethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}-/V-methyl-4- trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-{[6-({4-[(trifluoromethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(4-cyanophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3- (6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(ethylthio)-/\/- methylbenzenesulfonamide;
4- (ethylthio)-/V-methyl-3-(6-(4-(trifluoromethyl)phenylamino)pyrimidin-4- ylamino)benzenesulfonamide;
4-(ethylthio)-3-(6-(4-isopropylphenylamino)pyrimidin-4-ylamino)-/\/- methylbenzenesulfonamide; 3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-/\/-methyl-4-(2,2,2- trifluoroethylthio)benzenesulfonamide;
/V-methyl-4-(2,2,2-trifluoroethylthio)-3-(6-(4-(trifluoromethyl)phenylamino)pyrimi ylamino)benzenesulfonamide;
3- (6-(4-isopropylphenylamino)pyrimidin-4-ylamino)-/\/-methyl-4-(2,2,2- trifluoroethylthio)benzenesulfonamide;
4- fluoro-/V-methyl-3-{[6-({4-[(trifluoromethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3- {[6-({4-[(difluoromethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}-4-fluoro-/\/- methylbenzenesulfonamide;
4- chloro-/V-methyl-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-cyanophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(1 H-indazol-5-ylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3- (6-(4-(cyanomethyl)phenylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
4- (fert-butylsulfonyl)-3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifluoro-1 , 1- dimethylethyl)oxy]benzenesulfonamide;
3-({6-[(3-bromophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
3-({6-[(3-bromo-4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-[6-(3,4-dimethoxy-phenylamino)-pyrimidin-4-ylami
benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamin benzenesulfonamide;
3-[6-(3,5-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(4-cyano-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide; 3-[6-(benzo[1 ,3]dioxol-5-ylamino)-pyrimidin-4-ylamino]-/V-m
benzenesulfonamide;
3-[6-(benzothiazol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
/V-methyl-3-[6-(2-methyl-benzothiazol-5-ylamino)-pyrimidin-4-ylamino]-4- methylsulfanyl-benzenesulfonamide;
3-[6-(3-chloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide;
3-[6-(3,4-difluoro-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(4-morpholin-4-yl-phenylamino)-pyrimidin-4- ylamino]-benzenesulfonamide;
3-[6-(2,3-dihydro-benzo[1 ,4]dioxin-6-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(4-piperidin-1-yl-phenylamino)-pyrimidin-4-ylami benzenesulfonamide;
3-[6-(3-ethynyl-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamid;
3-[6-(3,5-dichloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-{6-[3-(2-methyl-thiazol-4-yl)-phenylamino]-pyrimidin-4- ylamino}-benzenesulfonamide;
3-(6-(3-methoxy-5-(trifluoromethyl)phenylamino)pyrimidin-4-ylamino)-/V-methyl-4 (methylthio)benzenesulfonamide;
3-[6-(1 /-/-indol-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide;
A/-methyl-4-methylsulfanyl-3-[6-(quinolin-6-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(3-chloro-4-cyano-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(4-[1 ,2,4]triazol-4-ylmethyl-phenylamino)-pyrimidin-4- ylamino]-benzenesulfonamide;
3-[6-(1 H-indazol-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(1 /-/-indol-6-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide; /V-methyl-4-(methylthio)-3-(6-(4-(piperazin-1 ^
ylamino)benzenesulfonamide;
/V-methyl-3-(6-(4-methyl-2-oxo-1 ,2-dihydroquinolin-7-ylamino)pyrimidin-4-ylamino)^ 4-(methylthio)benzenesulfonamide;
3-(6-(1-acetylindolin-6-ylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylthio)benzenesulfonamide;
/V-methyl-3-[6-(2-methyl-4-oxo-4H-chromen-7-ylamino)-pyrimidin-4-ylamino]-4- methylsulfanyl-benzenesulfonamide;
3-[6-(4-cyanomethyl-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfan benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(5-oxo-5,6,7,8-tetrahydro-naphthalen-2-ylamino)- pyrimidin-4-ylamino]-benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(3,4,5-trifluoro-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
/V-methyl-3-[6-(4-methyl-2-oxo-2H-chromen-7-ylamino)-pyrimidin-4-ylamino]-4- methylsulfanyl-benzenesulfonamide;
3-[6-(indan-5-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(1 H-indazol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
/V-methyl-3-(6-(2-methyl-1 ,3-dioxoisoindolin-5-ylamino)pyrimidin-4-ylamino)-4- (methylthio)benzenesulfonamide;
3-[6-(3,5-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
/V-methyl-3-[6-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(3-ethynyl-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide;
3-[6-(benzo[1 ,3]dioxol-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
3-[6-(3-chloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
3-[6-(3,4-difluoro-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamid
/V-methyl-3-[6-(4-piperidin-1 -yl-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(4-cyano-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide; /V-methyl-3-[6-(2-methyl-4-oxo-4H-chromen-7-ylamino)-pyrimidin-4-ylamin benzenesulfonamide;
3-[6-(3,5-dichloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
/V-methyl-3-{6-[3-(2-methyl-thiazol-4-yl)-phenylamino]-pyrimidin-4-ylamino}- benzenesulfonamide;
3-[6-(1 H-indazol-5-ylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide;
A/-methyl-3-[6-(5-oxo-5,6 ,7,8-tetrahydro-naphthalen-2-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(4-cyanomethyl-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
/V-methyl-3-[6-(4-methyl-2-oxo-2H-chromen-7-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(1-acetyl-2,3-dihydro-1 H-indol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl- benzenesulfonamide;
3-[6-(3-methoxy-5-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino]-/V-methyl- benzenesulfonamide;
/V-methyl-3-[6-(4-methyl-2-oxo-1 ,2-dihydro-quinolin-7-ylamino)-pyrimidin-4-ylamin benzenesulfonamide;
A/-methyl-3-[6-(3,4,5-trifluoro-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(indan-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-benzenesulfonamide
3-[6-(4-chloro-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-(propane-2-sulfonyl)- benzenesulfonamide;
3-(6-(3-bromo-5-methylphenylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(1 /-/-indol-6-ylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(3-ethynylphenylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-[6-(indan-5-ylamino)-pyrimidin-4-ylamino]-4-methanesulfonyl-/\/-methyl- benzenesulfonamide;
3- [6-(benzothiazol-6-ylamino)-pyrimidin-4-ylamino]-4-methanesulfonyl-/\/-methyl- benzenesulfonamide;
4- methanesulfonyl-/\/-methyl-3-[6-(5-oxo-5,6,7,8-tetrahydro-naphthalen-2-ylamino)- pyrimidin-4-ylamino]-benzenesulfonamide; /V-methyl-3-(6-(2-methylbenzo[d]thiazol-5-ylamino)pyrimidin-4-ylamino)-4- (methylsulfonyl)benzenesulfonamide;
A/-methyl-4-(methylsulfonyl)-3-[(6-{[4-(1 H-1 ,2,4-triazol-1 -ylmethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3- [6-(1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-4-methanesulfonyl-/V-methyl- benzenesulfonamide;
4- methanesulfonyl-/V-methyl-3-[6-(2-methyl-4-oxo-4H-chromen-7-ylamino)-pyrimidin^ 4-ylamino]-benzenesulfonamide;
5- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-2-fluoro-/\/- methylbenzenesulfonamide;
5-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-2-fluoro-/\/-methyl-4-(1 , 1 , 1 - trifluoropropan-2-yloxy)benzenesulfonamide;
1-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 /-/-indole-6- sulfonamide;
3-[(6-{[3,4-bis(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-({6-[(3,4-dichlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(3,4-dimethylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
/V-methyl-3-[(6-{[3-(1-methylethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[3-(1 , 1-dimethylethyl)phenyl]amino}-4-pyrimidinyl)amino]-A/- methylbenzenesulfonamide;
3-[(6-{[3-(ethyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-({6-[(4-fluorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
A/-methyl-3-[(6-{[3-(1 -pyrrolidinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[3-(4-methyl-1 -piperazinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3,5-dichlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-2,3-dihydro-1 H-indol-5-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide; /V-methyl-3-({6-[(2-oxo-2,3-dihydro-1 ,3-benzoxazol-6-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-2,3-dihydro-1 /-/-benzimidazol-5-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-1 ,2,3,4-tetrahydro-7-quinolinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(3-bromo-5-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
/V-methyl-3-{[6-({4-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
A/-methyl-3-[(6-{[3-(1 -pyrrolidinylmethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-({6-[(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(4-{[2-(dimethylamino)ethyl]oxy}phenyl)amino]-4-pyrimidinyl}am methylbenzenesulfonamide;
/V-methyl-3-{[6-({3-[(4-methyl-1 -piperazinyl)methyl]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
A/-methyl-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[4-(1-methylethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-{[6-({4-[(1 -methylethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-{[6-({4-[(difluoromethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(2-oxo-1-pyrrolidinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[3-chloro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-({6-[(4-cyclopropylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(1 /-/-pyrazol-1-yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide; 3-[(6-{[4-(3,5-dimethyl-1 H-pyrazol-1 -yl)phenyl]amino}-4-pyrimidinyl)amino]-A/- methylbenzenesulfonamide;
3-[(6-{[4-chloro-3-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(2-thienyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-[(6-{[4-(2-methyl-1 H-imidazol-1 -yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[4-(1-methylpropyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-{[6-(6-quinolinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-{[6-({4-[(trifluoromethyl)thio]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-({6-[(4-bromophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(methylthio)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-{[6-({4-[(trifluoromethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(dimethylamino)-/\/- methylbenzenesulfonamide;
4- (dimethylamino)-/\/-methyl-3-({6-[(3-methylphenyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-1-(6-{[4-(trifluoromethyl)phenyl]amino}-4-pyrimidinyl)-2,3-dihydro-1 H- indole-6-sulfonamide;
1-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/V-methyl-1 /-/-benzimidazole-6- sulfonamide ;
3-({6-[(5-bromo-6-methyl-2-pyridinyl)amino]-4-pyn
trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(1 - methylethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-(4- morpholinyl)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methyloxy)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-[ethyl(methyl)amino]-/\/- methylbenzenesulfonamide; 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-hydroxy-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-fluoro-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylthio)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2R)-2- (trifluoromethyl)-1 -pyrrolidinyl]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(3,3-difluoro-1-pyrrolidinyl)-/V^ methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(1 ,3-oxazol-5-yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-({6-[(3-methylphenyl)amino]-4-pyrimidinyl}amino)-4-(4- morpholinyl)benzenesulfonamide;
/V-methyl-4-(methyloxy)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-(methylthio)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3-bromo-5-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methyloxy)benzenesulfonamide;
1-{6-[(3-bromo-5-methylphenyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 /-/- indole-6-sulfonamide;
/V-methyl-3-{[6-({4-[(2,2,2-trifluoroethyl)oxy]phen^^
[(2,2,2-trifluoroethyl)thio]benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide;
/V-methyl-3-{[6-(4-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-{[6-(3-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-({6-[(5-methyl-3-pyridinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-3-{[6-(2-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-5-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}- pyridinesulfonamide; 3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
/V-methyl-3-{[6-(1 ,3-thiazol-2-ylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-({6-[(5-methyl-1 ,3-thiazol-2-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-{[6-(1 ,3,4-thiadiazol-2-ylamino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-{[6-(3-isoquinolinylamino)-4-pyrimidinyl]amino}-/V-methylbenzenesulfonam
/V-methyl-3-{[6-(2-quinolinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-{[6-(1 ,3-oxazol-2-ylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-[(6-{[4-(trifluoromethyl)-1 ,3-thiazol-2-yl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
methyl (2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3- thiazol-4-yl)acetate ;
A/-methyl-3-[(6-{[4-(1-methylethyl)-1 ,3-thiazol-2-yl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-({6-[(4-methyl-1 ,3-oxazol-2-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-4-(methyloxy)-3-{[6-(2-pyridinylamino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methyloxy)benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-3-{[6-(2-pyridinylamino)-4-pyrimidinyl]amino}-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylthio)benzenesulfonamide;
1-{6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 H-indole-^ sulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-^ pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-{[6-(4-pyridinylamino)-4-pyrimidinyl]amino}-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide; 3-({6-[(3-fluoro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-cyano-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-3-{[6-(4-pyrimidinylamino)-4-pyrimidinyl]amino}-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-3-fluoro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[6-(trifluoromethyl)-3-pyridinyl]amin pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(5-chloro-4-methyl-2-pyridinyl)amino]-4-pyrim^
trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(4,5-dichloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-6-methyl-2-pyridinyl)amino]-4-pyrim^
trifluoroethyl)oxy]benzenesulfonamide;
3-(6-(5-isopropylpyridin-2-ylamino)pyrimidin-4-ylamino)-/\/-methyl-4-(2,2,2- trifluoroethoxy)benzenesulfonamide;
3- ({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-4-fluoro-/\/- methylbenzenesulfonamide;
4- fluoro-/\/-methyl-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
4-chloro-3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
/V-methyl-4-(methylsulfonyl)-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-4-(methylsulfonyl)-3-{[6-(6-quinolinylamino)-4- pyrimidinyl]amino}benzenesulfonamide;
3- ({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}a
1-methylethyl)oxy]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoro-1 -methylethyl)oxy]-3-[(6-{[5-(trifluoromethyl)-2- pyridinyl]amino}-4-pyrimidinyl)amino]benzenesulfonamide;
4- (fert-butylsulfonyl)-/V-methyl-3-(6-(5-(trifluoromethyl)pyridin-2-ylamino)pyrim^ ylamino)benzenesulfonamide; 4- (fert-butylsulfonyl)-3-(6-(5-chloropyridin-2-ylam
methylbenzenesulfonamide;
/V-methyl-4-(propane-2-sulfonyl)-3-[6-(5-trifluoro
4-ylamino]-benzenesulfonamide;
3-[6-(5-chloro-pyridin-2-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-(propane-2- sulfonyl)-benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide;
1- [6-(5-chloro-pyridin-2-ylamino)-pyrimidin-4-yl]-3,3-dimethyl-2,3-dihydro-1 H-indole- 6-sulfonic acid methylamide;
5- (6-(5-chloropyridin-2-ylamino)pyrimidin-4-ylamino)-2-fluoro-/V-methyl-4-(1 , 1 , 1- trifluoropropan-2-yloxy)benzenesulfonamide;
5-[6-(5-chloro-pyridin-2-ylamino)-pyrimidin-4-ylamino]-2-fluoro-4-methanesulfonyl-^ methyl-benzenesulfonamide;
5-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}am
trifluoroethyl)oxy]benzenesulfonamide;
2- fluoro-/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-5-[(6-{[5-(trifluoromethyl)-2- pyridinyl]amino}-4-pyrimidinyl)amino]benzenesulfonamide;
3- ({6-[(5-fluoro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3- ({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-4-(ethylsulfonyl)-/\/- methylbenzenesulfonamide;
4- (ethylsulfonyl)-/V-methyl-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(5-cyano-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-({6-[(5-cyano-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifl 1 -methylethyl)oxy]benzenesulfonamide;
2- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3-thi carboxylic acid;
(2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3-thiazol-4- yl)acetic acid ;
1-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/V-methyl-1 H-indole-6-sulfonamide;
3- {6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/\/-methyl-2-oxo-2,3-dihydro-1 /-/- benzimidazole-5-sulfonamide; 3-{[6-({3-[6-(dimethylamino)-3-pyridinyl]phenyl}amino
methylbenzenesulfonamide;
A/-methyl-3-({6-[(5-methyl-3-biphenylyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-[(6-{[3-methyl-5-(3-pyridinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[3'-(dimethylamino)-3-biphenylyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
/V-methyl-3-[(6-{[4'-(4-morpholinyl)-3-biphenylyl]amino}-4-pyrimidinyl)amino]- benzenesulfonamide;
/V-methyl-3-{[6-({3-[6-(methyloxy)-3-pyridinyl]phenyl}am
benzenesulfonamide;
3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-4- biphenylcarboxamide;
/V-methyl-3-{[6-({3-[5-(methyloxy)-3-pyridinyl]phenyl}amino)-4-pyrimidinyl]amino}^ benzenesulfonamide;
3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-3- biphenylcarboxamide;
A/-methyl-3-{[6-({3'-[(methylsulfonyl)amino]-3-biphenylyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-[(6-{[4'-(dimethylamino)-3-biphenylyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
/V-methyl-3-{[6-({3-[4-(methyloxy)-3-pyridinyl]phenyl}amino)-4-pyrimidinyl]amino}- benzenesulfonamide;
/V-(3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-4- biphenylyl)acetamide;
/V-methyl-3-{[6-({4'-[(methylsulfonyl)amino]-3-biphenylyl}amino)-4-pyrimidinyl]amino benzenesulfonamide;
/\/-(3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-3- biphenylyl)acetamide;
A/-methyl-3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-4- biphenylsulfonamide;
A/-methyl-3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-3- biphenylsulfonamide;
3-[(6-{[4-chloro-3-(3-pyridinyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide; 2'-chloro-5'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]ami biphenylcarboxamide;
3- [(6-{[6-chloro-3'-(4-morpholinyl)-3-biphenylyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
4- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzoic acid; [(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)oxy]acetic acid;
/V,/V-dimethyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
/V,/V-dimethyl-2-[(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)oxy]acetamide;
/V-(2-hydroxyethyl)-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
A/-methyl-3-{[6-({4-[(4-methyl-1 -piperazinyl)carbonyl]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/-(1 -methyl-4- piperidinyl)benzamide;
A/-methyl-3-[(6-{[4-(1 -piperazinylcarbonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-[(6-{[4-({4-[2-(methyloxy)ethyl]-1-piperazinyl}carbonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/-[2- (methyloxy)ethyl]benzamide;
4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/-[3- (methyloxy)propyl]benzamide;
/V-[2-(dimethylamino)ethyl]-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
/V,/V-diethyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
A/-methyl-3-[(6-{[4-(1 -pyrrolidinylcarbonyl)phenyl]amino}- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-{[(3S)-3-(dimethylamino)-1 -pyrrolidinyl]carbonyl}phenyl)amino]-4- pyrimidinyl}amino)-/\/-methylbenzenesulfonamide;
A/-methyl-3-{[6-({4-[(4-methylhexahydro-1 H-1 ,4-diazepin-1 - yl)carbonyl]phenyl}amino)-4-pyrimidinyl]amino}benzenesulfonamide; /V-methyl-3-[(6-{[4-(4-thiomorpholinylcarbonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-{[6-({4-[(4,4-difluoro-1 -piperidinyl)carbonyl]phenyl}am
methylbenzenesulfonamide;
3-({6-[(4-{[(3R)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl}phenyl)amino]-4- pyrimidinyl}amino)-/\/-methylbenzenesulfonamide;
/V-[2-(dimethylamino)ethyl]-/V-methyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}am 4-pyrimidinyl]amino}benzamide;
/V-[2-(dimethylamino)ethyl]-/V-methyl-4-[(6-{[5-[(methylamino)sulfonyl]-2- (methylthio)phenyl]amino}-4-pyrimidinyl)amino]benzamide;
/\/-[(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)carbonyl]glycine;
A/-methyl-3-[(6-{[3-(6-oxo-1 ,6-dihydro-3-pyridinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3-hydroxyphenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonami
/V-methyl-4-(methylsulfonyl)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(isobutylsulfonyl)-/\/- methylbenzenesulfonamide;
3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(ethylsulfonyl)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifluoro-1 - methylethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifluoro-1 - methylethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl^
1 -methylethyl)oxy]benzenesulfonamide; and
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-tri 1 -methylethyl)oxy]benzenesulfonamide;
Representative compounds of this invention include the compounds of Examples
1 -380. The compounds according to Formula I may contain one or more asymmetric centers (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral centers, such as chiral carbon atoms, may also be present in a substituent such as an alkyl group. Where the stereochemistry of a chiral center present in Formula I, or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof. Thus, compounds according to Formula I containing one or more chiral center may be used as racemic mixtures, enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers.
Individual stereoisomers of a compound according to Formula I which contain one or more asymmetric centers may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1 ) by formation of
diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent. The skilled artisan will appreciate that where the desired stereoisomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired form. Alternatively, specific stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
When a disclosed compound or its salt is named or depicted by structure, it is to be understood that the compound or salt, including solvates (particularly, hydrates) thereof, may exist in crystalline forms, non-crystalline forms or a mixture thereof. The compound or salt, or solvates (particularly, hydrates) thereof, may also exhibit
polymorphism (i.e. the capacity to occur in different crystalline forms). These different crystalline forms are typically known as "polymorphs." It is to be understood that when named or depicted by structure, the disclosed compound, or solvates (particularly, hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
For solvates of the compounds of the invention, or salts thereof, that are in crystalline form, the skilled artisan will appreciate that pharmaceutically-acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice. Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates." Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes all such solvates.
Because of their potential use in medicine, the salts of the compounds of Formula I are preferably pharmaceutically acceptable. The compounds of this invention are bases, wherein a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid, such as glucuronic acid or galacturonic acid, alpha-hydroxy acid, such as citric acid or tartaric acid, amino acid, such as aspartic acid or glutamic acid, aromatic acid, such as benzoic acid or cinnamic acid, sulfonic acid, such as p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or the like. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1 ,6- dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates,
hydroxybenzoates, methoxybenzoates, phthalates, phenylacetates, phenylpropionates, phenylbutrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates mandelates, and sulfonates, such as xylenesulfonates, methanesulfonates, propanesulfonates, naphthalene-1 -sulfonates and naphthalene-2-sulfonates.
Salts of the disclosed compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base. Such a
pharmaceutically acceptable salt may be made with a base which affords a
pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, Λ/,Λ/'-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2- hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine,
dehydroabietylamine, /V,/V'-i)/sdehydroabietylamine, glucamine, /V-methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine.
If an inventive basic compound is isolated as a salt, the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pKa than the free base form of the compound. Similarly, if a disclosed compound containing a carboxylic acid or other acidic functional group is isolated as a salt, the corresponding free acid form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic acid, suitably an inorganic or organic acid having a lower pKa than the free acid form of the compound.
General Methods of Preparation
The compounds of Formula I may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist. The synthesis provided in these Schemes are applicable for producing compounds of the invention having a variety of different R1, R2, R3, R4, R5, R6, R7 and R8 groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula I, they are illustrative of processes that may be used to make the compounds of the invention.
Compound names were generated using the software naming program
ACD/Name Pro V6.02 available from Advanced Chemistry Development, Inc., 1 10 Yonge Street, 14th Floor, Toronto, Ontario, Canada, M5C 1T4 (http://www.acdlabs.com/).
As shown in Scheme 1 , the compounds of Formula I can be prepared under a variety of conditions by sequential reaction of an R6-amine and an aryl amine (e.g., Ar- NH-R5) with an activated pyrimidine. The order of the synthetic steps may be varied to arrive at the targeted compound. Additional synthetic manipulation of the functionality present in the amine moieties, as shown in Schemes 2-6, allows for further analog generation. Scheme 1
Figure imgf000042_0001
a) R -NH2, HCI, isopropanol or NMP, 150 °C, μνν b) R -NH2, HCI, isopropanol or isoamylalcohol, reflux c) R6-NH2, Pd2(dba)3, Xantphos, K3P04 or K2C03, 1 ,4- dioxane, μνν, 150 °C d) R6-NH2, Pd(OAc)2, BINAP, Cs2C03, 1 ,4-dioxane, μνν, 150 °C e) Ar-NH-R5, HCI, isopropanol, f-BuOH or NMP, μνν, 150 °C; f) Ar-NH-R5, AgOTf, 1 ,4-dioxane or NMP, μνν, 120-180 °C; g) Ar-NH-R5, HCI or p-TsOH, isopropanol or f-BuOH, reflux, h) Ar-NH-R5, K2C03, THF, μνν, 150 °C.
Scheme 2
Scheme 3
Figure imgf000042_0002
a) HCI, toluene, 145 °C.
Scheme 4
Figure imgf000042_0003
a) BBr3, CH2CI2, RT Scheme 5
Figure imgf000043_0001
a) NH2-X-C02R, HCI, isopropanol, μνν, 150 °C; then NaOH, THF, MeOH, rt or UOH/H2O, MeOH, rt; b) NHR7R8, EDC, HOBT, ;-Pr2NEt, THF, reflux.
Scheme 6
Figure imgf000043_0002
a) TPAP, NMO, 40 °C; b) NaB03.4H20, AcOH, 50 °C
The invention also includes various deuterated forms of the compounds of Formula I. Each available hydrogen atom attached to a carbon atom may be
independently replaced with a deuterium atom. A person of ordinary skill in the art will know how to synthesize deuterated forms of the compounds of Formula I. For example, deuterated alkyl group amines may be prepared by conventional techniques (see for example: methyl-c/3-amine available from Aldrich Chemical Co., Milwaukee, Wl, Cat. No.489, 689-2). Employing such compounds according to Schemes 1 -3 will allow for the preparation of compounds of Formula I in which various hydrogen atoms are replaced with a deuterium atom.
Methods of Use
The present invention is directed to a method of inhibiting TNNI3K which comprises contacting the kinase with a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of a TNNI3K-mediated disease or disorder comprising administering an effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof. As used herein, "patient" refers to a human or other mammal. Specifically, this invention is directed to a method of inhibiting TNNI3K activity, comprising contacting the kinase with an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. For example, TNNI3K activity may be inhibited in mammalian cardiac tissue by administering to a patient in need thereof, an effective amount a compound of Formula I or a pharmaceutically acceptable salt thereof.
The compounds of this invention may be particularly useful for treatment of TNNI3K-mediated diseases or disorders, specifically by inhibition of TNNI3K activity, where such diseases or disorders are selected from heart failure, particularly congestive heart failure; cardiac hypertrophy; and heart failure or congestive heart failure resulting from cardiac hypertrophy. The compounds of this invention may also be useful for the treatment of heart failure or congestive heart failure resulting from myocardial ischemia or myocardial infarction.
A therapeutically "effective amount" is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein. Thus, e.g., a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to modulate or inhibit the activity of TNNI3K such that a disease condition which is mediated by that activity is reduced, alleviated or prevented. The amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pXC5o), efficacy (EC5o), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art. Likewise, the duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or condition and its severity and the specific composition and method being used, but can nevertheless be determined by one of skill in the art.
"Treating" or "treatment" is intended to mean at least the mitigation of a disease condition in a patient, where the disease condition is caused or mediated by TNNI3K. The methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a disease. The compounds of Formula I of this invention may be useful for the treatment of heart failure, particularly congestive heart failure. The compounds of Formula I of this invention may be useful for the treatment of cardiac hypertrophy, and heart failure or congestive heart failure resulting from cardiac hypertrophy, myocardial ischemia or myocardial infarction.
The compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
Parenteral administration refers to routes of administration other than enteral,
transdermal, or by inhalation, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion. Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages. Topical administration includes application to the skin.
The compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
Treatment of TNNI3K-mediated disease conditions may be achieved using the compounds of this invention as a monotherapy, or in dual or multiple combination therapy, such as in combination with other cardiovascular agents, for example, in combination with one or more of the following agents: a beta-blocker, an ACE inhibitor, an angiotensin receptor blocker (ARB), a calcium channel blocker, a diuretic, a renin inhibitor, a centrally acting antihypertensive, a dual ACE/NEP inhibitor, an aldosterone synthase inhibitor, and an aldosterone-receptor antagonist, which are administered in effective amounts as is known in the art.
Examples of suitable beta blockers include timolol (such as BLOCARDEN™), carteolol (such as CARTROL™), carvedilol (such as COREG™), nadolol (such as
CORGARD™), propanolol (such as INNOPRAN XL™), betaxolol (such as KERLONE™), penbutolol (such as LEVATOL™), metoprolol (such as LOPRESSOR™ and TOPROL- XL™), atenolol (such as TENORMIN™), pindolol (such as VISKEN™), bisoprolol, bucindolol, esmolol, acebutolol, labetalol, nebivolol, celiprolol, sotalol, and oxprenolol. Examples of suitable ACE inhibitors include alacepril, benazepril, benazaprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipiril, moveltopril, perindopril, quinapril, quinaprilat, ramipril, ramiprilat, spirapril, temocapril, trandolapril, and zofenopril. Preferred ACE inhibitors are benazepril, enalpril, lisinopril, and ramipril. Examples of suitable angiotensin receptor blockers include candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan, and valsartan.
Examples of suitable calcium channel blockers include dihydropyridines (DHPs) and non- DHPs. Suitable DHPs include amlodipine, felodipine, ryosidine, isradipine, lacidipine, nicardipine, nifedipine, nigulpidine, niludipine, nimodiphine, nisoldipine, nitrendipine, and nivaldipine, and their pharmaceutically acceptable salts. Suitable non-DHPs are flunarizine, prenylamine, diltiazem, fendiline, gallopamil, mibefradil, anipamil, tiapamil, and verampimil, and their pharmaceutically acceptable salts. A suitable diuretic is a thiazide derivative selected from amiloride, chlorothiazide, hydrochlorothiazide,
methylchlorothiazide, and chlorothalidon. A suitable renin inhibitor is aliskiren. Examples of suitable centrally acting antiphypertensives include clonidine, guanabenz, guanfacine and methyldopa. Examples of suitable dual ACE/NEP inhibitors include omapatrilat, fasidotril, and fasidotrilat. Examples of suitable aldosterone synthase inhibitors include anastrozole, fadrozole, and exemestane. Examples of suitable aldosterone-receptor antagonists include spironolactone and eplerenone.
The invention further includes the use of compounds of the invention as an active therapeutic substance, in particular in the treatment of diseases mediated by TNNI3K. Specifically, the invention includes the use of compounds of the invention in the treatment of heart failure, particularly congestive heart failure; cardiac hypertrophy; heart failure or congestive heart failure resulting from cardiac hypertrophy; and heart failure or congestive heart failure resulting from myocardial ischemia or myocardial infarction.
In another aspect, the invention includes the use of compounds of the invention in the manufacture of a medicament for use in the treatment of the above disorders. Compositions
The compounds of the invention will normally, but not necessarily, be formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically-acceptable excipient.
The pharmaceutical compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection. Alternatively, the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form. For oral application, for example, one or more tablets or capsules may be administered. A dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula I or a salt, particularly a pharmaceutically acceptable salt, thereof). When prepared in unit dosage form, the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
The pharmaceutical compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
As used herein, "pharmaceutically-acceptable excipient" means a material, composition or vehicle involved in giving form or consistency to the composition. Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically-acceptable are avoided. In addition, each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
The compounds of the invention and the pharmaceutically-acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration. Conventional dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition. For example, certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically- acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body. Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents. The skilled artisan will appreciate that certain pharmaceutically-acceptable excipients may serve more than one function and may serve alternative functions depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation.
Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention. In addition, there are a number of resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically-acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
The pharmaceutical compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
Company). In one aspect, the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g. corn starch, potato starch, and pre-gelatinized starch), gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose. The oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
EXAMPLES
The following examples illustrate the invention. These examples are not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the present invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without departing from the spirit and scope of the invention.
the following experimental descriptions, the following abbreviations may be
Figure imgf000049_0001
DDQ 2,3-dichloro-5,6-dicyanobenzoquinone
DMF Λ/,/ν-dimethylformamide
DMSO dimethylsulfoxide
dppf 1 , 1 '-j /s(diphenylphosphino)ferrocene
EDC 1 -[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride
Et3N triethylamine
Et20 diethyl ether
EtOAc ethyl acetate
h hour(s)
HCI hydrochloric acid
HC02H formic acid
HOBt 1-hydroxybenzotriazole
H2S04'S03 fuming sulfuric acid
/-Pr2NEt Λ/,/ν-diisopropylethylamine
KOAc potassium acetate
K3PO4 potassium phosphate tribasic
LCMS liquid chromatography-mass spectroscopy
LiOH lithium hydroxide
MeOH methanol
MgS04 magnesium sulfate
min minute(s)
MS mass spectrum
μνν microwave
NaH sodium hydride
NaHC03 sodium bicarbonate
NaOH sodium hydroxide
Na2S04 sodium sulfate
NH4CI ammonium chloride
HC02-NH4 ammonium formate
NH4OH ammonium hydroxide
NMO 4-methylmorpholine /v-oxide
NMP /v-methyl-2-pyrrolidone
Pd/C palladium on carbon
Pd2(dba)3 f/7's(dibenzylideneacetone)dipalladium(0)
Pd(dppf)CI2 [1 ,1 '-6/s(diphenylphosphino)ferrocene] dichloropalladium(ll)
Pd(Ph3)4 fefra/ /s(triphenylphosphine)palladium(0)
Ph phenyl
POCI3 phosphoryl chloride
It room temperature
satd. saturated
sex strong cation exchange
TBAB tetrabutyl ammonium bromide TFA trifluoroacetic acid
THF tetrahydrofuran
TPAP tetrapropylammonium perruthenate
fe retention time
PREPARATION 1
/V-methyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzenesulfonamide
Figure imgf000051_0001
A mixture of 3-bromo-/V-methylbenzenesulfonamide (2.3 g, 9.0 mmol), 6/'s(pinacolato)diboron (2.5 g, 10.0 mmol), Pd(dppf)CI2 (0.725 g, 0.9 mmol), KOAc (2.6 g, 27 mmol), and dppf (0.700 g, 1 .26 mmol) in 1 ,4-dioxane was heated to 80 °C and stirred overnight under nitrogen. In the morning, the reaction mixture was filtered and concentrated in vacuo. The crude product was then purified via flash column chromatography (4:1 petroleum ether/EtOAc) to give A/-methyl-3-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)benzenesulfonamide as a white solid (1 .7 g, 65%).
PREPARATION 2
3-amino-4-fluoro-/V-methylbenzenesulfonamide
Figure imgf000051_0002
H2, Pd/C
THF
50 °C, 16 h
Figure imgf000051_0003
Step 1. 4-fluoro-3-nitrobenzenesulfonyl chloride
1-Fluoro-2-nitrobenzene (50.0 g, 0.354 mol) was added to chlorosulfonic acid (91 g, 0.778 mol) at 65 °C. The resulting mixture was then heated to 100 °C for 18 h. The mixture was cooled to rt, poured over ice and extracted with CH2CI2. The combined organic layers were then washed with NaHC03, then brine, dried over MgS04, filtered and concentrated in vacuo to afford 4-fluoro-3-nitrobenzenesulfonyl chloride (55.3 g, 65%) as a brown oil.
Step 2. 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide
To a solution of 4-fluoro-3-nitrobenzenesulfonyl chloride (43 g, 179.5 mmol) in THF (500 ml_), was added Et3N (150 ml_, 1.08 mol). The mixture was cooled to -35 °C and < Η3ΝΗ2·Η< Ι (14.5 g, 215.4 mmol) in water was added dropwise. After 1 h, the mixture was warmed to rt and diluted with 1 :1 water/EtOAc. The organic layer was separated and washed with satd. aq. NaHC03, then brine, dried over MgS04, filtered and concentrated in vacuo. The crude residue was purified via flash column chromatography (20% EtOAc/petroleum ether) to give 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide (38 g, 90%) as a yellow solid.
Step 3. 3-amino-4-fluoro-/V-methylbenzenesulfonamide
To a mixture of 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide (1 .6 g, 6.83 mmol) in THF (50 ml.) under nitrogen, Pd/C (0.600 g) was added. The flask was then evacuated and recharged with hydrogen. The resulting mixture was allowed to stir under a hydrogen atmosphere overnight at 50 °C. The mixture was then filtered and concentrated to afford 3-amino-4-fluoro-/V-methylbenzenesulfonamide (1.25 g, 89%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.26 (q, J = 4.85 Hz, 1 H), 7.13 - 7.22 (m, 2H), 6.90 (ddd, J = 2.38, 4.27, 8.41 Hz, 1 H), 5.63 (s, 2H), 2.40 (d, J = 5.02 Hz, 3H); MS (m/z) 205.1 (M+H)+.
PREPARATION 3
3-amino-/V-methyl-4-[(1 -methylethyl)oxy]benzenesulfonamide
Figure imgf000052_0001
Step 1 . A/-methyl-4-[(1 -methylethyl)oxy]-3-nitrobenzenesulfonamide
NaH (0.440 g, 1 1 mmol) was added to 20 mL of isopropanol and the resulting mixture stirred at rt. After 30 min, 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide (2.34 g, 10 mmol) was added. The reaction mixture was then stirred at rt overnight. The mixture was poured into EtOAc and water. The organic phase was separated, dried over Na2S04, and concentrated in vacuo to give the crude product. Purification via flash column chromatography (1 : 1 petroleum ether/ EtOAc) afforded A/-methyl-4-[(1 -methylethyl)oxy]-3- nitrobenzenesulfonamide (1 .6 g, 58%) as a yellow solid. MS (m/z) 274.7 (M+H)+.
Step 2. 3-amino-/V-methyl-4-[(1 -methylethyl)oxy]benzenesulfonamide
To a mixture of A/-methyl-4-[(1 -methylethyl)oxy]-3-nitrobenzenesulfonamide (1 .6 g, 5.8 mmol) in ethanol (20 mL) under nitrogen, Pd/C (0.160 g) was added. The flask was then evacuated and recharged with hydrogen three times. The resulting mixture was allowed to stir under a hydrogen atmosphere overnight at rt. The mixture was then filtered and concentrated to afford 3-amino-/V-methyl-4-[(1 -methylethyl)oxy]benzenesulfonamide (1 .1 g, 77%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.01 - 7.10 (m, 2H), 6.87 - 6.98 (m, 2H), 5.08 (br. s., 2H), 4.63 (dt, J = 5.93, 1 1 .98 Hz, 1 H), 2.34 - 2.41 (m, 3H), 1 .29 (d, J = 6.02 Hz, 6H); MS (m/z) 244.7 (M+H)+.
The following anilines were prepared from 4-fluoro-/V-methyl-3- nitrobenzenesulfonamide using the procedures analogous to those described in Preparation 3:
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
The following anilines were prepared from 1 , 1-dimethylethyl [(4-fluoro-3- nitrophenyl)sulfonyl]methylcarbamate using the procedures analogous to those described in Preparation 3: Conditions for
Aniline Product MS (m/z) Comment
Step 1
312.8
1 , 1-dimethylethyl ({3-amino-4- NaH, 1 ,1 , 1- (M+H)+ Isolated as a mixture of [(2,2,2-trifluoro-1 , 1- trifluoro-2- deprotected protected and
dimethylethyl)oxy]phenyl}sulfonyl methyl-2- 356.9 deprotected material. )methylcarbamate propanol
(M-tBu)+
1 , 1-dimethylethyl [(3-amino-4- NaH,
{[2,2,2-trifluoro-1- 1 , 1 , 1 ,3,3,3- 397.0
(trifluoromethyl)ethyl]oxy}phenyl) hexafluoro-2- (M-tBu)+
sulfonyl]methylcarbamate propanol
PREPARATION 4
3-amino-/V-methyl-4-(4-morpholinyl)benzenesulfonamide
Figure imgf000056_0001
Step 1. A/-methyl-4-(4-morpholinyl)-3-nitrobenzenesulfonamide
To a solution of 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide (2.00 g, 8.54 mmol) and morpholine (0.744 g, 8.54 mmol) in THF (100 mL), was added /'-Pr2NEt (2.21 g, 17.08 mmol). The resulting solution was stirred at 50 °C overnight. In the morning, the reaction mixture was cooled to rt and concentrated to dryness in vacuo. The residue was dissolved in EtOAc and washed with water and brine, dried over MgS04, filtered and concentrated in vacuo to obtain A/-methyl-4-(4-morpholinyl)-3-nitrobenzenesulfonamide (2.5 g, 97%) as a red oil. MS (m/z) 302.0 (M+H)+.
Step 2. 3-amino-/V-methyl-4-(4-morpholinyl)benzenesulfonamide
To a mixture of A/-methyl-4-(4-morpholinyl)-3-nitrobenzenesulfonamide (2.5 g, 8.30 mmol) in THF (100 mL) under nitrogen, Pd/C (0.8 g) was added. The flask was then evacuated and recharged with hydrogen three times. The resulting mixture was allowed to stir under a hydrogen atmosphere at 50 °C overnight. The mixture was then filtered and concentrated to afford 3-amino-/V-methyl-4-(4-morpholinyl)benzenesulfonamide (1.98 g, 88%). 1H NMR (400 MHz, DMSO-d6) δ 7.07 - 7.17 (m, 2H), 7.01 (d, J = 8.28 Hz, 1 H), 6.94 (dd, J = 1 .88, 8.16 Hz, 1 H), 5.20 (s, 2H), 3.72 - 3.81 (m, 4H), 2.80 - 2.89 (m, 4H), 2.38 (d, J = 4.77 Hz, 3H); MS (m/z) 272.2 (M+H)+.
The following anilines were prepared from 4-fluoro-/V-methyl-3- nitrobenzenesulfonamide and the indicated amine using the procedures analogous to those described in Preparation 4:
Figure imgf000057_0001
Figure imgf000058_0001
PREPARATION 5
-amino-/V-methyl-4-(methylthio)benzenesulfonamide
Figure imgf000058_0002
Step 1. /V-methyl-4-(methylthio)-3-nitrobenzenesulfonamide
To a solution of 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide (15 g, 64.01 mmol) in THF (150 mL), was added 20% CH3SNa (22.4 g, 64.01 mmol) dropwise. The resulting mixture was then stirred overnight. In the morning, the mixture was poured into EtOAc and water, the organic phase separated, dried over Na2S04, filtered and concentrated. The crude material was then purified via flash column chromatography (1 :1 EtOAc/petroleum ether) to afford A/-methyl-4-(methylthio)-3-nitrobenzenesulfonamide (3.29 g, 19%) as a yellow solid. MS (m/z) 262.7 (M+H)+.
Step 2. 3-amino-/V-methyl-4-(methylthio)benzenesulfonamide
To a solution of A/-methyl-4-(methylthio)-3-nitrobenzenesulfonamide (1 .0 g, 3.81 mmol) in 10 mL of ethanol and 10 mL of NH4CI, zinc dust (2.5 g, 3.81 mmol) was added. The reaction mixture was stirred overnight at rt. The mixture was then filtered and diluted with EtOAc and water. The organic phase was separated, washed with water and brine, dried over MgS04, filtered and concentrated to afford 3-amino-/V-methyl-4- (methylthio)benzenesulfonamide (0.500 g, 56%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.06 (d, J = 8.03 Hz, 1 H), 6.86 (s, 1 H), 6.67 - 6.76 (m, 1 H), 5.28 (br. s., 2H), 2.17 (s, 3H), 2.21 (s, 3H); MS (m/z) 232.7 (M+H)+.
PREPARATION 6
3-amino-4-(ethylthio)-/V-methylbenzenesulfonamide
Figure imgf000059_0001
Step 1 : 4-(ethylthio)-/V-methyl-3-nitrobenzenesulfonamide
Sodium ethyl thiolate (1.08 g, 12.8 mmol) was added to a mixture of 4-fluoro-/V- methyl-3-nitrobenzenesulfonamide (2 g, 8.6 mmol) in THF (20 mL) and the mixture stirred at rt for 5 h. Water was added to the reaction and extracted with EtOAc. The organic phases were combined, dried (Na2S04) and concentrated to give 4-(ethylthio)-/V-methyl-3- nitrobenzenesulfonamide (2.0 g, 85%) as a yellow solid. MS (m/z) 276.9 (M+H)+.
Step 2: 3-amino-4-(ethylthio)-/V-methylbenzenesulfonamide
Sodium borohydride (1 .1 g, 29 mmol) was added to a mixture of 4-(ethylthio)-/V- methyl-3-nitrobenzenesulfonamide (2.0 g, 7.3 mmol) and nickel (II) chloride hexahydrate (3.4 g, 14.5 mmol) in MeOH (20 ml.) and the mixture stirred for 5 min at 0 °C. The MeOH was then removed and the residual solid suspended in CH2CI2, filtered and the filtrate concentrated to give 3-amino-4-(ethylthio)-/V-methylbenzenesulfonamide (1 .5 g, 84%) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1 .16 (t, J=7.28 Hz, 3 H) 2.38 (d, J=4.85 Hz, 3 H) 2.85 (q, J=7.28 Hz, 2 H) 5.60 (br. s, 2 H) 6.87 (dd, J=7.94, 1 .98 Hz, 1 H) 7.08 (d, J=1 .98 Hz, 1 H) 7.26 (q, J=5.07 Hz, 1 H) 7.33 (d, J=8.16 Hz, 1 H); MS (m/z) 246.9 (M+H)+.
The following anilines were prepared from 4-fluoro-/V-methyl-3- nitrobenzenesulfonamide and the indicated thiol using the procedures described in Preparation 6:
Figure imgf000060_0001
Figure imgf000061_0001
PREPARATION 7
3-amino-4-hydroxy-/\/-methylbenzenesulfonamide
Figure imgf000061_0002
Step 1 . 4-hydroxy-/V-methyl-3-nitrobenzenesulfonamide
A suspension of 4-hydroxy-3-nitrobenzenesulfonyl chloride (0.749 g, 3.15 mmol) and DMAP (0.077 g, 0.630 mmol) in THF (7.880 mL) was treated with CH3NH2 (2 M in THF, 6.30 mL, 12.61 mmol). The resulting mixture was then stirred at rt overnight. The mixture was then filtered and the filtrate partitioned between CH2CI2 and satd. aq. NaHC03. The layers were separated by hydrophobic frit. The aq. layer was then extracted at pH 7, pH 5 (twice), and pH 2. The pH 5 and pH 2 extracts were then combined and concentrated to afford 4-hydroxy-/V-methyl-3-nitrobenzenesulfonamide (0.31 1 g, 42%) as a pale yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 12.09 (br. s., 1 H), 8.22 (d, J = 2.52 Hz, 1 H), 7.88 (dd, J = 2.27, 8.81 Hz, 1 H), 7.53 (q, J = 4.95 Hz, 1 H), 7.31 (d, J = 8.81 Hz, 1 H), 2.42 (d, J = 5.04 Hz, 3H); MS (m/z) 232.8 (M+H)+.
Step 2. 3-amino-4-hydroxy-/V-methylbenzenesulfonamide
A solution of 4-hydroxy-/V-methyl-3-nitrobenzenesulfonamide (0.280 g, 1 .206 mmol) in ethanol (0.269 mL) was added to a mixture of HC02 «NH4 (0.380 g, 6.03 mmol) and Pd/C (0.128 g, 0.121 mmol) in ethanol (0.269 mL) and the reaction heated to 80 °C. Once the reaction mixture reached 80 °C, it was allowed to cool to rt and stand overnight. The mixture was then filtered through Celite® and concentrated to give 3-amino-4-hydroxy-/V- methylbenzenesulfonamide (0.177 g, 73%) as a brown oil. 1H NMR (400 MHz, DMSO-d6) δ 9.88 (br. s., 1 H), 7.00 (d, J = 2.01 Hz, 2H), 6.80 - 6.87 (m, 1 H), 6.75 (d, J = 8.28 Hz, 1 H), 4.97 (br. s., 2H), 2.35 (d, J = 4.77 Hz, 3H); MS (m/z) 202.9 (M+H)+.
PREPARATION 8
3-amino-4-chloro-/\/-methylbenzenesulfonamide
Figure imgf000062_0001
Step 1. 4-chloro-/V-methyl-3-nitrobenzenesulfonamide
A solution of 4-chloro-3-nitrobenzenesulfonyl chloride (10 g, 39.1 mmol) in THF (100 mL) was cooled to -40 °C before being treated with a solution of ΟΗ3ΝΗ2·ΗΟΙ (2.64 g, 39.1 mmol) in 10 mL of water followed by TEA (5.44 mL, 39.1 mmol). The reaction mixture was stirred and allowed to warm to rt over 1 h before being partitioned between 350 mL EtOAc and 30 mL brine. The organic layer was washed twice with brine, dried over MgS04 and subjected to flash chromatography (330 g silica gel, 0-40% EtOAc/hexane) to afford 4-chloro-/V-methyl-3-nitrobenzenesulfonamide (6.38 g, 65%) as a light yellow solid. MS (m/z) 251 .0 (M+H)+.
Step 2. 3-amino-4-chloro-/V-methylbenzenesulfonamide
A solution of 4-chloro-/V-methyl-3-nitrobenzenesulfonamide (6.35 g, 25.3 mmol) in EtOH (150 mL) and water (50.0 mL) was treated with iron (14.15 g, 253 mmol) and NH4CI (13.55 g, 253 mmol) and heated at 90 °C for 4 h before being cooled and filtered through Celite®. The filter cake was washed with EtOAc and the combined filtrate was filtered again to remove precipitated NH4CI before being concentrated. The resulting crude material was partitioned between 350 mL EtOAc and 50 mL saturated aq. NaHC03. The organic layer was washed with brine, dried over MgS04, concentrated and subjected to flash column chromatography (330 g silica gel, 0-15% EtOAc/CH2CI2) to afford 3-amino-4- chloro-/V-methylbenzenesulfonamide (5.604 g, 100%) as a light yellow crystalline solid. 1H NMR (400 MHz, MeOD) δ ppm 7.39 (d, J=8.28 Hz, 1 H), 7.27 (d, J=2.26 Hz, 1 H), 7.03 (dd, J=8.28, 2.26 Hz, 1 H), 2.54 (s, 3 H). MS 221.0 (M+H)+.
The following aniline was prepared using the stated sulfonyl chloride and procedures analogous to those described in Preparation 7 and 8: Aniline Product Sulfonyl chloride and base in Conditions for MS (m/z)
Step 1 Step 2
3-amino-A/,4- 4-methyl-3-nitrobenzenesulfonyl HC02'NH4, 201 .0 dimethylbenzenesulfonamide chloride, Et3N Pd/C (M+H)+
PREPARATION 9 -/V-methyl-4-[methyl(2,2,2-trifluoroethyl)amino]benzenesulfonamid
Figure imgf000063_0001
Step 1 . phenylmethyl [(4-fluoro-3-nitrophenyl)sulfonyl]methylcarbamate
A solution of 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide (2 g, 8.54 mmol) in THF (20 ml.) was treated with Et3N (2.380 ml_, 17.08 mmol) followed by dropwise addition of benzyl chloroformate (3.75 ml_, 1 1 .10 mmol). The mixture was stirred at 25 °C for 5 h before being concentrated. The residue was treated with water and extracted with CH2CI2. The organic extracts were washed (brine), dried (Na2S04), concentrated, and subjected to flash chromatography (25-50% EtOAc-hexanes) to give a yellow solid, which was suspended in EtOAc-hexanes, collected by filtration, and washed with hexanes to give phenylmethyl [(4-fluoro-3-nitrophenyl)sulfonyl]methylcarbamate (1 g, 32%) as a white solid. MS (m/z) 391.0 (M+Na)+.
Step 2. phenylmethyl methyl({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl) carbamate
A solution of phenylmethyl [(4-fluoro-3-nitrophenyl)sulfonyl]methylcarbamate (1 g,
2.71 mmol) in THF (10 ml.) at 25 °C was treated with 2,2,2-trifluoroethylamine (0.592 g,
5.97 mmol) and stirred for 20 h before being concentrated to give a yellow oil, which was dissolved in EtOAc / hexanes. A yellow precipitate formed, which was collected by filtration and washed with hexanes to give phenylmethyl methyl({3-nitro-4-[(2,2,2- trifluoroethyl)amino]phenyl}sulfonyl)carbamate (1 .07 g, 88%) as a yellow solid. MS (m/z) 448.1 (M+H)+.
Step 3. phenylmethyl methyl({4-[methyl(2,2,2-trifluoroethyl)amino]-3-nitrophenyl}sulfonyl) carbamate
A solution of phenylmethyl methyl({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl} sulfonyl)carbamate (1 g, 2.24 mmol) in DMF (1 ml.) at 25 °C was treated with NaH (0.179 g, 4.47 mmol) and stirred for 2 min before being treated with iodomethane (0.42 ml_, 6.71 mmol). After 1 h, the mixture was diluted with water and extracted with EtOAc. The organic extract was washed (brine), dried (Na2S04), concentrated, and subjected to flash chromatography (10-35% EtOAc-hexanes) to give phenylmethyl methyl({4-[methyl(2,2,2- trifluoroethyl)amino]-3-nitrophenyl}sulfonyl) carbamate (539 mg, 52%) as a yellow oil. MS (m/z) 462.1 (M+H)+.
Step 4. 3-amino-/V-methyl-4-[methyl(2,2,2-trifluoroethyl)amino]benzenesulfonamide
A solution of phenylmethyl methyl({4-[methyl(2,2,2-trifluoroethyl)amino]-3- nitrophenyl}sulfonyl)carbamate (539 mg, 1 .17 mmol) in MeOH (10 ml.) at 25 °C was treated with 10% Pd/C (124 mg, 0.1 17 mmol) and stirred under an atmosphere of hydrogen (balloon) overnight before being filtered through Celite®. The filtrate was again filtered through a 0.45 micron syringe filter and concentrated to give 3-amino-/V-methyl-4- [methyl(2,2,2-trifluoroethyl)amino]benzenesulfonamide (320 mg, 92%) as a brown oil. 1H NMR (400 MHz, DMSO-d6) δ ppm 7.14 - 7.20 (m, 2 H), 7.12 (d, J=2.26 Hz, 1 H), 6.95 (dd, J=8.28, 2.26 Hz, 1 H), 5.23 (s, 2 H), 3.82 (q, J=9.87 Hz, 2 H), 2.83 (s, 3 H), 2.39 (d, J=5.02 Hz, 3 H). MS (m/z) 298.0 (M+H)+.
PREPARATION 10
5-amino-2-fluoro-/\/-methylbenzenesulfonamide
Figure imgf000065_0001
Step 1. 2-fluoro-5-nitrobenzenesulfonyl chloride
A mixture of 1 -fluoro-4-nitrobenzene (3.0 g, 21 .3 mmol) in chlorosulfonic acid (5.5 mL, 84 mmol) was stirred at 90-100 °C for 8 h before being cooled to rt and slowly poured into ice water and extracted with EtOAc. The organic extract was washed with saturated aq. NaHC03 and water, dried (Na2S04), and concentrated to give 2-fluoro-5- nitrobenzenesulfonyl chloride (3.2 g, 63%) as a colorless oil, which was used directly in the next step.
Step 2. 2-fluoro-/V-methyl-5-nitrobenzenesulfonamide
A solution of 2-fluoro-5-nitrobenzenesulfonyl chloride (3.2 g, 12.6 mmol) in THF (30 mL) at -45 °C was treated with methylamine hydrochloride (1.0 g, 15.1 mmol) and Et3N (2.1 mL, 15.1 mmol) and stirred for 30 min. The mixture was then treated with 6M aq. HCI to adjust the pH to 3 and warmed to rt before being diluted with water and extracted with EtOAc. The organic extract was dried (Na2S04), concentrated, and subjected to flash chromatography (5-20% EtOAc-petroleum ether) to give 2-fluoro-/V- methyl-5-nitrobenzenesulfonamide as a yellow solid (3.0 g, 93%). MS (m/z) 235.1 (M+H)+.
Step 3. 5-amino-2-fluoro-/V-methylbenzenesulfonamide
A solution of 2-fluoro-/V-methyl-5-nitrobenzenesulfonamide (3.0 g, 12.8 mmol) in MeOH (40 mL) was treated with 10% Pd/C (300 mg, 0.28 mmol) and stirred under hydrogen (40 psi) f o 8 h before being filtered through Celite® and concentrated to give 5- amino-2-fluoro-/V-methylbenzenesulfonamide (2.5 g, 96%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 7.40 - 7.49 (m, 1 H), 7.01 - 7.09 (m, 1 H), 6.94 (dd, J=5.95, 2.87 Hz, 1 H), 6.71 - 6.77 (m, 1 H), 5.49 (br. s., 2 H), 2.45 (d, J=4.85 Hz, 3 H). MS (m/z) 205.1 (M+H)+.
The following anilines were prepared from the indicated nitrobenzenes using procedures analogous to those described in Preparation 10:
Figure imgf000066_0002
PREPARATION 1 1
5-amino-4-(dimethylamino)-2-fluoro-/\/-methylbenzenesulfonamide
Figure imgf000066_0001
Step 1. 2,4-difluoro-5-nitrobenzenesulfonyl chloride
A mixture of 2, 4-difluoro-1 -nitrobenzene (20 g, 126 mmol) in chlorosulfonic acid (44 g, 378 mmol) was stirred at 100 °C for 48 h before being poured into ice-water and extracted with EtOAc. The organic extract was dried (Na2S04) and concentrated, and the residue was triturated with 10% EtOAc-petroleum ether to give 2,4-difluoro-5- nitrobenzenesulfonyl chloride as a brown oil (21 g, 81 %) which was used directly in the next step.
Step 2. 2,4-difluoro-/V-methyl-5-nitrobenzenesulfonamide
A solution of 2,4-difluoro-5-nitrobenzenesulfonyl chloride (21 g, 81 mmol) in THF (400 mL) at -60 °C was treated with methylamine hydrochloride (6.6 g, 97 mmol) and then treated dropwise with Et3N (22.6 mL, 162 mmol). After stirring for 6 h at -60 to -40 °C the mixture was adjusted to pH 3 with the addition of 15% aq. HCI, diluted with water, and extracted with EtOAc. The organic extracts were dried (Na2S04), concentrated, and subjected to flash chromatography (17% EtOAc-petroleum ether) to give 2,4-difluoro-/V- methyl-5-nitrobenzenesulfonamide (8 g, 38%) as a brown solid.
1H NMR (400 MHz, CDCI3) δ ppm 8.66 - 8.74 (m, 1 H), 7.20 - 7.25 (m, 1 H), 4.81 - 4.91 (m, 1 H), 2.78 - 2.81 (m, 3 H).
Step 3. 4-(dimethylamino)-2-fluoro-/\/-methyl-5-nitrobenzenesulfonamide
A solution of 2,4-difluoro-/V-methyl-5-nitrobenzenesulfonamide (8.0 g, 31 .6 mmol) in CH2CI2 (200 mL) at -20 °C was treated with dimethylamine hydrochloride (2.56 g, 31.6 mmol). The resulting mixture was treated dropwise with Et3N and stirred for 1 h before being treated with 15% aq. HCI to adjust the pH, diluted with water, and extracted with EtOAc. The organic extract was dried (Na2S04), concentrated, and subjected to flash chromatography (20-50% EtOAc-petroleum ether) to give 4-(dimethylamino)-2-fluoro-/\/- methyl-5-nitrobenzenesulfonamide (4.0 g, 46%) as a yellow solid. MS (m/z) 278.1 (M+H)+.
Step 4. 5-amino-4-(dimethylamino)-2-fluoro-/\/-methylbenzenesulfonamide
A solution of 4-(dimethylamino)-2-fluoro-/\/-methyl-5-nitrobenzenesulfonamide (4.0 g, 14.3 mmol) in MeOH (100 mL) was treated with 10% Pd/C (400 mg) and stirred under H2 (50 psi) for 16 h before being filtered, concentrated, and subjected to flash chromatography (33-50% EtOAc-petroleum ether) to give 5-amino-4-(dimethylamino)-2- fluoro-/V-methylbenzenesulfonamide as a white solid (2.5 g, 71 %). 1H NMR (400 MHz, CDCI3) δ ppm 7.13 (d, J=7.28 Hz, 1 H), 6.75 (d, J=1 1.69 Hz, 1 H), 4.58 (q, J=4.85 Hz, 1 H), 3.87 (br. s., 2 H), 2.66 (d, J=5.51 Hz, 3 H). MS (m/z) 248.1 (M+H)+. PREPARATION 12
5-amino-2-fluoro-/V-methyl-4-(methylthio)benzenesulfonamide
Figure imgf000068_0001
Step 1 : 2-fluoro-/V-methyl-4-(methylthio)-5-nitrobenzenesulfonamide
A mixture of 2,4-difluoro-/\/-methyl-5-nitrobenzenesulfonamide (2 g, 7.9 mmol) and pyridine (1 .25 g, 15.9 mmol) in MeOH (1 ml.) was cooled to 0 °C. Sodium methanethiolate (21 %, 2.92 g, 8.6 mmol) was then added slowly and the mixture stirred at 0 °C for 30 min. The recation was then diluted by the addition of CH2CI2. The organic was separated and washed with brine, dried (Na2S04) and then concentrated. The crude was combined with another batch of material and recrystallised from CH2CI2/petroleum ether to give 5-amino- 2-fluoro-/V-methyl-4-(methylthio)benzenesulfonamide as a yellow solid. MS (m/z) 281 .0 (M+H)+.
Step 2: 5-amino-2-fluoro-/V-methyl-4-(methylthio)benzenesulfonamide
To a solution of 2-fluoro-/V-methyl-4-(methylthio)-5-nitrobenzenesulfonamide (3 g, 10.7 mmol) in MeOH at 0 °C was added nickel (II) chloride hexahydrate (5. 04 g, 21.4 mmol) and sodium borohydride (1.62 g, 42.8 mmol). After 5 min the MeOH was removed, water added to the residue and the solution extracted with CH2CI2. The CH2CI2was then dried (Na2S04) and concentrated. The residue was combined with that from another batch and purified via flash chromatography (silica gel, 5:1 petroleum ethenEtOAc) to give 5- amino-2-fluoro-/V-methyl-4-(methylthio)benzenesulfonamide (50% over two batches) as a white solid. MS (m/z) 251 .1 (M+H)+.
PREPARATION 13 5-amino-2-fluoro-/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonamid
Figure imgf000069_0001
Step 1. 4-fluoro-1 -nitro-2-[(2,2,2-trifluoroethyl)oxy]benzene
A mixture of 2, 4-difluoro-1 -nitrobenzene (10 g, 62.9 mmol) and 2,2,2- trifluoroethanol (6.29 g, 62.9 mmol) in THF (100 mL) at 25 °C was treated with Cs2C03 (20.5 g, 62.9 mmol) and stirred for 8 h before being diluted with the addition of water and extracted with EtOAc. The organic extract was dried (Na2S04), concentrated, and subjected to flash chromatography (3% EtOAc-petroleum ether) to give 4-fluoro-1-nitro-2- [(2,2,2-trifluoroethyl)oxy]benzene (10 g, 67%) as a yellow solid. MS (m/z) 240.0 (M+H)+.
Step 2. 2-fluoro-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonyl chloride
A mixture of 4-fluoro-1 -nitro-2-[(2,2,2-trifluoroethyl)oxy]benzene (10 g, 41 .8 mmol) in chlorosulfonic acid (82 mL, 125.5 mmol) was stirred at 50 °C for 8 h before being poured into ice and extracted with EtOAc. The organic extracts were dried (Na2S04) and concentrated to give 2-fluoro-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonyl chloride (15 g, crude) as a brown oil, which was used directly in the next step.
Step 3. 2-fluoro-/V-methyl-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonamide
A mixture of 2-fluoro-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonyl chloride (15 g, crude) in THF (150 mL) at -45 °C was treated with methylamine hydrochloride (5.96 g, 89 mmol) and then treated dropwise with Et3N (12.4 mL, 89 mmol). After stirring for 1 h at -45 °C, the mixture was adjusted to pH 3 by the addition of aq. 3M HCI, warmed to rt, diluted with water, and extracted with EtOAc. The organic extract was dried (Na2S04), concentrated, and subjected to flash chromatography (9-17% EtOAc-petroleum ether) to give 2-fluoro-/V-methyl-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonamide (10 g, 72% for two steps) as a yellow solid. MS (m/z) 333.0 (M+H)+. Step 4. 5-amino-2-fluoro-/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonamide
A mixture of 2-fluoro-/V-methyl-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzene- sulfonamide (10 g, 30.1 mmol) in MeOH (150 mL) was treated with 10% Pd/C (1 g) and stirred under H2 (45 psi) at 45 °C for 10 h before being filtered. The filtrate was concentrated to give 5-amino-2-fluoro-/\/-methyl-4-[(2,2,2-trifluoroethyl)oxy]benzene- sulfonamide (8 g, 88%) as a white solid. 1H NMR (400 MHz, DMSO-c/6) δ ppm 7.40 (q, J=5.07 Hz, 1 H), 7.10 (d, J=1 1 .69 Hz, 1 H), 7.05 (d, J=7.28 Hz, 1 H), 5.04 (s, 2 H), 4.83 (q, J=8.82 Hz, 2 H), 2.42 (d, J=4.41 Hz, 3 H). MS (m/z) 303.0 (M+H)+.
The following aniline was prepared from 2, 4-difluoro-1 -nitrobenzene and the indicated alcohol using procedures analogous to those described in Preparation 13:
Figure imgf000070_0002
PREPARATION 14 5-amino-A/-methyl-3-pyridinesulfonamide
Figure imgf000070_0001
Step 1 . 5-bromo-3-pyridinesulfonyl chloride
A mixture of 3-pyridinesulfonyl chloride hydrochloride (8.9 g, 44 mmol) and bromine (14 g, 88 mmol) was heated to 130 °C for 8 h. The mixture was cooled and used directly in the next step.
Step 2. 5-bromo-A/-methyl-3-pyridinesulfonamide
To CH3NH2 (50 mL of a 23-30 weight percent in H20) at 0 °C, was added 5-bromo- 3-pyridinesulfonyl chloride (44 mmol). The mixture was then warmed to rt and stirred for 3 h. The mixture was then extracted with EtOAc and concentrated in vacuo. The crude material was combined with that from an additional experiment (10 mmol scale) run under identical conditions and washed with 10:1 hot petroleum ether/EtOAc to afford 5-bromo-/V- methyl-3-pyridinesulfonamide (2.4 g, 18% combined yield over two steps).
Step 3. 5-amino-/V-methyl-3-pyridinesulfonamide
A mixture of 5-bromo-/V-methyl-3-pyridinesulfonamide (2.4 g, 9.6 mmol), CuCI (0.100 g, 1.01 mmol), and NH4OH (5 mL) was heated to 130 °C for 18 h in a sealed tube. The reaction mixture was then treated with sodium sulfide and extracted with EtOAc. The combined organic extracts were then concentrated in vacuo and the crude material washed with 20:5:3 hot petroleum ether/EtOAc/MeOH to afford 5-amino-/V-methyl-3- pyridinesulfonamide (1.1 g, 61 %) as a brown solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.1 1 (d, J = 2.51 Hz, 1 H), 8.04 (d, J = 1.76 Hz, 1 H), 7.47 (br. s., 1 H), 7.24 (t, J = 2.13 Hz, 1 H), 5.83 (br. s., 2H), 2.44 (s, 3H); MS (m/z) 188.1 (M+H)+.
PREPARATION 15
3-chloro-/V-methyl-5-nitrobenzenesulfonamide
Figure imgf000071_0001
Step 1. 3,5-dinitrobenzenesulfonyl chloride
(3,5-dinitrophenyl)amine (5 g, 27.3 mmol) was added in one portion to a well stirred solution of concentrated HCI (cone.) (20 mL) and 20 mL water and the mixture was cooled to -10 °C before a solution of NaN02 (2.072 g, 30.0 mmol) in water (5 mL) was added dropwise at such a rate that the temperature did not exceed -5 °C. The mixture was stirred for 45 min at -10 °C after the addition. While the diazotization reaction proceeded, a separate well-stirred solution of AcOH (6.67 mL) and 30 mL water was saturated with S02 by bubbling the gas into the solution until all gas introduced emerged to the surface. CuCI (0.676 g, 6.83 mmol) was added to the solution and the introduction of S02 was continued until the yellow-green suspension became blue-green. The S02/CuCI mixture was then cooled to 10 °C before being treated with the diazotization reaction mixture in portions over a 20 min period. The foaming that occurred upon addition was disrupted with a few drops of Et20. After the addition was complete, the dark red mixture was poured into ice-water (100 mL) and stirred until the ice melted before being filtered. The collected solid was dried in air to afford 3,5-dinitrobenzenesulfonyl chloride (6.01 g, 83%) as a red solid that was used directly in the next step.
Step 2. A/-methyl-3,5-dinitrobenzenesulfonamide
A light brown solution of 3,5-dinitrobenzenesulfonyl chloride (7.28 g, 27.3 mmol) in THF (200 mL) was treated with pyridine (100 mL) to give a dark brown solution, which was cooled to -10 °C before methyl amine (in THF) (13.65 mL, 27.3 mmol) was added slowly by syringe. The resulting solution was stirred at rt for 48 h before being concentrated. The crude residue was partitioned between 600 mL EtOAc and 150 mL 1 N HCI. The organic layer was washed twice with 100 mL 1 N HCI, brine (50 mL), dried over MgS04, concentrated, and subjected to flash column chromatography (330 g silica gel, 0-10% EtOAc / CH2CI2) to afford A/-methyl-3,5-dinitrobenzenesulfonamide (1 .98 g, 28%). 1H NMR (400 MHz, MeOD) δ ppm 9.20 (s, 1 H), 8.96 (d, J=2.01 Hz, 2 H), 2.65 (s, 3 H).
Step 3. 3-amino-/V-methyl-5-nitrobenzenesulfonamide
A light red solution of A/-methyl-3,5-dinitrobenzenesulfonamide (1.98 g, 7.58 mmol) in ethanol (120 mL) was treated with a solution of ammonium sulfide (2.58 g, 37.9 mmol) in water (15 mL). The resulting dark red solution was heated at 80 °C before being filtered, concentrated, and extracted three times with EtOAc (100 mL). The organic layer was dried over MgS04, concentrated, and purified by SCX ion exchange column (20 g x 2, washed with MeOH and eluted with 3 M ammonia in MeOH). The appropriate fractions were concentrated to afford a dark brown solid. The aqueous phase contained significant amount of target product, thus, it was concentrated and the residue was re-distributed in 200 mL EtOAc and then concentrated. The resulting brown oil was combined with the above solid and purified by flash column chromatography (120 g silica column, 0-10% MeOH (w/ 0.1 % aq. NH4OH)/CH2CI2) to afford 3-amino-/v-methyl-5- nitrobenzenesulfonamide (0.698 g, 39.8%) as a yellow-brown solid. 1 H NMR (400 MHz, MeOD) δ ppm 7.77 (m, 1 H), 7.62 - 7.69 (m, 1 H), 7.40 (m, 1 H), 2.58 (s, 3 H). MS (m/z) 232.0 (M+H)+. Step 4. 3-chloro-/V-methyl-5-nitrobenzenesulfonamide
3-amino-/\/-methyl-5-nitrobenzenesulfonamide (0.698 g, 3.02 mmol) was added in one portion into a solution of HCI (cone.) (10 mL, 329 mmol) and 10 mL water and the mixture was cooled to -10 °C before a solution of sodium nitrite (0.208 g, 3.02 mmol) in 5 mL water was added dropwise. The resulting mixture was stirred at -10 °C for 30 min before being added slowly into a mixture of CuCI (0.075 g, 0.755 mmol) in 20 mL of concentrated HCI at 4 °C. The reaction mixture was stirred at 0 °C for 15 min before being poured into 150 mL water, filtered, washed with water and dried in air to afford 3- chloro-/V-methyl-5-nitrobenzenesulfonamide (0.510 g, 67.4%) as a light brown solid. 1 H NMR (400 MHz, MeOD) δ ppm 8.55 (m, 2 H), 8.23 (m, 1 H), 2.62 (s, 3 H). MS (m/z) 251 .0 (M+H)+.
PREPARATION 16
3-amino-5-chloro-/V-methylbenzenesulfonamide
Figure imgf000073_0001
A solution of 3-chloro-/V-methyl-5-nitrobenzenesulfonamide (104 mg, 0.415 mmol) in ethanol (10 mL) was treated with tin(ll) chloride (315 mg, 1.660 mmol) and heated at 84 °C for 3 h before being concentrated and subjected to flash column chromatography (40 g silica column, 0-100% EtOAc/Hexane) to afford 3-amino-5-chloro-/V- methylbenzenesulfonamide (63 mg, 68.8%) as a white solid. 1H NMR (400 MHz, MeOD) δ ppm 7.00 (d, J=1 .76 Hz, 1 H), 6.98 (t, J=1.63 Hz, 1 H), 6.86 (t, J=1 .88 Hz, 1 H), 2.55 (s, 3 H). MS (m/z) 221 .0 (M+H)+.
PREPARATION 17
3-amino-5-(dimethylamino)-/V-methylbenzenesulfonamide
Figure imgf000073_0002
Step 1 . 3-(dimethylamino)-/V-methyl-5-nitrobenzenesulfonamide
A mixture of 3-chloro-/V-methyl-5-nitrobenzenesulfonamide (150 mg, 0.598 mmol) and dimethylamine (2 M in water) (1 .496 mL, 2.99 mmol) in DMSO (4 mL) was heated under microwave irradiation at 1 10 °C for 30 min before being subjected to reverse phase HPLC (Sunfire 30x100 C-18 column, 10-50% CH3CN/water (w/ 0.1 % TFA) over 14 min) to afford 69 mg of a light yellow solid. HNMR analysis demonstrated that this solid was 3:1 mixture of starting material and product. Thus, the solid was dissolved in 6 mL DMSO, treated with a solution of dimethylamine (1.5 mL, 2 M aq. solution) and heated at 1 10 °C for 20 h before being partitioned between 120 mL EtOAc and 20 mL brine. The organic layer was dried over MgS04, concentrated, and subjected to flash column chromatography (40 g silica column, 0-40% EtOAc/hexane) to afford 3-(dimethylamino)- A/-methyl-5-nitrobenzenesulfonamide (42 mg, 27.1 %) as a yellow solid. 1H NMR (400 MHz, MeOD) δ ppm 7.84 (d, J=1.51 Hz, 1 H), 7.70 (d, J=2.01 Hz, 1 H), 7.42 (d, J=1.25 Hz, 1 H), 3.14 (s, 6 H), 2.58 (s, 3 H). MS (m/z) 260.0 (M+H)+.
Step 2. 3-amino-5-(dimethylamino)-/V-methylbenzenesulfonamide
A solution of 3-(dimethylamino)-/V-methyl-5-nitrobenzenesulfonamide (42 mg, 0.162 mmol) in MeOH (15 mL) was purged with nitrogen before being treated with Pd/C (1.724 mg, 0.016 mmol) and then placed under a hydrogen balloon. The mixture was stirred at rt for 4 h before being filtered and concentrated to afford 3-amino-5- (dimethylamino)-/V-methylbenzenesulfonamide (38 mg, 0.166 mmol, 102%) as a light brown oil, which was used immediately in the subsequent reaction. MS (m/z) 230.1 (M+H)+.
PREPARATION 18
/V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide
Figure imgf000074_0001
Step 1 . 2,3-dihydro-1 H-indole-6-sulfonic acid
H2S04'S03 (20%, 21 ml_, 0.42 mmol) was cooled to 0 °C. Indoline (5.0 g, 0.042 mmol) was added dropwise such that the temperature of the reaction mixture did not rise above 35 °C. When the addition was complete the mixture was heated to 135 °C for 0.5 h. After cooling, the solution was poured into an ice bath at which time the product crystallized. The mixture was then filtered and washed with water and acetone to give 2,3-dihydro-1 H-indole-6-sulfonic acid (6.9 g, 82%) as a white solid.
Step 2. 1 -acetyl-2,3-dihydro-1 H-indole-6-sulfonic acid
To a slurry of 2,3-dihydro-1 H-indole-6-sulfonic acid (6.9 g, 34.6 mmol) in AcOH (40 ml_), was added acetic anhydride (3.5 g, 34.6 mmol) and pyridine (15 ml_). The mixture was then heated to 100 °C for 24 h before it was cooled and concentrated to afford 1- acetyl-2,3-dihydro-1 H-indole-6-sulfonic acid (8.8 g, 84%) as a brown oil that was used in the next step without further purification.
Step 3. 1 -acetyl-2,3-dihydro-1 H-indole-6-sulfonyl chloride
To a mixture of POCI3 (12.6 g, 153.33 mmol) and one drop of DMF in CH3CN (100 ml_), was added 1 -acetyl-2,3-dihydro-1 H-indole-6-sulfonic acid (8.8 g, 27.5 mmol). The mixture was heated to reflux for 1 h and then concentrated to give a pale yellow oil. The oil was then poured into ice and filtered to give 1 -acetyl-2,3-dihydro-1 H-indole-6-sulfonyl chloride (7.0 g) as a brown solid that was used in the next step without further purification.
Step 4. 1 -acetyl-/V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide
To a solution of 1-acetyl-2,3-dihydro-1 H-indole-6-sulfonyl chloride (7.0 g, 27.0 mmol) in 100 ml. of CH2CI2, 30% aq. methyl amine was added dropwise at a rate such that the internal temperature of the reaction did not rise above 22 °C. The mixture was then stirred for 2 h. The solution was washed with water, then brine, dried over Na2S04, filtered and concentrated in vacuo. The residue was purified via flash column chromatography (1 :1 petroleum ether/EtOAc) to give 1 -acetyl-/V-methyl-2,3-dihydro-1 /-/- indole-6-sulfonamide (5.0 g, 74%) as a brown solid. MS (m/z) 255.3 (M+H)+.
Step 5. /V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide
A slurry of 1-acetyl-/V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide (5.0 g, 19.7 mmol) was purged with HCI gas for 30 min. The solution was then stirred at rt for 2 h before the solution was concentrated in vacuo. The resulting solid was dissolved in satd. aq. NaHC03 and EtOAc. The layers were separated and the organic layer washed with water, then brine, dried over Na2S04, filtered and concentrated in vacuo. The crude material was then purified via flash column chromatography (silica gel, 1 :1 EtOAc/petroleum ether) to afford /V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide (1 .49 g, 32%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.13 - 7.23 (m, 2H), 6.90 (dd, J = 1 .51 , 7.53 Hz, 1 H), 6.77 - 6.83 (m, 1 H), 5.96 (s, 1 H), 3.44 - 3.54 (m, 2H), 2.97 (t, J = 8.66 Hz, 2H), 2.37 (d, J = 5.02 Hz, 3H); MS (m/z) 255.3 (M+H)+.
PREPARATION 19
/V,3,3-trimethyl-2,3-dihydro-1 H-indole-6-sulfonamide
Figure imgf000076_0001
Step 1. /V-(2-methyl-2-propen-1 -yl)-/V-phenylacetamide
/V-phenylacetamide (25.0 g, 185.2 mmol), potassium carbonate (28.1 g, 203.7 mmol), NaOH (8.1 g, 203.7 mmol), TBAB (1.2 g, 3.7 mmol) and toluene (500 mL) were mixed and heated to 75 °C with vigorous stirring. The reaction was stirred for 16 h at 75 - °C. The mixture was then cooled to rt, water was added and the mixture stirred until all the solids had dissolved. The aqueous layer was separated and the toluene layer washed with 5N HCI and water. The solvent was then removed under reduced pressure to give N- (2-methyl-2-propen-1 -yl)-/V-phenylacetamide (30 g, 85%) as an oil. MS (m/z) 255.3 (M+H)+. Step 2. 1 -acetyl-3,3-dimethyl-2,3-dihydro-1 H-indole
/V-(2-methyl-2-propen-1-yl)-/V-phenylacetamide (25.0 g, 131 mmol) was added slowly to a stirred suspension of aluminium trichloride (38.0 g, 289 mmol) in chlorobenzene (25 mL) at 1 15 °C under nitrogen. The temperature was maintained at 1 15-120 °C for the duration of the addition. The reaction was then stirred for 1 h at 1 15- 120 °C then cooled to rt. Toluene was added and the mixture stirred to give a solution. Water was then slowly added at such a rate to maintain the internal temperature to below 45 °C with cooling applied. The organic layer was separated and washed with 6N HCI and then concentrated to give 1-acetyl-3,3-dimethyl-2,3-dihydro-1 /-/-indole (22.0 g, 88%) as a brown solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ ppm 1 .34 (s, 6 H) 2.21 (s, 3 H) 3.76 (s, 2 1-1) 7.01 - 7.06 (m, 1 H) 7.1 1 (s, 1 H) 7.16 - 7.22 (m, 1 H) 8.17 (d, J=8.16 Hz, 1 H)
Step 3. 3,3-dimethyl-2,3-dihydro-1 H-indole
To a solution of 1-acetyl-3,3-dimethyl-2,3-dihydro-1 H-indole (22.0 g, 1 15.8 mmol) in MeOH (100 mL) was added 4M HCI in MeOH (100 mL) and the mixture stirred at 50 °C for 16 h. The solvent was then removed under reduced pressure. Water was added to the residue, the pH was adjusted to pH 8 and the aqueous layer was extracted with EtOAc. The organic layer was then dried (Na2S04), filtered and then concentrated to give 3,3- dimethyl-2,3-dihydro-1 H-indole (16.0 g, 94%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1 .30 (s, 6 H) 3.30 (s, 2 H) 6.62 - 6.66 (m, 1 H) 6.71 - 6.76 (m, 1 H) 7.02 (s, 2 H)
Step 4. 3,3-dimethyl-2,3-dihydro-1 /-/-indole-6-sulfonic acid
A mixture of 3, 3-dimethyl-2,3-dihydro-1 /-/-indole (16.0 g, 109 mmol) in fuming sulphuric acid (60 mL) was stirred at rt for 45 min. The reaction was then heated to 135 °C for 1 h. After cooling the solution was poured into ice water, cooled to -50 °C and allowed to stand for 2 h. The resultant precipitate was collected by filtration to give 3,3- dimethyl-2,3-dihydro-1 H-indole-6-sulfonic acid (7 g, 28 %). MS (m/z) 228.0 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ ppm 1 .31 (s, 6 H) 3.52 (s, 2 H) 7.40 (d, J=7.94 Hz, 1 H) 7.58 (s, 1 H) 7.64 (dd, J=7.83, 1 .43 Hz, 1 H)
Step 5. 1 -acetyl-3,3-dimethyl-2,3-dihydro-1 H-indole-6-sulfonic acid
To a suspension of 3,3-dimethyl-2,3-dihydro-1 /-/-indole-6-sulfonic acid (7.0 g, 30.8 mmol) in AcOH (70 mL) was added acetic anhydride (6.3 g, 61.6 mmol) and pyridine (4.9 g, 61.6 mmol). The mixture was stirred at 80 °C for 1 h. The reaction was concentrated and the residue washed with 10:1 petroleum ether:EtOAc to give 1-acetyl-3,3-dimethyl- 2,3-dihydro-1 H-indole-6-sulfonic acid (9.0 g, 84%) as a brown solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.24 (s, 6 H) 3.81 (s, 2 H) 7.12 (d, J=7.72 Hz, 1 H) 7.27 (d, J=6.84 Hz, 1 H) 8.00 (t, J=6.84 Hz, 2 H) 8.27 (s, 1 H) 8.52 (t, J=7.83 Hz, 1 H) 8.88 (d, J=5.07 Hz, 2 H)
Step 6. 1 -acetyl-3,3-dimethyl-2,3-dihydro-1 /-/-indole-6-sulfonyl chloride
To a solution of 1 -acetyl-3,3-dimethyl-2,3-dihydro-1 /-/-indole-6-sulfonic acid (9.0 g, 25 mmol) in CH3CN (100 ml.) was added POCI3 (1 1.5 g, 75 mmol) and the mixture refluxed for 2 h. The mixture was concentrated and EtOAc and water were added. The layers were separated and the aqueous layer was extracted several times with EtOAc. The combined organics were then dried (Na2S04), filtered and the solvent removed under reduced pressure to give 1-acetyl-3,3-dimethyl-2,3-dihydro-1 H-indole-6-sulfonyl chloride (5.1 g, 64%) which was used directly in the next step. MS (m/z) 288.1 (M+H)+.
Step 7. 1 -acetyl-/V,3,3-trimethyl-2,3-dihydro-1 H-indole-6-sulfonamide
A solution of 1 -acetyl-3,3-dimethyl-2,3-dihydro-1 H-indole-6-sulfonyl chloride (5.1 g, 17.8 mmol) in anhydrous dichloromethane (150 ml.) was added to a solution of methylamine in ethanol (50 ml_, 30 %). The mixture was stirred at rt for 30 min. Water was then added to the mixture and the two layers were separated. The aqueous layer was extracted twice with additional dichloromethane. The combined organics were then dried (Na2S04), filtered and the solvent removed under reduced pressure to give 1 -acetyl-/V,3,3- trimethyl-2,3-dihydro-1 H-indole-6-sulfonamide (4.5 g, 89%) as a brown solid. MS (m/z) 283.0 (M+H)+.
Step 8. A/,3,3-trimethyl-2,3-dihydro-1 /-/-indole-6-sulfonamide
To a solution of 1-acetyl-/V,3,3-trimethyl-2,3-dihydro-1 /-/-indole-6-sulfonamide (4.5 g, 15.9 mmol) in MeOH (45 ml.) was added 4M HCI in MeOH solution (45 ml.) and the mixture stired for 15 h at 50 °C. The mixture was then concentrated. The residue was diluted with EtOAc and the pH adjusted to pH 8. The two layers were separated and the aqueous layer was extracted twice with additional EtOAc. The combined organics were then dried (Na2S04), filtered and the solvent removed under reduced pressure. The residue was then purified via flash column chromatography (silica gel, 5:1 to 2: petroleum ether:EtOAc) to to give A/,3,3-trimethyl-2,3-dihydro-1 H-indole-6-sulfonamide (3.5 g, 76%) as a white solid. MS (m/z) 241.1 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.21 (s, 6 H) 2.36 (d, J=5.07 Hz, 3 H) 3.22 (d, J=1.54 Hz, 2 H) 5.93 (s, 1 H) 6.80 (d, J=1 .76 Hz, 1 H) 6.93 (dd, J=7.61 , 1 .65 Hz, 1 H) 7.12 (d, J=7.72 Hz, 1 H) 7.16 (d, J=5.07 Hz, 1 H) PREPARATION 20
/V-methyl-1 H-indole-6-sulfonamide
Figure imgf000079_0001
A mixture of /V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide (500 mg, 2.356 mmol) in 1 ,4-dioxane (5.889 mL) was treated with DDQ (802 mg, 3.53 mmol) and the reaction stirred for 1 h. The reaction was filtered and the filtrate loaded onto a SCX column (10 g, washed with MeOH followed by 2M ammonia in MeOH). The product eluted in the MeOH wash, and concentration of the appropriate fractions yielded A/-methyl-1 /-/-indole-6- sulfonamide (230 mg, crude) as a brown oil which was used as is as an intermediate.
PREPARATION 21
2-methyl-1 ,2,3,4-tetrahydro-7-isoquinolinamine
Figure imgf000079_0002
Step 1. 2-methyl-7-nitro-1 ,2,3,4-tetrahydroisoquinoline
To a mixture of formaldehyde (26 mL, 944 mmol) and HC02H (15 mL), was added 7- nitro-1 ,2,3,4-tetrahydroisoquinoline (6.32 g, 29.4 mmol). The mixture was heated at 100 °C for 4 h. The reaction was then cooled to rt, poured into ice, and basified to pH 1 1 with aq. ammonia. The gummy residue which precipitated was extracted with CH2CI2 (2 x 150 mL). The combined organic extracts were dried over MgS04, filtered, and concentrated in vacuo. The compound was loaded onto florisil and purified via flash column chromatography (ISCO, 120 g silica, 0-5% HCI/ CH2CI2) to give 2-methyl-7-nitro-1 , 2,3,4- tetrahydroisoquinoline (5 g, 84%) as an orange solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.95 - 8.00 (m, 2H), 7.39 (d, J = 8.81 Hz, 1 H), 3.58 (s, 2H), 2.93 (t, J = 5.79 Hz, 2H), 2.62 (t, J = 5.92 Hz, 2H), 2.36 (s, 3H); MS (m/z) 193.1 (M+H)+. Step 2. 2-methyl-1 ,2,3,4-tetrahydro-7-isoquinolinamine
To a mixture of 2-methyl-7-nitro-1 ,2,3,4-tetrahydroisoquinoline (5 g, 26.0 mmol), in ethanol (87 mL), were added 10% Pd/C (2.77 g, 2.60 mmol) and HC02 «NH4 (8.20 g, 130 mmol). The resulting mixture was then heated to 80 °C for 3 h. The reaction mixture was then cooled to rt, filtered through Celite®, and concentrated in vacuo to afford 2-methyl- 1 ,2,3,4-tetrahydro-7-isoquinolinamine (3.2 g, 72%) as a tan solid. 1H NMR (400 MHz, methanol-d4) δ 6.88 (d, J = 8.06 Hz, 1 H), 6.58 (dd, J = 2.39, 8.18 Hz, 1 H), 6.46 (d, J = 2.01 Hz, 1 H), 3.51 (s, 2H), 2.82 (t, J = 5.92 Hz, 2H), 2.70 (t, J = 6.04 Hz, 2H), 2.43 (s, 3H); MS (m/z) 163.1 (M+H)+.
PREPARATION 22
6-chloro-/V-(3-methylphenyl)-4-pyrimidinamine
Figure imgf000080_0001
A mixture of dichloropyrimidine (0.556 g, 3.73 mmol) and 3-methyl aniline (0.200 g, 1.866 mmol) in isopropanol (1.678 mL) was heated in a microwave reactor at 150 °C for 10 min. The reaction was concentrated and the residue dissolved in CH2CI2 and purified by silica solid phase extraction (5 g column, washed with CH2CI2 and Et20). Concentration of the ethereal fractions yielded 6-chloro-/V-(3-methylphenyl)-4- pyrimidinamine (0.264 g, 61 %) as a cream solid. 1H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 1 H), 8.48 (s, 1 H), 7.38 - 7.46 (m, 2H), 7.25 (t, J = 7.65 Hz, 1 H), 6.92 (d, J = 7.28 Hz, 1 H), 6.79 (s, 1 H), 2.31 (s, 3H); MS (m/z) 220.0 (M+H)+.
The following pyrimidinamines were prepared from 4,6-dichloropyrimidine and the aniline indicated using a procedure analogous to that described in Preparation 22:
Figure imgf000080_0002
3-[(6-chloro-4-pyrimidinyl)arnino]-A/-methyl-4- 3-amino-A/-methyl-4-(2-methyl-1- 382.0 (2-methyl-1-pyrrolidinyl)benzenesulfonamide pyrrolidinyl)benzenesulfonamide (M+H)+
1-(6-chloro-4-pyrimidinyl)-A/-methyl-2,3- A/-methyl-2,3-dihydro-1 H-indole- 325.0 dihydro-1 /-/-indole-6-sulfonamide 6-sulfonamide (M+H)+
5-amino-2-fluoro-A/-methyl-4-
5-[(6-chloro-4-pyrimidinyl)amino]-2-fluoro-A/- [(2,2,2- 415.0 methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfona (M+H)+ trifluoroethyl)oxy]benzenesulfonamide
mide
1-(6-chloro-4-pyrimidinyl)-A/,3,3-trimethyl-2,3- A/,3,3-trimethyl-2,3-dihydro-1 H- 352.9 dihydro-1 /-/-indole-6-sulfonamide indole-6-sulfonamide (M+H)+
1 , 1-dimethylethyl [(3-amino-4-
3-[(6-chloro-4-pyrimidinyl)arnino]-A/-methyl-4- {[2,2,2-trifluoro-1- 424.9 [(2,2,2-trifluoro-1 ,1- (trifluoromethyl)ethyl]oxy}phenyl)s (M+H)+ dimethylethyl)oxy]benzenesulfonamide
ulfonyl]methylcarbamate
PREPARATION 23 6-chloro-/V-(4-chlorophenyl)-4-pyrimidinamine hydrochloride
Figure imgf000081_0001
A mixture of 4,6 dichloropyrimidine (0.584 g, 3.92 mmol), 4-chloroaniline (0.250 g, 1.960 mmol) and a few drops of concentrated HCI in isopropanol (4.899 mL) was heated at 80 °C for 18 h. The reaction turned from a clear yellow solution to one containing a white precipitate. This precipitate was collected by filtration to give 6-chloro-/V-(4- chlorophenyl)-4-pyrimidinamine hydrochloride (0.443 g, 82%). 1H NMR (400 MHz, DMSO-de) δ 10.33 (s, 1 H), 8.50 (s, 1 H), 7.69 - 7.78 (m, J = 8.78 Hz, 2H), 7.36 - 7.43 (m, 2H), 6.93 (s, 1 H).
The following pyrimidinamines were prepared from 4,6-dichloropyrimidine and the aniline indicated using procedures analogous to that described in Preparation 23: Pyrimidinamine Aniline Note MS (m/z)
f-BuOH used as
3-[(6-chloro-4- solvent, p-TsOH
3-amino-A/-methylbenzene 299.0 pyrimidinyl)amino]-/V- can be
sulfonamide (M+H)+ methylbenzenesulfonamide substituted for
HCI
6-chloro-A/-[4-
274.0 (trifluoromethyl)phenyl]-4- 4-(trifluoromethyl)aniline
(M+H)+ pyrimidinamine hydrochloride
A/-(3-bromo-5-methylphenyl)-6- 299.9
3-bromo-5-methylaniline
chloro-4-pyrimidinamine (M+H)+
6-chloro-A/-(3-fluorophenyl)-4- 224.0
3-fluoroaniline
pyrimidinamine (M+H)+
6-chloro-A/-[4-(1-
[4-(1- 248.1 methylethyl)phenyl]-4- methylethyl)phenyl]amine (M+H)+ pyrimidinamine
6-chloro-A/-[3-chloro-4-
3-chloro-4- 270.1
(methyloxy)phenyl]-4- (methyloxy)aniline (M+H)+ pyrimidinamine
6-chloro-A/-[4-(2,2,2-
4-(2,2,2- 288.0 trifluoroethyl)phenyl]-4- trifluoroethyl)aniline (M+H)+ pyrimidinamine
6-chloro-A/-[4-(2,2,2-
4-[(2,2,2- 304.0 trifluoroethyl)phenyl]-4- trifluoroethyl)oxy]aniline (M+H)+ pyrimidinamine
6-chloro-A/-[4-(1 H-pyrazol-1- 272.0
4-(1 /-/-pyrazol-1-yl)aniline
yl)phenyl]-4-pyrimidinamine (M+H)+
3-[(6-chloro-4- 3-amino-A/-methyl-4-
345.0 pyrimidinyl)amino]-A/-methyl-4- (methylthio)benzenesulfona
(M+H)+ (methylthio)benzenesulfonamide mide
3-[(6-chloro-4- 3-amino-A/-methyl-4-
329.0 pyrimidinyl)amino]-A/-methyl-4- (methyloxy)benzenesulfona
(M+H)+ (methyloxy)benzenesulfonamide mide
3-[(6-chloro-4- pyrimidinyl)amino]-A/-methyl-4- 3-amino-A/-methyl-4-[(2,2,2-
397.0 [(2,2,2- trifluoroethyl)oxy]benzenes
(M+H)+ trifluoroethyl)oxy]benzenesulfon ulfonamide
amide 3-[(6-chloro-4-
3-amino-4-(ethylthio)-/V- 359.0 pyrimidinyl)amino]-4-(ethylthio)- methylbenzenesulfonamide (M+H)+ /V-methylbenzenesulfonamide
3-[(6-chloro-4- pyrimidinyl)amino]-A/-methyl-4- 3-amino-A/-methyl-4-[(2-
386.7 [(2- methylpropyl)thio]benzenes
(M+H)+ methylpropyl)thio]benzenesulfon ulfonamide
amide
3-[(6-chloro-4-
3-amino-4-[(1 ,1- pyrimidinyl)amino]-4-[(1 ,1- 387.0 dimethylethyl)thio]-/V- dimethylethyl)thio]-/V- (M+H)+ methylbenzenesulfonamide
methylbenzenesulfonamide
3-[(6-chloro-4- pyrimidinyl)amino]-A/-methyl-4- 3-amino-A/-methyl-4-[(1 - 372.9 [(1- methylethyl)thio]benzenesul (M+H)+ methylethyl)thio]benzenesulfona fonamide
mide
3-[(6-chloro-4- pyrimidinyl)amino]-A/-methyl-4- 3-amino-A/-methyl-4-[(2,2,2- 413.0 [(2,2,2- trifluoroethyl)thio]benzenes (M+H)+ trifluoroethyl)thio]benzenesulfon ulfonamide
amide
3-[(6-chloro-4- 317.0
3-amino-4-fluoro-/V- pyrimidinyl)amino]-4-fluoro-/V- (M+H)+ methylbenzenesulfonamide
methylbenzenesulfonamide
4-ch loro-3-[(6-ch loro-4- 333.0
3-amino-4-chloro-/V- pyrimidinyl)amino]-/V- (M+H)+ methylbenzenesulfonamide
methylbenzenesulfonamide
5-[(6-chloro-4-
5-amino-2-fluoro-A/-methyl- pyrimidinyl)amino]-2-fluoro-/V- 428.9
4-[(2,2,2-trifluoro-1- methyl-4-[(2,2,2-trifluoro-1- (M+H)+ methylethyl)oxy]benzenesul
methylethyl)oxy]benzenesulfona
fonamide
mide
5-[(6-chloro-4- 5-amino-2-fluoro-A/-methyl-
363.0 pyrimidinyl)amino]-2-fluoro-/V- 4- (M+H)+ methyl-4- (methylthio)benzenesulfona
(methylthio)benzenesulfonamide mide PREPARATION 24 3-[(6-chloro-4-pyrimidinyl)amino]-4-(dim
Figure imgf000084_0001
A mixture of 4,6-dichloropyrimidine (0.065 g, 0.436 mmol), 3-amino-4- (dimethylamino)-/\/-methylbenzenesulfonamide (0.100 g, 0.436 mmol) and AgOTf (0.1 12 g, 0.436 mmol) in 1 ,4-dioxane (1 .744 mL) was heated in a microwave reactor at 120 °C for 50 min in 10 min intervals. The reaction was filtered through Celite® and the filtrate loaded onto a SCX column (5 g, washed with MeOH and eluted with 2 M ammonia in MeOH). Concentration of the ammonia/MeOH fractions yielded a brown oil which was subsequently loaded onto a silica solid phase extraction column (5 g, eluted with CH2CI2, 50:50 CH2CI2:Et20, then Et20). Concentration of the appropriate fractions yielded 3-[(6- chloro-4-pyrimidinyl)amino]-4-(dimethylamino)-/\/-methylbenzenesulfonamide (0.071 g, 48%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.41 (s, 1 H), 8.44 (s, 1 H), 8.04 (s, 1 H), 7.50 (dd, J = 2.01 , 8.53 Hz, 1 H), 7.31 (q, J = 4.94 Hz, 1 H), 7.22 (d, J = 8.53 Hz, 1 H), 6.89 (br. s., 1 H), 2.73 (s, 6H), 2.42 (d, J = 5.02 Hz, 3H); MS (m/z) 341 .9 (M+H)+.
The following intermediates were prepared from 4,6-dichloropyrimidine and the aniline indicated using procedures analogous to that described in Preparation 24:
Figure imgf000084_0002
PREPARATION 25
4-amino-/\/-[2-(methyloxy)ethyl]benzamide
Figure imgf000085_0001
Step 1 : A/-[2-(methyloxy)ethyl]-4-nitrobenzamide
A mixture of 4-nitrobenzoic acid (1 g, 5.98 mmol), 2-(methyloxy)ethanamine (618 μΙ, 7.17 mmol), HOBT (1 .833 g, 1 1 .97 mmol), DIPEA (2.090 mL, 1 1.97 mmol) and EDC (2.294 g, 1 1 .97 mmol) in THF (27.200 mL) was heated to 90 °C for 1 hr. The reaction mixture was concentrated and the residue purified by silica SPE (20 g, eluted with CH2CI2, Et20, MeOH). Concentration of the appropriate fractions yielded 1 .76g of a yellow solid which was then partitioned between water and EtOAc. The organic layer was separated and concentrated to give A/-[2-(methyloxy)ethyl]-4-nitrobenzamide (1 .51 g, crude) which was used as is in the next step.
Step 2: 4-amino-/V-[2-(methyloxy)ethyl]benzamide
A solution of A/-[2-(methyloxy)ethyl]-4-nitrobenzamide (1 .51 g, 6.73 mmol) in ethanol (33.7 mL) and treated with HC02 «NH4 (2.123 g, 33.7 mmol) and Pd/C (0.717 g, 0.673 mmol) then stirred at 40 °C for 2 h. The reaction mixture was filtered through Celite®, and the filtrate concentrated to give ~1 g of a brown oil which was purified by silica SPE (20 g, eluted with Et20, 50:50 Et20:EtOAc; EtOAc) to give 4-amino-/v-[2- (methyloxy)ethyl]benzamide (791 mg, crude) as a yellow oil which was used as is in the next step.
Step 3: 4-[(6-chloro-4-pyrimidinyl)amino]-/\/-[2-(methyloxy)ethyl]benzamide
A mixture of 4-amino-/V-[2-(methyloxy)ethyl]benzamide (791 mg, 4.07 mmol),
K3P04 (1 .729 g, 8.15 mmol), 4,6-dichloropyrimidine (1213 mg, 8.14 mmol), Xantphos (94 mg, 0.163 mmol) and Pd2(dba)3 (74.6 mg, 0.081 mmol) in 1 ,4-dioxane (20.4 mL) was heated at 80 °C under reflux for 24 h. The reaction mixture was then concentrated to give a brown-orange oil, which was then partitioned between CH2CI2/water and separated by hydrophobic frit. The organic layers were concentrated to give ~1 g orange oil. The residue was then loaded onto a silica SPE (20 g, eluted with CH2CI2, 25:75 Et20:CH2CI2, 50:50 CH2CI2: Et20, Et20 and MeOH) to give 4-[(6-chloro-4-pyrimidinyl)amino]-/\/-[2- (methyloxy)ethyl]benzamide as an orange solid, (433 mg, 35%). MS (m/z) 307.0 (M+H)+.
PREPARATION 26
1-(6-chloro-4-pyrimidinyl)-/\/-methyl-1 /-/-benzimidazole-6-sulfonamide
Figure imgf000086_0001
Step 1 : phenylmethyl [(4-fluoro-3-nitrophenyl)sulfonyl]methylcarbamate
A solution of 4-fluoro-/V-methyl-3-nitrobenzenesulfonamide (3.0 g, 12.8 mmol) in THF (30 ml.) was treated with Et3N (1.3 g, 12.8 mmol) and then dropwise with phenylmethyl chloridocarbonate (3.27 g, 19.3 mmol) and the mixture stirred at rt for 3 h. The mixture was then concentrated and the residue partitioned between CH2CI2 and water, The organic was then collected and concentrated to give phenylmethyl [(4-fluoro- 3-nitrophenyl)sulfonyl]methylcarbamate (3 g, 64%) as a yellow solid. MS (m/z) 391 .0 (M+Na)+.
Step 2: phenylmethyl [(4-amino-3-nitrophenyl)sulfonyl]methylcarbamate
A solution of phenylmethyl [(4-fluoro-3-nitrophenyl)sulfonyl]methylcarbamate (3.0 g, 8.5 mmol) in THF (15 ml.) was treated with ammonia/MeOH solution (7 M, 5.8 ml.) and stirred at rt for 5 h. The reaction mixture was concentrated and the residue (2.8 g, yellow solid) taken on as is into the next step. MS (m/z) 388.1 (M+Na)+. Step 3: phenylmethyl [(3,4-diaminophenyl)sulfonyl]methylcarbamate
A suspension of phenylmethyl [(4-amino-3-nitrophenyl)sulfonyl]methylcarbamate (2.8 g, 7.7 mmol) and platinum oxide (174 mg, 0.77 mmol) in ethanol (40 mL) was stirred at rt under hydrogen balloon. The mixture was filtered through Celite® and concentrated to give phenylmethyl [(3,4-diaminophenyl)sulfonyl]methylcarbamate (2.7 g, 95%) as a brown oil. MS (m/z) 336.2 (M+H)+.
Step 4: phenylmethyl (1 H-benzimidazol-5-ylsulfonyl)methylcarbamate
A solution of phenylmethyl [(3,4-diaminophenyl)sulfonyl]methylcarbamate (2.5 g, 7.46 mmol) in formic acid (20 mL) was heated to 100 °C for 6 h. The reaction was then extracted with CH2CI2. The aqueous layer was adjusted to pH 8 and extracted with CH2CI2. The combined organics were then dried (Na2S04), concentrated and combined with material from a 100 mg trial scale reaction to give phenylmethyl (1 H-benzimidazol-5- ylsulfonyl)methylcarbamate (2.1 g, 81 %) as a pink solid. MS (m/z) 346.0 (M+H)+
Step 5: 1 -(6-chloro-4-pyrimidinyl)-/\/-methyl-1 H-benzimidazole-6-sulfonamide
A solution of phenylmethyl (1 H-benzimidazol-5-ylsulfonyl)methylcarbamate (100 mg, 0.290 mmol) and 4,6-dichloropyrimidine (86 mg, 0.579 mmol) in DMF (1367 μΙ) was treated with Et3N (81 μΙ, 0.579 mmol) and heated in the microwave at 150 °C for 90 min. The reaction was diluted by the addition of EtOAc (5 mL) and water (5 mL). The organic layer was separated and concentrated to give a brown oil which was then purified by silica SPE (5 g, eluted with CH2CI2, 50:50 CH2CI2: Et20, Et20, EtOAc then MeOH). Concentration of the appropriate fractions gave 1-(6-chloro-4-pyrimidinyl)-/\/-methyl-1 /-/- benzimidazole-6-sulfonamide (40 mg, 1 :1 mix of regiosomers) that was used as is in the next step. MS (m/z) 324.0 (M+H)+.
PREPARATION 27
4-amino-/V-[2-(methyloxy)ethyl]benzamide
Figure imgf000087_0001
,ΡΟ,
Dioxan A mixture of 4,6-dichloropyrimidine (476 mg, 3.22 mmol, 6-bromo-4-methyl-2- pyridinamine (300 mg, 1.62 mmol, prepared according to procedures outlined in WO2005061496 and references therein), Pd2(dba)3 (28 mg, 0.032 mmol), Xantphos (36 mg, 0.064 mmol) and potassium carbonate (670 mg, 4.89 mmol) in 1 ,4-dioxane (5 ml.) was heated in the microwave at 130 °C for 1 h. The reaction mixture was then poured onto water and the resultant solid collected by filtration and then purified via flash column chromatography (silica gel, 10:1 to 5:1 petroleum Et20: EtOAc) to afford 4-amino-/V-[2- (methyloxy)ethyl]benzamide (160 mg, 33%) as a white solid, MS (m/z) 300.9 (M+H)+.
PREPARATION 28
6-chloro-/V-(3,5-dichloro-2-pyridinyl)-4-pyrimidinamine
Figure imgf000088_0001
Cs2C03
Dioxan
A mixture of 4,6-dichloropyrimidine (823 mg, 5.52 mmol), 3,5-dichloro-2- pyridinamine (450 mg, 2.76 mmol), Cs2C03 (2698 mg, 8.28 mmol), BINAP (68.8 mg, 0.1 10 mmol) and PdOAc2 (24.79 mg, 0.1 10 mmol) was dissolved in 1 ,4-dioxane (6902 μΙ) and heated in the microwave at 150°C for 30 min. The reaction was then concentrated and the residue was then purified by silica SPE (20 g, eluted with 50-50 CH2CI2:hexanes, CH2CI2, 75-25 CH2CI2: Et20). Concentration of the appropriate fractions yielded 6-chloro- A/-(3,5-dichloro-2-pyridinyl)-4-pyrimidinamine (126 mg, crude) as a yellow solid and a second batch of 6-chloro-/V-(3,5-dichloro-2-pyridinyl)-4-pyrimidinamine (310 mg, crude) both batches were used as is in the next step.
The following analog was prepared from the stated pyridinamine and 4,6- dichloropyridine in a procedure analogous to that of Preparation 28: Pyrimidinamine Aniline MS (m/z)
A/-(5-bromo-6-methyl-2-pyridinyl)-6-chloro-4- 5-bromo-6-methyl-2- 299.9 pyrimidinamine pyridinamine (M+H)+
PREPARATION 29
3-[(6-chloro-4-pyrimidinyl)amino]-A/-methyl-4-(methy ^
Figure imgf000089_0001
A mixture of 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methyl-4-(methylthio) benzenesulfonamide (5.0 g, 14.5 mmol) and sodium perborate tetrahydrate (7.76 g, 43.5 mmol) in AcOH (60 mL) was stirred at 50 °C. The mixture was filtered and the filtrate concentrated. The residue was then purified via flash chromatography to give 3-[(6-chloro- 4-pyrimidinyl)amino]-/\/-methyl-4-(methylsulfonyl)benzenesulfonamide (2.1 g, 38%) as a white solid, MS (m/z) 376.9 (M+H)+.
The following examples were prepared from the stated sulphide using a procedure analogous to that detailed in Preparation 29:
Figure imgf000089_0002
EXAMPLE 1
/V-methyl-3-({6-[(3-methylphenyl)amino]-4-pyrimidinyl}amino)b
trifluoroacetate
Figure imgf000090_0001
A mixture of 6-chloro-/V-(3-methylphenyl)-4-pyrimidinamine (0.264 g, 1 .202 mmol), 3-amino-/V-methylbenzenesulfonamide (0.224 g, 1.202 mmol) and HCI (0.037 mL, 1 .202 mmol) in isopropanol (3.005 mL) was heated in a microwave reactor at 150 °C for 5 min. The reaction mixture was heated for an additional 10 min at 150 °C. Additional HCI (0.037 mL, 1.202 mmol) was added and the reaction heated for 10 min in the microwave reactor at 150 °C. The reaction was then concentrated and the residue dissolved in CH2CI2 (added a few drops of MeOH to aid solubility) and purified by silica solid phase extraction column (10 g, washed with CH2CI2, Et20, EtOAc and acetone). Concentration of the appropriate fractions yielded the crude product. Reverse phase HPLC purification then gave A/-methyl-3-({6-[(3-methylphenyl)amino]-4-pyrimidinyl}amino) benzenesulfonamide trifluoroacetate (0.089 g, 15%) as a cream colored solid.
The following compounds were prepared with procedures analogous to that described in Example 1 using the specified pyrimidine in either the free base or HCI salt form and 3-amino-/V-methylbenzenesulfonamide:
Figure imgf000090_0002
Figure imgf000091_0001
The following compounds were prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-(4-chlorophenyl)-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline using I PA or NMP as the solvent:
Figure imgf000091_0002
3-({6-[(4-chlorophenyl)amino]-4-
3-amino-4-[(1 ,2- pyrimidinyl}amino)-4-[(1 ,2- dimethylpropyl)oxy]-/V- dimethylpropyl)oxy]-/V- methylbenzenesulfona methylbenzenesulfonamide
mide
trifluoroacetate
4-chloro-3-({6-[(4- chlorophenyl)amino]-4- 3-amino-4-chloro-/V- pyrimidinyl}amino)-/V- methylbenzenesulfona methylbenzenesulfonamide mide
Figure imgf000092_0001
trifluoroacetate
3-({6-[(4-chlorophenyl)amino]-4- pyrimidinyl}amino)-A/-methyl-4- 3-amino-A/-methyl-4-
[(2,2,2-trifluoroethyl)oxy]- [(2,2,2- benzenesulfonamide trifluoroethyl)oxy]benz trifluoroacetate enesulfonamide
3-({6-[(4-chlorophenyl)amino]-4-
3-amino-4- pyrimidinyl}amino)-4- Js
(cyclohexyloxy)-A/-
(cyclohexyloxy)-A/- methylbenzenesulfona methylbenzenesulfonamide
mide
trifluoroacetate
3-({6-[(4-chlorophenyl)amino]-4-
3-amino-4-[(1- pyrimidinyl}amino)-4-[(1- ethylpropyl)oxy]-/V- ethylpropyl)oxy]-/V- methylbenzenesulfona methylbenzenesulfonamide
mide
trifluoroacetate
3-({6-[(4-chlorophenyl)amino]-4-
3-amino-A/-methyl-4- pyrimidinyl}amino)-A/-methyl-4- [(3,3,3-
[(3,3,3-trifluoropropyl)oxy]- trifluoropropyl)oxy]ben benzenesulfonamide
zenesulfonamide trifluoroacetate
3-({6-[(4-chlorophenyl)amino]-4-
3-amino-4- pyrimidinyl}amino)-4- (cyclopentyloxy)-A/-
(cyclopentyloxy)-A/- methylbenzenesulfona methylbenzenesulfonamide
mide
trifluoroacetate
Figure imgf000093_0001
H XJ mide 3-({6-[(4-chlorophenyl)amino]-4- 3-amino-4-(3,3- pyrimidinyl}amino)-4-(3,3-difluoro-1- difluoro-1-piperidinyl)-
25 piperidinyl)-/V- /V-methylbenzenesulfo methylbenzenesulfonamide Namide
trifluoracetate
Figure imgf000094_0001
1 , 1-dimethylethyl [(3-
3-({6-[(4-chlorophenyl)amino]-4- amino-4-{[2,2,2- pyrimidinyl}amino)-A/-methyl-4- trifluoro-1-
26 {[2,2,2-trifluoro-1-
(trifluoromethyl)ethyl]oxy}benzenes ii r T (trifluoromethyl)ethyl]o xy}phenyl)sulfonyl]met ulfonamide trifluoroacetate H
hylcarbamate
The following compounds were prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-(3-fluorophenyl)-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline:
Figure imgf000094_0002
The following compound was prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-[4-(1 -methylethyl)phenyl]-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline:
Figure imgf000095_0001
The following compounds were prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-(4-{[2-(methyloxy)ethyl]oxy}phenyl)-4- pyrimidinamine in either the free base or HCI salt form and the specified aniline:
Ex. Name Structure Aniline
A/-methyl-4-(methyloxy)-3-({6-[(4-{[2- 3-amino-/V- (methyloxy)ethyl]oxy}phenyl)amino]-4- methyl-4-
34
pyrimidinyl}amino)benzenesulfonamide (methyloxy)benz hydrochloride enesulfonamide A/-methyl-3-({6-[(4-{[2- 3-amino-/V-
(methyloxy)ethyl]oxy}phenyl)amino]-4- 1 T °\ methyl-4-[(2,2,2-
35 pyrimidinyl}amino)-4-[(2,2,2- trifluoroethyl)oxy trifluoroethyl)oxy]benzenesulfonamide ]benzenesulfona trifluoroacetate mide
The following compounds were prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-[4-(2,2,2-trifluoroethyl)phenyl]-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline:
Figure imgf000096_0001
The following compound was prepared with procedures analogous to that described in Example 1 using 4-[(6-chloro-4-pyrimidinyl)amino]-/\/-[2- (methyloxy)ethyl]benzamide in either the free base or HCI salt form and the specified aniline:
Figure imgf000096_0002
The following compounds were prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-[4-(1 /-/-pyrazol-1-yl)phenyl]-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline:
Figure imgf000097_0001
The following compound was prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-{4-[(2,2,2-trifluoroethyl)oxy]phenyl}-4- pyrimidinamine in either the free base or HCI salt form and the specified aniline:
Figure imgf000097_0002
The following compounds were prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-[4-(trifluoromethyl)phenyl]-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline in NMP as the solvent: Ex. Name Structure Aniline
A/-methyl-4-[(2,2,2- trifluoroethyl)oxy]-3-[(6-{[4- 3- amino-A/-methyl- (trifluoromethyl)phenyl]amino}-4- 4- [(2,2,2-
43
pyrimidinyl)amino]benzenesulfon trifluoroethyl)oxy]be amide trifluoroacetate H nzenesulfonamide
.TFA
The following compounds were prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-(3,4-difluorophenyl)-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline using IPA or NMP as the solvent:
Figure imgf000098_0001
The following compound was prepared with procedures analogous to that described in Example 1 using A/-(6-bromo-4-methyl-2-pyridinyl)-6-chloro-4-pyrimid in either the free base or HCI salt form and the specified aniline:
Figure imgf000099_0001
The following compound was prepared with procedures analogous to that described in Example 1 using 6-chloro-/V-(3,5-dichloro-2-pyridinyl)-4-pyrimidinamine in either the free base or HCI salt form and the specified aniline:
Figure imgf000099_0003
EXAMPLE 49
3-{[6-(3-biphenylylamino)-4-pyrimidinyl]amino}-/\/-methylbenzenesulfonamide
trifluoroacetate
Figure imgf000099_0002
A mixture of 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methylbenzenesulfonamide (0.150 g, 0.447 mmol), 3-biphenylamine (0.151 g, 0.895 mmol) and cone. HCI (few drops) in isopropanol (1.1 19 ml_) was heated in a microwave reactor at 150 °C for 20 min. The reaction mixture was concentrated and the residue partitioned between CH2CI2 and water. The organic layer was collected via hydrophobic frit, a precipitate was noted and collected by filtration. This material was dissolved in MeOH/DMSO and purified by reverse phase HPLC (20-65% CH3CN/H20 with 0.1 % TFA). Concentration of the appropriate fractions yielded 3-{[6-(3-biphenylylamino)-4-pyrimidinyl]am
trifluoroacetate (0.165 g, 64%) as a white solid.
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
e trifluoroacetate
Figure imgf000103_0001
trifluoroacetate
Figure imgf000104_0001
trifluoroacetate •TFA
Figure imgf000105_0001
methylbenzenesulfonamide
Figure imgf000106_0001
trifluoroacetamide H 0 -TFA
Figure imgf000107_0001
mide trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- (methylthio)benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000108_0001
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-4-(diethylamino)-/\/- methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Ex. Name Structure Aniline
3-({6-[(4-chlorophenyl)amino]-4- r
pyrimidinyl}amino)-4- I I
1 1 1 (diethylamino)-A/- 4-chloroaniline methylbenzenesulfonamide 1 1 ll
trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-4-(2,5-dimethyl-1 - pyrrolidinyl)-/V-methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Ex. Name Structure Aniline
3-({6-[(4-chlorophenyl)amino]-4- pyrimidinyl}amino)-4-(2,5-dimethyl-
1 12 1-pyrrolidinyl)-/V- 4-chloroaniline
1 1 ll
methylbenzenesulfonamide
trifluoroacetate The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methyl-4-(2-methyl-1 - pyrrolidinyl)benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000109_0001
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/\/,4- dimethylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000109_0002
Figure imgf000110_0001
trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000110_0002
mide hydrochloride 3-({6-[(4-cyanophenyl)amino]-4- pyrimidinyl}amino)-A/-methyl-4-
121 [(2,2,2- 4-aminobenzonitrile trifluoroethyl)oxy]benzenesulfona
Figure imgf000111_0001
mide trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-4-(ethylthio)-/\/- methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000111_0002
trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methyl-4-[(2,2,2- trifluoroethyl)thio]benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000111_0003
Figure imgf000112_0001
de trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-4-fluoro-/\/- methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Ex. Name Structure Aniline
4-fluoro-/V-methyl-3-{[6-({4-
[(trifluoromethyl)oxy]phenyl}amino) nr methyl)oxy]
128 -4- F 4-[(trifluoro
aniline
pyrimidinyl]amino}benzenesulfona
mide trifluoroacetate
3-{[6-({4-
[(difluoromethyl)oxy]phenyl}amino)
]
129 -4-pyrimidinyl]amino}-4-fluoro-A/- ° rF 4-[(difluoromethyl)oxy aniline methylbenzenesulfonamide
trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 49 using 4-chloro-3-[(6-chloro-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000112_0002
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- (methylsulfonyl)benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000113_0001
The following compounds were prepared with procedures analogous to that described in Example 49 using 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methyl-4-[(2,2,2- trifluoro-1 , 1-dimethylethyl)oxy]benzenesulfonamide the stated pyrimidine as either the free base or HCI salt and the specified aniline:
Figure imgf000114_0002
EXAMPLE 137
3-({6-[(3-bromophenyl)amino]-4-pyrimidinyl}amino)-/\/-methylbenzenesulfonamide
Figure imgf000114_0001
To a solution of 3-({6-[(3-bromophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide (15 g, 50 mmol) and 3-bromoaniline (7.8 g, 43 mmol) in isoamylalcohol (10 ml_), HCI (3 ml. of a 2 M solution, 6 mmol) was added. The resulting mixture was then heated to reflux for 6 h. The mixture was cooled and quenched with NH4OH and water and stirred for 30 min by which time a precipitate had formed. The precipitate was filtered, washed with hexanes, and dried to give 3-({6-[(3- bromophenyl)amino]-4-pyrimidinyl}amino)-/\/-methylbenzenesulfonamide (17.5 g, 93%) as a yellow solid.
The following compound was prepared with a procedure analogous to that described in Example 137 using the specified pyrimidine and the appropriate aniline: Ex. Name Structure Pyrimidine
3-({6-[(3-bromo-4- 3-[(6-chloro-4-
138 chlorophenyl)amino]-4- NH Br pyrimidinyl)amino]-/V- pyrimidinyl}amino)-/V- methylbenzene- methyl benzenesulfonamide H sulfonamide
EXAMPLE 139
3-[(6-{[3,4-bis(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/-methyl-4- (methylthio)benzenesulfonamide trifluoroacetate
Figure imgf000115_0001
FA
A mixture of 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methyl-4-(methylthio) benzenesulfonamide (140 mg, 0.406 mmol) and 3,4-bis(methyloxy)aniline (61 mg, 0.406 mol) in isopropanol (10 ml.) and a few drops of conc.HCI were heated at reflux for 12 h. The mixture was then concentrated and purified by preparative HPLC to give 3-[(6-{[3,4- bis(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/-methyl-4-(methylthio)
benzenesulfonamide trifluoroacetate (38 mg, 46%) as a white solid.
The following compounds were prepared with procedures analogous to that described in Example 139 using 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methyl-4-(methylthio) benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000115_0002
Figure imgf000116_0001
trifluoroacetate
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
trifluoroacetate A0
Figure imgf000120_0001
trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 139 using 3-[(6-chloro-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000120_0002
Figure imgf000121_0001
Figure imgf000122_0001
trifluoroacetate The following compounds were prepared with procedures analogous to that described in Example 139 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(1 - methylethyl)sulfonyl]benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000123_0001
The following compounds were prepared with procedures analogous to that described in Example 139 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- (methylsulfonyl)benzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000123_0002
3-[6-(indan-5-ylamino)- pyrimidin-4-ylamino]-4- methanesulfonyl-A/-methyl- 2,3-dihydro-1 H-inden-5- benzenesulfonamide ylamine
Figure imgf000124_0001
3-[6-(benzothiazol-6- ylamino)-pyrimidin-4-
1 ,3-benzothiazol-6- ylamino]-4-methanesulfonyl- amine /V-methyl- benzenesulfonamide
4-methanesulfonyl-A/-methyl-
3-[6-(5-oxo-5,6,7,8- tetrahydro-naphthalen-2- 6-amino-3,4-dihydro- ylamino)-pyrimidin-4- 1 (2/-/)-naphthalenone ylamino]-
Figure imgf000124_0002
benzenesulfonamide
A/-methyl-3-(6-(2- methylbenzo[d]thiazol-5- ylamino)pyrimidin-4- 2-methyl-1 ,3- ylamino)-4- benzothiazol-5-amine
(methylsulfonyl)benzenesulf
onamide
A/-methyl-4-(methylsulfonyl)-
3-[(6-{[4-(1 H-1 ,2,4-triazol-1- ylmethyl)phenyl]amino}-4- * j 4-(1 H-1 ,2,4-triazol-1 - pyrimidinyl)amino]benzenes ylmethyl)aniline ulfonamide
3-[6-(1 H-indol-5-ylamino)- : :
pyrimidin-4-ylamino]-4- v°
methanesulfonyl-A/-methyl- 1 /-/-indol-5-amine benzenesulfonamide
4-methanesulfonyl-A/-methyl-
3-[6-(2-methyl-4-oxo-4H-
7-amino-2-methyl-4/-/- chromen-7-ylamino)- chromen-4-one pyrimidin-4-ylamino]- benzenesulfonamide The following compound was prepared with the procedure analogous to that described in Example 139 using 5-[(6-chloro-4-pyrimidinyl)amino]-2-fluoro-/\/- methylbenzenesulfonamide as either the free base or HCI salt and the specified aniline:
Figure imgf000125_0002
EXAMPLE 205
1 -{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/\/-methyl-2,3-dihydro-1 /-/-indole-6-sulfonamide hydrochloride
Figure imgf000125_0001
A mixture of 6-chloro-/V-(4-chlorophenyl)-4-pyrimidinamine (0.250 g, 1 .041 mmol), /V-methyl-2,3-dihydro-1 H-indole-6-sulfonamide (0.221 g, 1 .041 mmol) and a few drops of HCI and isopropanol (2.083 ml.) was heated in a microwave reactor at 150 °C for 30 min. The reaction was filtered, washed with Et20 and the solid collected to afford 1-{6-[(4- chlorophenyl)amino]-4-pyrimidinyl}-/\/-methyl-2,3-dihydro-1 /-/-indole-6-sulfonamide hydrochloride (0.360 g, 73%) as an off-white solid.
EXAMPLE 206
3-[(6-{[3,4-6/s(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/V-methylbenzenesulfonamide trifluoroacetate
Figure imgf000126_0001
A mixture of 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methylbenzenesulfonamide (0.150 g, 0.502 mmol) and 3,4-6/'s(methyloxy)aniline (0.096 g, 0.648 mmol) in NMP (1.255 ml.) was treated with a few drops of concentrated HCI and heated in a microwave reactor at 150 °C for 20 min. Additional aniline (0.038 g, 0.251 mmol) was added and the mixture heated 10 min at 150 °C. Reactions were filtered and purified via reverse phase HPLC (Waters, Sunfire 30 x 100 mm column, 10-90% CH3CN /Water with 0.1 % TFA) to afford 3-[(6-{[3,4-6/'s(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/-methyl benzenesulfonamide trifluoroacetate (0.184 g, 65%) as a brown solid.
The following compounds were prepared with procedures analogous to that described in Example 206 using the specified 3-[(6-chloro-4-pyrimidinyl)amino]-/\/- methylbenzene-sulfonamide as either the free base, TFA, or HCI salt and the appropriate aniline:
Figure imgf000126_0002
Figure imgf000127_0001
trifluoroacetate
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
amide trifluoroacetate
Figure imgf000131_0001
The following compounds were prepared with procedures analogous to that described in Example 206 using the 3-[(6-chloro-4-pyrimidinyl)amino]-4-(dimethylamino)- /V-methylbenzene-sulfonamide as either the free base, TFA, or HCI salt and the specified aniline:
Figure imgf000131_0002
4-(dimethylamino)-A/-methyl-3- ({6-[(3-methylphenyl)amino]-4-
246 3-methylaniline
pyrimidinyl}amino)benzenesulf
onamide trifluoroacetate
The following compound was prepared with procedures analogous to that described in Example 206 using 1 -(6-chloro-4-pyrimidinyl)-/V-methyl-2,3-dihydro-1 /-/- indole-6-sulfonamide as either the free base, TFA, or HCI salt and the specified aniline:
Figure imgf000132_0001
The following compound was prepared with procedures analogous to that described in Example 206 using 1 -(6-chloro-4-pyrimidinyl)-/V-methyl-1 H-benzimidazole-6- sulfonamide as either the free base, TFA, or HCI salt and the specified aniline:
Figure imgf000132_0002
The following compound was prepared with procedures analogous to that described in Example 206 using A/-(5-bromo-6-methyl-2-pyridinyl)-6-chloro-4- pyrimidinamine as either the free base, TFA, or HCI salt and the specified aniline:
Figure imgf000133_0001
EXAMPLE 250
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(1 - methylethyl)oxy]benzenesulfonamide trifluoroacetate
Figure imgf000133_0002
A mixture of 6-chloro-/V-(4-chlorophenyl)-4-pyrimidinamine hydrochloride (0.176 g, 0.586 mmol), 3-amino-/V-methyl-4-[(1 -methylethyl)oxy]benzenesulfonamide (0.179 g, 0.733 mmol) and AgOTf (0.151 g, 0.586 mmol) in NMP (1.562 mL) was heated in a microwave reactor at 180 °C for 30 min. The reaction mixture was filtered and purified by mass directed autoprep (Waters, Sunfire prep C18 OBD, 30 x 150 mm, 30-70% CH3CN/water with 0.1 % TFA). Concentration of the appropriate fractions yielded 3-({6- [(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(1 - methylethyl)oxy]benzenesulfonamide trifluoroacetate (0.150 g, 43%) as a brown solid.
The following compounds were prepared with procedures analogous to that described in Example 250 using 6-chloro-/V-(4-chlorophenyl)-4-pyrimidinamine as the free base, TFA, or HCI salt and the specified aniline:
Figure imgf000134_0001
3-({6-[(4-chlorophenyl)amino]-4- 3-amino-4-(3,3-difluoro- pyrimidinyl}amino)-4-(3,3-difluoro- 1-pyrrolidinyl)-/V-
259 1-pyrrolidinyl)-/V-
11 1 methylbenzenesulfonam methylbenzenesulfonamide
ide
trifluoroacetate
The following compound was prepared with procedures analogous to that described in Example 250 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methylbenzene- sulfonamide as the free base, TFA, or HCI salt and the specified aniline:
Figure imgf000135_0001
sulfonamide trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 250 using 6-chloro-/V-(3-methylphenyl)-4-pyrimidinamine as the free base, TFA, or HCI salt and the specified aniline:
Ex. Name Structure Aniline
A/-methyl-3-({6-[(3- methylphenyl)amino]-4- 3-amino-A/-methyl-4-(4-
261 pyrimidinyl}amino)-4-(4- morpholinyl)benzenesulf morpholinyl)benzenesulfonamid onamide
e trifluoroacetate
Figure imgf000135_0002
The following compounds were prepared with procedures analogous to that described in Example 250 using 6-chloro-/V-[4-(trifluoromethyl)phenyl]-4-pyrimidinamine as the free base, TFA, or HCI salt and the specifiede aniline: Ex. Name Structure Aniline
A/-methyl-4-(methyloxy)-3-[(6- {[4- 3-amino-A/-methyl-4-
262 (trifluoromethyl)phenyl]amino}- (methyloxy)benzenesu 4-pyrimidinyl)amino]benzene Ifonamide
Figure imgf000136_0001
sulfonamide trifluoroacetate
A/-methyl-4-(methylthio)-3-[(6- {[4- 3-amino-A/-methyl-4-
263 (trifluoromethyl)phenyl]amino}- (methylthio)benzenesu 4-pyrimidinyl)amino]benzene Ifonamide
H -TFA
sulfonamide trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 250 using A/-(3-bromo-5-methylphenyl)-6-chloro-4-pyrimidinamine as the free base, TFA, or HCI salt and the specified aniline:
Ex. Name Structure Aniline
3-({6-[(3-bromo-5- methylphenyl)amino]-4- 3-amino-A/-methyl-4-
264 pyrimidinyl}amino)-A/-methyl-4- (methyloxy)benzenesu (methyloxy)benzenesulfonamid Ifonamide
Figure imgf000136_0002
e trifluoroacetate
1-{6-[(3-bromo-5- methylphenyl)amino]-4- A/-methyl-2,3-dihydro-
265 pyrimidinyl}-A/-methyl-2,3- 1 H-indole-6- dihydro-1 /-/-indole-6- sulfonamide
H
•TFA
sulfonamide trifluoroacetate
The following compound was prepared with procedures analogous to that described in Example 250 using 6-chloro-/V-{4-[(2,2,2-trifluoroethyl)oxy]phenyl}-4- pyrimidinamine as the free base, TFA, or HCI salt and the appropriate aniline:
Figure imgf000136_0003
The following compound was prepared with procedures analogous to that described in Example 250 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide as the free base, TFA, or HCI salt and the specified aniline:
Figure imgf000137_0002
EXAMPLE 268
A/-methyl-3-{[6-(4-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide
trifluoroacetate
Figure imgf000137_0001
A mixture of 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methylbenzenesulfonamide (0.150 g, 0.502 mmol), 4-pyridinamine (0.059 g, 0.628 mmol), Pd2(dba)3 (0.009 g, 0.010 mmol), xantphos (1 1.62 mg, 0.020 mmol) and K3P04 (0.213 g, 1 .004 mmol) in 1 ,4- dioxane (1 .255 mL) was heated in a microwave reactor at 150 °C for 30 min. The reaction mixture was loaded onto an ion exchange column (SCX, 5 g, washed with MeOH and eluted with 2 M ammonia in MeOH). Concentration of the ammonia/MeOH fractions yielded 0.243 g of a yellow oil, that was then dissolved in NMP, filtered, and purified by mass directed autoprep (Waters, Sunfire prep C18 OBD, 30 x 150 mm, 10-50% CH3CN/water plus 0.1 % TFA). Concentration of the appropriate fractions yielded N- methyl-3-{[6-(4-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide trifluoroacetate (0.053 g, 21 %) as a white solid. The following compounds were prepared with procedures analogous to that described in Example 268 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methylbenzene- sulfonamide in its free base, TFA, or HCI salt form and the specified amine:
Figure imgf000138_0001
Figure imgf000139_0001
onamide trifluoroacetate
Figure imgf000140_0001
onamide
The following compounds were prepared with procedures analogous to that described in Example 268 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- (methyloxy)benzenesulfonamide in its free base, TFA, or HCI salt form and the specified amine using either K3P04 or K2C03 as the base:
Figure imgf000140_0002
The following compounds were prepared with procedures analogous to that described in Example 268 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000140_0003
A/-methyl-3-{[6-(2- pyridinylamino)-4-
288 pyrimidinyl]amino}-4-[(2,2,2- 2-pyridinamine
trifluoroethyl)oxy]benzenesulf
onamide trifluoroacetate
Figure imgf000141_0001
The following compounds were prepared with procedures analogous to that described in Example 268 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- (methylthio)benzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000141_0002
The following compounds were prepared with procedures analogous to that described in Example 268 using 1 -(6-chloro-4-pyrimidinyl)-/V-methyl-2,3-dihydro-1 /-/- indole-6-sulfonamide as either the free base or HCI salt and the specified amine using K2C03 as the base:
Figure imgf000141_0003
EXAMPLE 291
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[5-(trifluoromethyl)-2-pyri
pyrimidinyl)amino]benzenesulfonamide trifluoroacetate
Figure imgf000142_0001
A mixture of 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide (330 mg, 0.832 mmol), 5-(trifluoromethyl)-2- pyridinamine (539 mg, 3.33 mmol), Pd2dba3 (15.23 mg, 0.017 mmol), Xantphos (19.25 mg, 0.033 mmol) and potassium carbonate (1 149 mg, 8.32 mmol) in 1 ,4-dioxane (3327 μΙ) was heated in the microwave at 180 °C for a total of 90 min. The reaction was filtered and the filtrate loaded onto a SCX (10 g, washed with MeOH and eluted with 2M ammonia in MeOH). Concentration of the ammonia/MeOH fractions yielded a brown solid which was subsequently dissolved in DMSO/MeOH and purified by mass directed autoprep (Waters, Sunfire prep C18 OBD, 30 x 150 mm, 20-60% CH3CN/water plus 0.1 % TFA) to give A/-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide trifluoroacetate (33 mg, 5.9%) as a pale yellow solid.
The following compounds were prepared with procedures analogous to that described in Example 291 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide as either the free base or HCI salt and the specified amine :
Figure imgf000142_0002
Figure imgf000143_0001
onamide trifluoroacetate TFA 3- ({6-[(4,5-dichloro-2- pyridinyl)amino]-4- pyrimidinyl}amino)-A/-methyl- 4,5-dichloro-2-
299
4- [(2,2,2- pyridinamine trifluoroethyl)oxy]benzenesulf
onamide trifluoroacetate
3- ({6-[(5-chloro-6-methyl-2- pyridinyl)amino]-4- pyrimidinyl}amino)-A/-methyl- 5-chloro-6-methyl-2-
300
4- [(2,2,2- 11 1 pyridinamine trifluoroethyl)oxy]benzenesulf
onamide trifluoroacetate
3-(6-(5-isopropylpyridin-2- ylamino)pyrimidin-4-ylamino)- (1-methylethyl)-2-
301 A/-methyl-4-(2,2,2- fr° ~½ 5- pyridinamine trifluoroethoxy)benzenesulfon
amide trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 291 using 3-[(6-chloro-4-pyrimidinyl)amino]-4-fluoro-/\/- methylbenzenesulfonamide in its free base, TFA, or HCI salt form and the specified amine:
Figure imgf000144_0001
The following compound was prepared with procedures analogous to that described in Example 291 using 4-chloro-3-[(6-chloro-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide in its free base, TFA, or HCI salt form and the specified amine:
Figure imgf000145_0001
The following compounds were prepared with procedures analogous to that described in Example 291 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- (methylsulfonyl)benzenesulfonamide in its free base, TFA, or HCI salt form and the specified amine:
Figure imgf000145_0002
The following compounds were prepared with procedures analogous to that described in Example 291 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoro-1-methylethyl)oxy]benzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000146_0001
The following compounds were prepared with procedures analogous to that described in Example 291 using 3-[(6-chloro-4-pyrimidinyl)amino]-4-[(1 ,1 - dimethylethyl)sulfonyl]-/V-methylbenzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000146_0002
The following compounds were prepared with procedures analogous to that described in Example 291 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(1- methylethyl)sulfonyl]benzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000147_0001
The following compounds were prepared with procedures analogous to that described in Example 291 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000147_0002
The following compounds were prepared with procedures analogous to that described in Example 291 using 1-(6-chloro-4-pyrimidinyl)-/\/,3,3-trimethyl-2,3-dihydro-1 /-/- indole-6-sulfonamide as either the free base or HCI salt and the specified amine: Ex. Name Structure Amine
1-[6-(5-chloro-pyridin-2- ylamino)-pyrimidin-4-yl]-3,3-
315 dimethyl-2,3-dihydro-1 H- 5-chloro-2-pyridinamine indole-6-sulfonic acid
Figure imgf000148_0001
methylamide trifluoroacetate .TFA
The following compounds were prepared with procedures analogous to that described in Example 291 using 5-[(6-chloro-4-pyrimidinyl)amino]-2-fluoro-/\/-methyl-4- [(2,2,2-trifluoro-1-methylethyl)oxy]benzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000148_0002
The following compounds were prepared with procedures analogous to that described in Example 291 using 5-[(6-chloro-4-pyrimidinyl)amino]-2-fluoro-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide as either the free base or HCI salt and the specified amine:
Figure imgf000148_0003
EXAMPLE 318
5-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-2-fluoro-/V-m
trifluoroethyl)oxy]benzenesulfonamide trifluoroacetate
Figure imgf000149_0001
A mixture of 5-[(6-chloro-4-pyrimidinyl)amino]-2-fluoro-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide (550 mg, 1 .326 mmol), 5-chloro-2-pyridinamine (682 mg, 5.30 mmol), Cs2C03 (1296 mg, 3.98 mmol), Pd(OAc)2 (5.95 mg, 0.027 mmol) and BI NAP (16.51 mg, 0.027 mmol) in 1 ,4-dioxane (3315 μΙ) was heated in the microwave at 150°c for 30 min. The reaction mixture was concentrated, dissolved in NMP, filtered and purified by MDAP (Waters, Sunfire 30 x 150 mm, 20-60% acetonitrile +0.1 % TFA:water +0.1 % TFA) to give 158mg of a white solid, 90% pure by NMR. This solid was then purified by silica SPE (5 g, eluted with 50-50 CH2CI2:Et20, 25-75 CH2CI2:Et20, Et20, EtOAc then MeOH). Concentration of the appropriate fractions yielded 5-({6-[(5-chloro-2- pyridinyl)amino]-4-pyrimidinyl}amino)-2-fluoro-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide trifluoroacetate (51 mg, 5.8%) as a white solid.
The following compound was prepared with procedures analogous to that described in Example 318 using 5-[(6-chloro-4-pyrimidinyl)amino]-2-fluoro-/\/-methyl-4- [(2,2,2-trifluoroethyl)oxy]benzenesulfonamide as either the free base or HCI salt, and the specified amine:
Figure imgf000149_0002
The following compound was prepared with procedures analogous to that described in Example 318 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide as either the free base or HCI salt, and the specified amine:
Figure imgf000150_0001
The following compound was prepared with procedures analogous to that described in Example 318 using 3-[(6-chloro-4-pyrimidinyl)amino]-4-(ethylsulfonyl)-/\/- methylbenzenesulfonamide as either the free base or HCI salt, and the specified amine:
Figure imgf000150_0002
The following compound was prepared with procedures analogous to that described in Example 318 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4- (methylsulfonyl)benzenesulfonamide as either the free base or HCI salt, and the specified amine:
Figure imgf000151_0001
The following compound was prepared with procedures analogous to that described in Example 318 using 3-[(6-chloro-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoro-1 -methylethyl)oxy]benzenesulfonamide as either the free base or HCI salt, and the specified amine:
Figure imgf000151_0003
EXAMPLE 325
2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3-thiazole-5- carboxylic acid
Figure imgf000151_0002
Step 1 . methyl 2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3- thiazole-5-carboxylate
A mixture of 3-[(6-chloro-4-pyrimidinyl)amino]-/\/-methylbenzenesulfonamide (0.150 g, 0.502 mmol), K3P04 (0.213 g, 1 .004 mmol), xantphos (0.01 1 g, 0.020 mmol), Pd2(dba)3 (9.20 mg, 0.010 mmol), and methyl 2-amino-1 ,3-thiazole-5-carboxylate (0.079 g, 0.502 mmol) was heated in a microwave reactor at 170 °C for 90 min. The reaction crude mixture was purified via flash column chromatography (ISCO, 40 g silica column, 0-10% MeOH/CH2CI2) to afford methyl 2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}-1 ,3-thiazole-5-carboxylate (0.030 mg, 14%) as an oil. (m/z) 421.0 (M+H+)
Step 2. 2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3-thiazole- 5-carboxylic acid
A solution of methyl 2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}-1 ,3-thiazole-5-carboxylate (0.030 g, 0.071 mmol) in THF (6 mL) and water (2 mL) was treated with NaOH (1 mL, 2.0 mmol) at rt for 24 h. The solvent was removed in vacuo and the residue treated with HCI (1 mL, 2.0 mmol). Collection of the yellow precipitate by filtration followed by lyophilization afforded 2-{[6-({3- [(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3-thiazole-5-carboxylic acid (0.019 g, 62%).
The following compound was prepared with a procedure analogous to that described in Example 325 using the indicated aniline:
Figure imgf000152_0001
EXAMPLE 327
1-{6-[(4-chlorophenyl)amino]-4-pyrimi
trifluoroacetate
Figure imgf000153_0001
A mixture of /V-methyl-1 H-indole-6-sulfonamide (230 mg, 1 .094 mmol), 6-chloro-/V- (4-chlorophenyl)-4-pyrimidinamine (263 mg, 1.094 mmol) in THF was
heated in the microwave for 60 min at 150 °C. The reaction was filtered and the filtrate concentrated. The residue was dissolved in NMP and purified by mass directed autoprep (Waters, Sunfire prep C18 OBD, 30x 150 mm, (40-90 % CH3CN+0.1 %TFA/water +0.1 % TFA) Concentration of the appropriate fractions yielded 1-{6-[(4-chlorophenyl)amino]-4- pyrimidinyl}-/V-methyl-1 H-indole-6-sulfonamide trifluoroacetate (63 mg, 5.7%) as a brown solid.
EXAMPLE 328
3-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/\/-methyl-2-oxo-2,3-dihydro-1 /-/- benzimidazole-5-sulfonamide trifluoroacetate
Figure imgf000153_0002
A mixture of 4-amino-3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide (400 mg, 0.494 mmol) and carbonyl diimidazole (136 mg, 0.840 mmol) in 1 ,4-dioxane (1976 μΙ) was stirred at rt for 5 h then 12 h at 50 °C. LCMS analysis of the reaction mixture showed incomplete reaction. The reaction was concentrated and the residue partitioned between CH2CI2 and 2N HCI. The organic layers were concentrated and the residue was dissolved in 1 ,4-dioxane (2 mL), treated with carbonyl diimidazole (120 mg, 0.741 mmol) and heated in the microwave at 100 °C for a total of 25 min. The reaction mixture was concentrated, the residue was dissolved in NMP, filtered and purified by mass directed autoprep (Waters, Sunfire prep C18 OBD, 30x 150 mm, (30-70 % CH3CN+0.1 %TFA/water +0.1 % TFA) Concentration of the appropriate fractions yielded 3-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/\/-methyl-2-oxo- 2,3-dihydro-1 H-benzimidazole-5-sulfonamide trifluoroacetate (12.2 mg, 4.1 %) as a solid.
EXAMPLE 329
-[6-(dimethylamino)-3-pyridinyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- methylbenzenesulfonamide
Figure imgf000154_0001
A mixture of 3-({6-[(3-bromophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide (0.500 g, 1.15 mmol), /V,/V-dimethyl-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-2-pyridinamine (0.429, 1 .732), K3P04 (1 .23 g, 4.6 mmol), and Pd(Ph3)4 (0.133 g, 0.1 15 mmol) was heated in DMF (6 mL) and water (0.6 mL) in a microwave reactor for 40 min at 150 °C. The reaction mixture was then cooled, diluted with 10% MeOH/CH2Cl2 (50 mL), filtered, and concentrated. The crude material was then purified via flash column chromatography (40 g silica column, 20:1 :0.1 CH2Cl2:MeOH:Et3N) to give 3-{[6-({3-[6-(dimethylamino)-3-pyridinyl]phenyl}amino)-4- pyrimidinyl]amino}-/V-methylbenzenesulfonamide (0.350 g) in 85% purity. This material was then purified via HPLC (Gilson, PRC-ODS 20 x 250 mm column, 55-70% CH3CN/H20 with 0.01 % NH4HC03) to afford 3-{[6-({3-[6-(dimethylamino)-3- pyridinyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/-methylbenzenesulfonamide in >99% purity (0.150 g, 35%) as a white solid.
The following compounds were prepared with procedures analogous to that described in Example 329 using 3-({6-[(3-bromo-5-methylphenyl)amino]-4- pyrimidinyl}amino)-/V-methylbenzenesulfonamide as the free base, TFA, or HCI salt and the specified boronic acid: Ex. Name Structure Boronate
A/-methyl-3-({6-[(5-methyl- 3-biphenylyl)amino]-4-
330 Phenyl boronic acid
pyrimidinyl}amino)benzene
sulfonamide trifluoroacetate
A/-methyl-3-[(6-{[3-methyl-5-
(3-pyridinyl)phenyl]amino}-
331 4-pyrimidinyl)amino]- 3-pyridinylboronic acid benzenesulfonamide
Figure imgf000155_0001
trifluoroacetate
The following compounds were prepared with procedures analogous to that described in Example 329 using 3-({6-[(3-bromophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide as the free base, TFA, or HCI salt and the specified boronate:
Figure imgf000155_0002
Figure imgf000156_0001
Figure imgf000157_0001
The following compounds were prepared with procedures analogous to that described in Example 329 using 3-({6-[(3-bromo-4-chlorophenyl)amino]-4- pyrimidinyl}amino)-/V-methylbenzenesulfonamide as the free base, TFA, or HCI salt and the specified boronate:
Figure imgf000157_0002
EXAMPLE 349
-[(methylamino)sulfonyl]phenyl}amin^ acid
Figure imgf000158_0001
A suspension of methyl 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoate (0.070 g, 0.169 mmol), in MeOH (0.212 mL) and THF (0.212 mL) was treated with 2 M NaOH (0.339 mL, 0.677 mmol). After about 15 min, a clear solution was observed. After 1 h additional 2 M NaOH (0.339 mL, 0.677 mmol) was added and the reaction was stirred at rt overnight.
The reaction was acidified to pH 4, the solvent removed in vacuo, and the residue partitioned between CH2CI2 and water. The organic layer was collected via hydrophobic frit. A solid was noted at the interface which was collected by filtration and then dissolved in MeOH and combined with the CH2CI2 extracts. Concentration then afforded 4-{[6-({3- [(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzoic acid (0.044 g, 62%) as an off-white solid.
The following carboxylic acid was prepared with a procedure analogous to that described in Example 349 using the specified ester starting material:
Figure imgf000158_0002
EXAMPLE 351
/V,/V-dimethyl-4-{[6-({3-[(methylamino)sulfonyl]ph
pyrimidinyl]amino}benzamide
Figure imgf000159_0001
To a solution of 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoic acid (0.200 g, 0.50 mmol), dimethylamine (0.027 g, 0.60 mmol), and /'-Pr2NEt (0.223 g, 1 .72 mmol) in THF (15 ml_), EDC (0.191 g, 1.0 mmol) and HOBT (0.135 g, 1.0 mmol) were added. The resulting mixture was heated to reflux for 1 h. The solvent was removed, the residue diluted with water and filtered to afford N,N- dimethyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzamide (0.140, 65%) as a white solid.
The following compounds were prepared with [(3-{[6-({3- [(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}ph acid and the specified amine:
Figure imgf000159_0002
The following compounds were prepared with procedures analogous to that described in Example 351 using 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoic acid and the specified amine:
Figure imgf000159_0003
Figure imgf000160_0001
pyrimidinyl]amino}benzamide
Figure imgf000161_0001
methylbenzenesulfonamide A/-[2-(dimethylamino)ethyl]-A/- methyl-4-{[6-({3- [2-
368 [(methylamino)sulfonyl]phenyl} (dimethylamino)ethyl]meth amino)-4- ylamine
pyrimidinyl]amino}benzamide
Figure imgf000162_0001
The following compound was prepared with procedures analogous to that described in Example 351 using the 4-[(6-{[5-[(methylamino)sulfonyl]-2- (methylthio)phenyl]amino}-4-pyrimidinyl)amino]benzoic acid and the appropriate amine:
Figure imgf000162_0003
EXAMPLE 370
/\/-[(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)carbonyl]glycine
Figure imgf000162_0002
Step 1 . ethyl /\/-[(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino} phenyl)carbonyl]glycinate
To a solution of 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoic acid (0.200 g, 0.50 mmol), ethyl glycinate (0.099 g, 0.75 mmol), and /-Pr2NEt (0.260 g, 2.00 mmol) in THF (50 mL), EDC (0.196 g, 1.0 mmol) and HOBT (0.135 g, 1 .0 mmol) were added. The resulting mixture was heated to reflux for 0.5 h. The solvent was removed, the residue diluted with water and filtered to afford ethyl Λ/-[(4- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}phenyl)carbonyl] glycinate (0.200 g, 83%) as a white solid.
Step 2. /\/-[(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino} phenyl) carbonyl]glycine
A mixture of /\/-[(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)carbonyl]glycinate (0.200 g, 0.414 mmol) and LiOH (6 mL of a 1 M solution in water, 6.0 mmol) in MeOH (20 mL) was stirred at rt. When the ester had been consumed, the MeOH was removed in vacuo and the residue acidified to pH 5. A white solid then formed which was removed via filtration to afford Λ/-[(4-{[6-({3- [(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino} phenyl)carbonyl]glycine (0.040 g, 21 %).
EXAMPLE 371
A/-methyl-3-[(6-{[3-(6-oxo-1 ,6-dihydro-3-pyridinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide
Figure imgf000163_0001
To a solution of A/-methyl-3-{[6-({3-[6-(methyloxy)-3-pyridinyl]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide (0.200 g, 0.44 mmol) in toluene (4 mL), HCI (2 mL of a 35% solution) was added. The reaction mixture was then heated to 145 °C in a sealed tube for 2 h. The crude material was then purified via preparatory HPLC (250 x 19 mm column, 35-60% 0.01 % NH4HC03 in H20/CH3CN) to afford W-methyl-3-[(6-{[3-(6-oxo- 1 ,6-dihydro-3-pyridinyl)phenyl]amino}-4-pyrimidinyl)amino]benzenesulfonamide (0.128 g, 65%) as a yellow solid. EXAMPLE 372
3-({6-[(3-hydroxyphenyl)amino]-4-pyrimidinyl}amino)-/V-methylben
trifluoroacetate
Figure imgf000164_0001
•TFA
A solution of A/-methyl-3-[(6-{[3-(methyloxy)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide (0.040 g, 0.104 mmol) in CH2CI2 (15 mL) was treated with BBr3 (0.059 mL, 0.623 mmol) at rt for 24 h. The reaction mixture was quenched slowly with a satd. NH4CI solution (1 mL) and then partitioned between 100 mL EtOAc and 20 mL of brine. The organic layer was separated, dried over MgS04, filtered and concentrated in vacuo. The crude material was then purified through reverse phase HPLC (Sunfire C-18 prep column, 30 x 50 mm column, 10-50% CH3CN/water with 0.1 % TFA over 14 min). The appropriate fractions were then concentrated and lyophilized to afford 3-({6-[(3-hydroxyphenyl)amino]-4-pyrimidinyl}amino)-/\/-methylbenzenesulfonamide trifluoroacetate (0.019 g, 36%) as a white solid.
EXAMPLE 373
A/-methyl-4-(methylsulfonyl)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide
Figure imgf000164_0002
A mixture of A/-methyl-4-(methylthio)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide (100 mg, 0.213 mmol), NMO (74.9 mg, 0.639 mmol), TPAP (3.74 mg, 10.65 μηηοΙ) and 4A powdered molecular sieves (0.213 mmol) in CH3CN (0.532 mL) was stirred at 40 °C for 3 h. An additional portion of TPAP (3.74 mg, 10.65 μηηοΙ) was added and the reaction was stirred at 40 °C for an additional 20 hrs before being cooled to rt and loaded onto a silica solid phase extraction column (2g, washed with CH2CI2, Et20, EtOAc, acetone). Concentration of the appropriate fractions yielded the crude product, which was further purified by ion exchange column (SCX, 2g, washed with MeOH and eluted with 10% 2M ammonia in MeOH in CH2CI2). Concentration of the appropriate fractions yielded a solid which was triturated with CH2CI2 to afford A/-methyl-4-(methylsulfonyl)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide (5 mg, 3%) as a white solid.
EXAMPLE 374
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide trifluoroacetate
Figure imgf000165_0001
A mixture of 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylthio)benzenesulfonamide (100 mg, 0.229 mmol) and sodium perborate tetrahydrate (141 mg, 0.918 mmol) in AcOH (0.184 mL) was heated at 50 °C overnight. The reaction was then diluted by the addition of water and extracted with CH2CI2. The organic was collected by hydrophobic frit and concentrated to give a orange solid, 96 mg. This solid was then purified by mass directed autoprep (Waters, Sunfire prep C18 OBD, 30x 150 mm, (30-70 % CH3CN+0.1 %TFA/water +0.1 % TFA). Concentration of the appropriate fractions yielded 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl- 4-(methylsulfonyl)benzenesulfonamide trifluoroacetate (52 mg, 32 %) as a peach coloured solid.
The following examples were prepared with procedures analogous to that described in Example 374 using the specified sulphide: Ex. Name Structure Sulphide
3- ({6-[(4-
3- (6-(4- chlorophenyl)amino]- chlorophenylamino)pyrimidin-
4- pyrimidinyl}amino)-
375 4- ylamino)-4-(isobutylsulfonyl)- .S NH
A/-methyl-4-[(2- /V-methylbenzenesulfonamide
methylpropyl)thio]benz trifluoroacetate H
.TFA enesulfonamide
3- ({6-[(4-
3- (6-(4- chlorophenyl)amino]- chlorophenylamino)pyrimidin-
4- pyrimidinyl}amino)-
376 4- ylamino)-4-(ethylsulfonyl)-/V- 4-(ethylthio)-/V- methylbenzenesulfonamide
methylbenzenesulfona trifluoroacetate H
.TFA mide
EXAMPLES 377 & 378
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}am
methylethyl)oxy]benzenesulfonamide (enantiomer 1 ) 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}am
methylethyl)oxy]benzenesulfonamide (enantiomer 2)
Figure imgf000166_0001
A racemic mixture of 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl- 4-[(2,2,2-trifluoro-1-methylethyl)oxy]benzenesulfonamide (475 mg) was subjected to chiral chromatography (Chiralpak AD-H, 60% IPA, 40% hexanes) to provide 3-({6-[(4- chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2-trifluoro-1-methylethyl)oxy] benzenesulfonamide (unassigned enantiomer 1 , 20.2 mg) and 3-({6-[(4- chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2-trifluoro-1- methylethyl)oxy]benzenesulfonamide (unassigned enantiomer 2, 20.8 mg) EXAMPLES 379 & 380
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyri
methylethyl)oxy]benzenesulfonamide (enantiomer 1 ) 3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2-trifluoro-1 - methylethyl)oxy]benzenesulfonamide (enantiomer 2)
Figure imgf000167_0001
A racemic mixture of 3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/- methyl-4-[(2,2,2-trifluoro-1 -methylethyl)oxy]benzenesulfonamide (373 mg) was subjected to chiral chromatography (Chiralpak AD-H, 60% I PA, 40% hexanes with 0.1 % DEA ad a modifier) to provide 3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- [(2,2,2-trifluoro-1 -methylethyl)oxy]benzenesulfonamide (unassigned enantiomer 1 , 80 mg) & 3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2-trifluoro- 1 -methylethyl)oxy]benzenesulfonamide (unassigned enantiomer 2.39 mg, 85 % ee).
Spectroscopic data for Exampl
Figure imgf000167_0002
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
a LCMS Method: Agilent 1 100 Series LC/MSD SL or VL using electrospray positive [ES+ve to give M+H+] equipped with a Sunfire C18 5.0 μιη column (3.0 mm x 50 mm, i.d.), eluting with 0.05% TFA in water (solvent A) and 0.05% TFA in CH3CN (solvent B), using the following elution gradient: 10- 100% (solvent B) over 2.5 min and holding at 100% for 1.7 min at a flow rate of 1 .0 mL/min.
b LCMS Method: Agilent 1 100 Series LC/MSD SL or VL using electrospray positive [ES+ve to give M+H+] equipped with a Sunfire C18 5.0 μιη column (3.0 mm x 50 mm, i.d.), eluting with 0.05% TFA in water (solvent A) and 0.05% TFA in CH3CN (solvent B), using the following elution gradient 10- 100% (solvent B) over 10.0 min and holding at 100% for 1.7 min at a flow rate of 1.0 mL/min. c LCMS Method: Agilent 1200 Series LC/MSD SL or VL using electrospray positive [ES+ve to give M+H+] equipped with a XBridge C18 3.5 μιη column (50 x 4.6 mm, i.d.), eluting with 10 mM NH4HCO3 in water (solvent A) and CH3CN (solvent B), using the following elution gradient 5- 95% (solvent B) over 1.2 min and holding at 95% for 1.5 min at a flow rate of 2.0 mL/min.
d LCMS Method: Agilent 1200 Series LC/MSD VL using electrospray positive [ES+ve to give M+H+] equipped with a shim-pack XR-ODS 2.2 μΐη column (3.0 mm x 30 mm, 3.0 mm i.d.) eluting with 0.0375% TFA in water (solvent A) and 0.01875% TFA in CH3CN (solvent B), using the following elution gradient 10-80% (solvent B) over 0.9 min and holding at 80% for 0.6 min at a flow rate of 1.2 mL/min.
Pharmaceutical Compositions
Example A
Tablets are prepared using conventional methods and are formulated as follows:
Ingredient Amount per tablet
Compound of Example I 5 mg
Microcrystalline cellulose 100 mg
Lactose 100 mg
Sodium starch glycollate 30 mg
Magnesium stearate 2 mg
Total 237 mg
Example B
Capsules are prepared using conventional methods and are formulated as follows:
Ingredient Amount per tablet
Compound of Example 3 15 mg
Dried starch 178 mg
Magnesium stearate 2 mg
Total 195 mg Biological Assay(s)
Materials: His-MBP-TEV-Full length human TNNI3K (hTNNI3K) was expressed in Baculokinase system and purified from amylase affinity column followed by Superdex200. The fluorescent ligand 5-({[2-({[3-({4-[(5-hydroxy-2-methylphenyl)amino]-2- pyrimidinyl}amino)phenyl]carbonyl}amino)ethyl]amino}carbonyl)-2-(6-hydroxy-3-oxo-3/-/- xanthen-9-yl)benzoic acid was used. The preparation of this fluorescent ligand is disclosed in U.S. Provisional Patent Application No. 61/237,815 filed August 28, 2009, the disclosure of which is incorporated by reference herein. The other buffer components, including MgCI2 (Catalog Number M1028), Bis-Tris (Catalog Number B7535), DTT (Catalog Number D9779) and Chaps (Catalog Number C3023) were purchased from Sigma-Aldrich.
Biological Assay Method I:
A fluorescent polarization assay was used to determine does response of compound inhibition on hTNNI3K ATP binding. The binding of 5-({[2-({[3-({4-[(5-hydroxy- 2-methylphenyl)amino]-2-pyrimidinyl}amino)phenyl]carbonyl}amino)ethyl]amino}carbonyl)- 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid to the hTNNI3K ATP binding pocket results in increase of fluorescent polarization and the displacement of 5-({[2-({[3-({4-[(5- hydroxy-2-methylphenyl)amino]-2-pyrimidinyl}amino)phenyl]carbonyl}amino)ethyl]amino} carbonyl)-2-(6-hydroxy-3-oxo-3/-/-xanthen-9-yl)benzoic acid by a competitive compound leads to fluorescent polarization decrease.
Solution 1 : Ten (10) ml. of a 5 nM 5-({[2-({[3-({4-[(5-hydroxy-2-methylphenyl) amino]-2-pyrimidinyl}amino)phenyl]carbonyl}amino)ethyl]amino}carbonyl)-2-(6-hydroxy-3- oxo-3H-xanthen-9-yl)benzoic acid solution (Solution 1 ) was prepared by mixing 5 μΙ_ of 1 M DTT and 80 μΙ_ of 10% (w/v) Chaps and 5 μΙ_ of a 10 μΜ 5-({[2-({[3-({4-[(5-hydroxy-2- methylphenyl)amino]-2-pyrimidinyl}amino)phenyl]carbonyl}amino) ethyl]amino}carbonyl)- 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid stock solution into 9910 μΙ_ buffer (20 mM Tris, 15 mM MgCI2, pH 7.5). (Stock solution: 10 μΜ solution of 5-({[2-({[3-({4-[(5- hydroxy-2-methylphenyl)amino]-2-pyrimidinyl}amino)phenyl]carbonyl}amino)
ethyl]amino}carbonyl)-2-(6-hydroxy-3-oxo-3/-/-xanthen-9-yl)benzoic acid in 100% DMSO)
Solution 2 was formed by mixing 53.8 μΙ_ of 2.6 μΜ hTNNI3K with a 6946.2 μΙ_ aliquot of Solution 1 (the above 5-({[2-({[3-({4-[(5-hydroxy-2-methylphenyl)amino]-2- pyrimidinyl}amino)phenyl]carbonyl}amino)ethyl]amino}carbonyl)-2-(6-hydroxy-3-oxo-3/-/- xanthen-9-yl)benzoic acid solution) to make up a 7 ml. of mixture of hTNNI3K and 5-({[2- ({[3-({4-[(5-hydroxy-2-methylphenyl)amino]-2-pyrimidinyl}amino)phenyl]carbonyl} amino)ethyl]amino}carbonyl)-2-(6-hy acid (Solution
2).
Fifty (50) nl_ of inhibitors in DMSO (or DMSO controls) were stamped into a 384-well low volume Greiner black plate, followed by addition of 5 μΙ_ of Solution 1 to column 18 and 5 μΙ_ Solution 2 to columns 1-17 and 19-24 of the plate. The plate was then spun at 500 rpm for 30 seconds and incubated at rt for 60 min. After that, the fluorescent polarization was measured on Analyst (ex/em: 485/530 nm, Dichroic: 505). For dose response experiments, normalized data were fit by ABASE/XC50 and pXC50 = (log((b-y)/(y-a)))/d - log(x), where x is the compound concentration and y is the% activity at specified compound concentration, a is the minimum% activity, b is the maximum% activity, and d is the Hill slope.
The pXC50s are averaged to determine a mean value, for a minimum of 2 experiments. As determined using the above method, the compounds of Examples 1 -380 exhibited a pXC50 greater than or equal to approximately 6.0. For instance, the compounds of Example 55 and Example 284 each inhibited hTNNI3K in the above method with a mean pXC50 of approximately 7.0.

Claims

What is claimed is:
1. A compound according to Formula I:
Figure imgf000249_0001
H wherein:
R1 is (CrC4)alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen, halogen, (d-C4)alkyl, (Ci-C4)haloalkyl, (C3-C6)cycloalkyl, aryl, hydroxyl, hydroxy(Ci-C4)alkyl-, (Ci-C4)alkoxy, (CrC4)alkoxy(Ci-C4)alkyl-,
(Ci-C4)haloalkoxy, (C3-C6)cycloalkyloxy, (Ci-C4)alkylthio-, amino, (Ci-C4)alkylamino, or ((Ci-C4)alkyl)((Ci-C4)alkyl)amino;
R4 is hydrogen, halogen, (CrC8)alkyl, (Ci-C8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl, hydroxy(CrC8)alkyl-, (CrC8)alkoxy, (C1-C4)alkoxy(C1-C8)alkyl-, (CrC8)haloalkoxy, (C3-C8)cycloalkyloxy, (CrC8)alkylthio-, (CrC8)haloalkylthio-, -S02(CrC4)alkyl, amino, -NHR7, or -NR7R8;
R5 is hydrogen;
or R4 and R5 taken together with atoms through which they are connected form a 5 or 6 membered ring, optionally containing one or two additional heteroatoms selected from N, O and S, which ring may be unsubstituted or substituted with one to three substituents independently selected from (Ci-C4)alkyl, (Ci-C4)haloalkyl,
hydroxy(Ci-C4)alkyl-, oxo, hydroxyl, (Ci-C4)alkoxy, (Ci-C4)haloalkoxy, and
(Ci-C4)alkylthio-;
R6 is (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, or heteroaryl, wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl,
(C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(C C2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(Ci-C2)alkyl-, R7R8N(C C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, R70(C C2)alkyl-, cyano(C C2)alkyl-, aryl, heteroaryl, or heteroaryl(Ci-C2)alkyl-, wherein any said aryl or heteroaryl is optionally substituted one to three times, independently, by halogen, (d-C6)alkyl, (C3-C6)cycloalkyl, (Ci-C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(CrC4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(Ci-C2)alkyl-;
R7 is (CrC )alkyl, aryl, heterocycloalkyl, or heterocycloalkyl(Ci-C2)alkyl, wherein said (CrC4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl, (CrC4)alkoxy, amino, (CrC4)alkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino, -C02H, -C02(C C4)alkyl, -CONH2, -CONH(C C4)alkyl, or
-CON((C1-C4)alkyl)((C1-C4)alkyl); and wherein any heterocycloalkyl is optionally substituted by (Ci-C )alkyl; and
R8 is (CrC4)alkyl;
or R7 and R8 taken together with the nitrogen to which they are attached represent a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted one or two times, independently, by halogen, (Ci-C )alkyl, (Ci-C )haloalkyl, amino,
(Ci-C )alkylamino, ((Ci-C )alkyl)((Ci-C )alkyl)amino, hydroxyl, oxo, (Ci-C )alkoxy, or (C C4)alkoxy(Ci-C4)alkyl;
or a salt thereof.
2. The compound or salt according to claim 1 , wherein R1 is methyl.
3. The compound or salt according to claim 1 or 2, wherein R2 and R3 are each hydrogen.
4. The compound or salt according to any one of claims 1-3, wherein R4 is hydrogen, halogen, (Ci-C8)alkyl, (CrC8)haloalkyl, (C3-C8)cycloalkyl, hydroxyl,
hydroxy(CrC8)alkyl-, (CrC8)alkoxy, (C1-C4)alkoxy(C1-C8)alkyl-, (d-Cs^aloalkoxy, (C3-C8)cycloalkyloxy, (CrCs^lkylthio-, (CrCs^aloalkylthio-, -S02(CrC4)alkyl, amino, (CrC4)alkylamino, (d-C^haloalkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino,
((Ci-C4)alkyl)((Ci-C4)haloalkyl)amino, ((Ci-C4)haloalkyl)((C C4)haloalkyl)amino, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, wherein said pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl is optionally substituted one or two times, independently, by halogen, (d-C4)alkyl, (CrC4)haloalkyl, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (Ci-C4)alkoxy, or
(Ci-C4)alkoxy(Ci-C4)alkyl.
5. The compound or salt according to any one of claims 1-3, wherein R4 and R5 taken together represent -CH2CH2-.
6. The compound or salt according to any one of claims 1-5, wherein R6 is (C1-C6)alkyl, phenyl, dihydroindenyl, tetrahydronaphthalenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, indolyl, indazolyl, dihydroindolyl, dihydroisoindolyl, chromenyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl,
dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxolyl, or dihydrobenzodioxinyl, wherein said phenyl, dihydroindenyl, tetrahydronaphthalenyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, indolyl, indazolyl, dihydroindolyl, dihydroisoindolyl, chromenyl,
dihydrobenzimidazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzoisothiazolyl, quinolinyl, isoquinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxolyl, or dihydrobenzodioxinyl group is optionally substituted one to three times, independently, by halogen, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, (Ci-C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(CrC2)alkyl-, R702C(C C2)alkyl-, cyano(C C2)alkyl-, -SR7, -S02(Ci-C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(Ci-C2)alkyl-, R7R8N(C C2)alkyl-, triazolyl(C C2)alkyl-, -NHCO(C C4)alkyl,
-NHS02(Ci-C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, R70(C C2)alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, (CrC4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(d-C2)alkyl-.
7. The compound or salt according to any one of claims 1-5, wherein R6 is phenyl optionally substituted one to three times, independently, by halogen, (CrC6)alkyl,
(C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(C C2)alkyl-, cyano(CrC2)alkyl-, -SR7, -S02(Ci-C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(C C2)alkyl-, R7R8N(C C2)alkyl-, triazolyl(Ci-C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(Ci-C2)alkyl-, R70(Ci-C2)alkyl-, phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl, wherein said phenyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, or pyridinyl is optionally substituted one or two times, independently, by halogen, (C C6)alkyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(C C2)alkyl-.
8. The compound or salt according to any one of claims 1-5, wherein R6 is pyridinyl optionally substituted one or two times, independently, by halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C C4)haloalkyl, cyano, -CO(C C4)alkyl, -C02H, -C02R7, -CONH2, -CONHR7, -CONR7R8, H02C(C C2)alkyl-, R702C(C C2)alkyl-, -SR7, -S02(C C4)alkyl, -S02NH2, -S02NHR7, -S02NR7R8, nitro, amino, -NHR7, -NR7R8, amino(C C2)alkyl-, R7HN(Ci-C2)alkyl-, R7R8N(C C2)alkyl-, -NHCO(C C4)alkyl, -NHS02(C C4)alkyl, oxo, hydroxyl, -OR7, hydroxy(C C2)alkyl-, or R70(C C2)alkyl-.
9. The compound or salt according to any one of claims 1-8, wherein R7 is (Ci-C4)alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or pyrrolidinyl(Ci-C2)alkyl, piperidinyl(CrC2)alkyl, morpholinyl(Ci-C2)alkyl,
thiomorpholinyl(Ci-C2)alkyl, or piperazinyl(Ci-C2)alkyl, wherein said (CrC4)alkyl is optionally substituted one to three times, independently, by halogen, hydroxyl,
(Ci-C4)alkoxy, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, -C02H, -C02(CrC4)alkyl, -CONH2, -CONH(C C4)alkyl, or -CON((Ci-C4)alkyl)((C C4)alkyl); and wherein any pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl is optionally substituted by (CrC4)alkyl.
10. The compound or salt according to any one of claims 1-8, wherein R7 and R8 taken together with the nitrogen to which they are attached represent pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or hexahydro-1 H-1 ,4-diazepinyl, each optionally substituted one or two times, independently, by halogen, (Ci-C4)alkyl, (Ci-C4)haloalkyl, amino, (Ci-C4)alkylamino, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino, hydroxyl, oxo, (Ci-C4)alkoxy, or (Ci-C4)alkoxy(CrC4)alkyl.
1 1. A compound which is:
/V-methyl-3-({6-[(3-methylphenyl)amino]-4-pyrimidinyl}amino)benzenesulfonam
3-({6-[(3-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
/V-methyl-3-{[6-(methylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
3-{[6-(ethylamino)-4-pyrimidinyl]amino}-/V-methylbenzenesulfonamide;
3,3'-(4,6-pyrimidinediyldiimino)bis(/\/-methylbenzenesulfonamide);
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-5-(dimethylamino)-/\/- methylbenzenesulfonamide;
3-chloro-5-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (propyloxy)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(ethyloxy)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2- methylpropyl)oxy]benzenesulfonamide;
3- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-[(1 ,2-dimethylpropyl)oxy]-/\/- methylbenzenesulfonamide;
4- chloro-3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]-benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(cyclohexyloxy)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-[(1 -ethylpropyl)oxy]-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(3,3,3- trifluoropropyl)oxy]-benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(cyclopentyloxy)-/\/- methylbenzenesulfonamide;
5- (6-(4-chlorophenylamino)pyrimidin-4-ylamino)-2-fluoro-4-methoxy-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[methyl(2,2,2- trifluoroethyl)amino]benzenesulfonamide;
1-[6-(4-chloro-phenylamino)-pyrimidin-4-yl]-3,3-dimethyl-2,3-dihydro-1 /-/-indole-6- sulfonic acid methylamide; 3- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl^
methylethyl)oxy]benzenesulfonamide;
5-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-2-fluoro-/\/-methyl-4-(2,2,2- trifluoroethoxy)benzenesulfonamide;
4- amino-3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
5- [6-(4-chloro-phenylamino)-pyrimidin-4-ylamino]-4-dimethylamino-2-fluoro-/\/- methyl-benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(3,3-difluoro-1-piperidinyl)-/V^ methylbenzenesulfonamide;
3- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-{[2,2,2-trifluoro-1 - (trifluoromethyl)ethyl]oxy}benzenesulfonamide;
4- (dimethylamino)-3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-(4- morpholinyl)benzenesulfonamide;
1-{6-[(3-fluorophenyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 /-/-indole-6- sulfonamide;
3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methyloxy)benzenesulfonamide;
/V-methyl-3-[(6-{[4-(1-methylethyl)phenyl]amino}-4-pyrimidinyl)amino]-4- (methylthio)benzenesulfonamide;
3-[(6-{[3-chloro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-[(6-{[3-chloro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/-methyl-4- (methyloxy)benzenesulfonamide;
/V-methyl-4-(methyloxy)-3-({6-[(4-{[2-(methyloxy)ethyl]oxy}phenyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-3-({6-[(4-{[2-(methyloxy)ethyl]oxy}phenyl)amino]-4-pyrimidinyl}amino)-4- [(2,2,2-trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-4-(methyloxy)-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4-pyrimidinyl)amino]-4-[(2,2,2 trifluoroethyl)thio]benzenesulfonamide; 4-[(6-{[5-[(methylamino)sulfonyl]-2-(methylthio)phenyl]amino}-4-pyrimidin
A/-[2-(methyloxy)ethyl]benzamide;
A/-methyl-4-(methyloxy)-3-[(6-{[4-(1 /-/-pyrazol-1-yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-[(6-{[4-(1 H-pyrazol-1-yl)phenyl]amino}-4-pyrimidinyl)amino]-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
A/-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-{[6-({4-[(2,2,2- trifluoroethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-4-fluoro-/\/- methylbenzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}am
methylethyl)oxy]benzenesulfonamide;
1-{6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}-/V,3,3-trimethyl-2,3-dihydro-1 H-in 6-sulfonamide;
3-[6-(6-bromo-4-methyl-pyridin-2-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-(2,2,2- trifluoro-ethoxy)-benzenesulfonamide;
3-({6-[(3,5-dichloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-{[6-(3-biphenylylamino)-4-pyrimidinyl]amino}-/V-methylbenzenesulfonamide;
/V-methyl-3-({6-[(4-methylphenyl)amino]-4-pyrimidinyl}amino)benzenesulfonami
3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzamide;
3- ({6-[(3-acetylphenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide; A/-methyl-3-[(6-{[3-(methyloxy)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/\/-(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)acetamide;
/V-methyl-3-{[6-(phenylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
4- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzamide; 3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide; A/-methyl-3-[(6-{[3-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-({6-[(2-methyl-1 ,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(2-fluorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide; A/-methyl-3-[(6-{[3-(4-morpholinylsulfonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-{[6-({3-[(ethylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[3-(methylsulfonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[6-(1 H-indazol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide;
3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- phenylbenzamide;
3-{[6-({3-[(dimethylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- methylbenzenesulfonamide;
3-[(6-{[3-(aminosulfonyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/-(1 - methylethyl)benzenesulfonamide;
3- ({6-[(4-acetylphenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide; A/-methyl-3-[(6-{[4-(methylsulfonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/\/-(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)acetamide;
/\/-(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)propanamide;
4- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/- phenylbenzamide;
3-({6-[(1 ,1 -dioxido-2,3-dihydro-1 ,2-benzisothiazol-6-yl)amino]-4-pyrimidinyl}amino)- /V-methylbenzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-2,3-dihydro-1 H-indol-6-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-3-[6-(2-methyl-benzothiazol-5-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
/V-methyl-3-({6-[(3-nitrophenyl)amino]-4-pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-[(6-{[4-(4-morpholinylcarbonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide; 3-[6-(2,3-dihydro-benzo[1 ,4]dioxin-6-ylamino)-pyrimidin-4-ylamino]-/V-meth benzenesulfonamide;
A/-methyl-3-[(6-{[4-(methyloxy)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[4-(4-morpholinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[4-(1 , 1-dimethylethyl)phenyl]amino}-4-pyrimidinyl)amino]-A/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[3-(4-morpholinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3-bromo-5-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-[(6-{[4-(dimethylamino)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-[(6-{[3-(dimethylamino)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
methyl 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoate;
1-methylethyl 4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzoate;
3-({6-[(4-chloro-3-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-fluoro-3-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-{[6-(1 H-indol-6-ylamino)-4-pyrimidinyl]amino}-/V-methyl benzenesulfonamide;
A/-methyl-3-{[6-({3-[(methylsulfonyl)amino]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
A/-methyl-3-({6-[(3-methyl-1 H-indazol-6-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(4-{[2-(diethylamino)ethyl]oxy}phenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
1-methylethyl [(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)oxy]acetate;
3-[6-(benzothiazol-6-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-benzenesulfonamide;
3-[6-(1 /-/-indol-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-benzenesulfonamide; 3-{[6-(1 ,3-benzothiazol-5-ylamino)-4-pyrimidinyl]amino}-A/- methylbenzenesulfonamide;
3-({6-[(3-fluoro-4-methylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide ;
3-({6-[(3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
3-[(6-{[3-fluoro-4-(trifluoromethyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
/V-methyl-3-[(6-{[4-(methyloxy)-3-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-chloro-3-fluorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-[(6-{[3-fluoro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
/V-methyl-3-[(6-{[4-methyl-3-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3- [(6-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-(methylthio)-3-({6-[(2-oxo-1 ,2,3,4-tetrahydro-7-quinolinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
4- [(6-{[5-[(methylamino)sulfonyl]-2-(methylthio)phenyl]amino}-4- pyrimidinyl)amino]benzoic acid;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(diethylamino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}am
methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-(2-methyl-1 - pyrrolidinyl)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/,4- dimethylbenzenesulfonamide;
3- (6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(isobutylthio)-/\/- methylbenzenesulfonamide;
4- (isobutylthio)-/V-methyl-3-(6-(4-(trifluoromethyl)phenylamino)pyrimidin-4- ylamino)benzenesulfonamide; 4-(isobutylthio)-3-(6-(4-isopropylphenylamino)pyrimidin-4-ylamino)-/\/- methylbenzenesulfonamide;
3-{[6-({4-[(difluoromethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}-/V-methyl-4-[(^ trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-{[6-({4-[(trifluoromethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(4-cyanophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3- (6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(ethylthio)-/\/- methylbenzenesulfonamide;
4- (ethylthio)-/V-methyl-3-(6-(4-(trifluoromethyl)phenylamino)pyrimidin-4- ylamino)benzenesulfonamide;
4-(ethylthio)-3-(6-(4-isopropylphenylamino)pyrimidin-4-ylamino)-/\/- methylbenzenesulfonamide;
3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-/\/-methyl-4-(2,2,2- trifluoroethylthio)benzenesulfonamide;
/V-methyl-4-(2,2,2-trifluoroethylthio)-3-(6-(4-(trifluoromethyl)phenylamino)pyrimi ylamino)benzenesulfonamide;
3- (6-(4-isopropylphenylamino)pyrimidin-4-ylamino)-/\/-methyl-4-(2,2,2- trifluoroethylthio)benzenesulfonamide;
4- fluoro-/V-methyl-3-{[6-({4-[(trifluoromethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3- {[6-({4-[(difluoromethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}-4-fluoro-/\/- methylbenzenesulfonamide;
4- chloro-/V-methyl-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-cyanophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(1 H-indazol-5-ylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(4-(cyanomethyl)phenylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide; 4-(fert-butylsulfonyl)-3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifluoro-1 , 1- dimethylethyl)oxy]benzenesulfonamide;
3-({6-[(3-bromophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
3-({6-[(3-bromo-4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-[6-(3,4-dimethoxy-phenylamino)-pyrimidin-4-ylamm^
benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamin benzenesulfonamide;
3-[6-(3,5-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(4-cyano-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(benzo[1 ,3]dioxol-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(benzothiazol-6-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide;
A/-methyl-3-[6-(2-methyl-benzothiazol-5-ylamino)-pyrimidin-4-ylamino]-4- methylsulfanyl-benzenesulfonamide;
3-[6-(3-chloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide;
3-[6-(3,4-difluoro-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamide;
A/-methyl-4-methylsulfanyl-3-[6-(4-morpholin-4-yl-phenylamino)-pyrimidin-4- ylamino]-benzenesulfonamide;
3-[6-(2,3-dihydro-benzo[1 ,4]dioxin-6-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide;
A/-methyl-4-methylsulfanyl-3-[6-(4-piperidin-1-yl-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(3-ethynyl-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-methylsulfanyl- benzenesulfonamid;
3-[6-(3,5-dichloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide; /V-methyl-4-methylsulfanyl-3-{6-[3-(2-methyl-thiazol-4-yl)-phenylamino]-pyrimi ylamino}-benzenesulfonamide;
3-(6-(3-methoxy-5-(trifluoromethyl)phenylamino)pyrimidin-4-ylamino)-/V-meth (methylthio)benzenesulfonamide;
3-[6-(1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(quinolin-6-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(3-chloro-4-cyano-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl-4- methylsulfanyl-benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(4-[1 ,2,4]triazol-4-y^
ylamino]-benzenesulfonamide;
3-[6-(1 H-indazol-5-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(1 H-indol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
/V-methyl-4-(methylthio)-3-(6-(4-(piperazin-1 -yl)phenylamino)pyrimidin-4- ylamino)benzenesulfonamide;
/V-methyl-3-(6-(4-methyl-2-oxo-1 ,2-dihydroquinolin-7-ylamino)pyrimidin-4-ylamino)- 4-(methylthio)benzenesulfonamide;
3-(6-(1-acetylindolin-6-ylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylthio)benzenesulfonamide;
/V-methyl-3-[6-(2-methyl-4-oxo-4H-chromen-7-ylamino)-pyrimidin-4-ylamino]-4- methylsulfanyl-benzenesulfonamide;
3-[6-(4-cyanomethyl-phenylamino)-pyrimidin-4-ylam
benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(5-oxo-5,6,7,8-tetrahydro-naphthalen-2-ylamino)- pyrimidin-4-ylamino]-benzenesulfonamide;
/V-methyl-4-methylsulfanyl-3-[6-(3,4,5-trifluoro-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
/V-methyl-3-[6-(4-methyl-2-oxo-2H-chromen-7-ylamino)-pyrimidin-4-ylamino]-4- methylsulfanyl-benzenesulfonamide;
3-[6-(indan-5-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide;
3-[6-(1 H-indazol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl-4-methylsulfanyl- benzenesulfonamide; /V-methyl-3-(6-(2-methyl-1 ,3-dioxoisoindolin-5-ylamino)pyrimidin-4-ylami
(methylthio)benzenesulfonamide;
3-[6-(3,5-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
/V-methyl-3-[6-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(3-ethynyl-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide;
3-[6-(benzo[1 ,3]dioxol-5-ylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
3-[6-(3-chloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
3-[6-(3,4-difluoro-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide^
/V-methyl-3-[6-(4-piperidin-1 -yl-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(4-cyano-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide;
/V-methyl-3-[6-(2-methyl-4-oxo-4H-chromen-7-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(3,5-dichloro-4-hydroxy-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
/V-methyl-3-{6-[3-(2-methyl-thiazol-4-yl)-phenylamino]-pyrimidin-4-ylamino}- benzenesulfonamide;
3-[6-(1 H-indazol-5-ylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide;
A/-methyl-3-[6-(5-oxo-5,6 ,7,8-tetrahydro-naphthalen-2-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(4-cyanomethyl-phenylamino)-pyrimidin-4-ylamino]-/\/-methyl- benzenesulfonamide;
/V-methyl-3-[6-(4-methyl-2-oxo-2H-chromen-7-ylamino)-pyrimidin-4-ylamino]- benzenesulfonamide;
3-[6-(1-acetyl-2,3-dihydro-1 H-indol-6-ylamino)-pyrimidin-4-ylamino]-/V-methyl- benzenesulfonamide;
3-[6-(3-methoxy-5-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino]-/V-methyl- benzenesulfonamide;
/V-methyl-3-[6-(4-methyl-2-oxo-1 ,2-dihydro-quinolin-7-ylamino)-pyrimidin-4-ylamin benzenesulfonamide;
/V-methyl-3-[6-(3,4,5-trifluoro-phenylamino)-pyrimidin-4-ylamino]- benzenesulfonamide; 3-[6-(indan-5-ylamino)-pyrimidin-4-ylamino]-/V-methyl-benzenesulfonamide
3-[6-(4-chloro-phenylamino)-pyrimidin-4-ylamino]-/V-methyl-4-(propane-2-sulfonyl)- benzenesulfonamide;
3-(6-(3-bromo-5-methylphenylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(1 H-indol-6-ylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-(6-(3-ethynylphenylamino)pyrimidin-4-ylamino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-[6-(indan-5-ylamino)-pyrimidin-4-ylamino]-4-methanesulfonyl-/V-methyl- benzenesulfonamide;
3- [6-(benzothiazol-6-ylamino)-pyrimidin-4-ylamino]-4-methanesulfonyl-/\/-methyl- benzenesulfonamide;
4- methanesulfonyl-/\/-methyl-3-[6-(5-oxo-5,6,7,8-tetrahydro-naphthalen-2-ylamino)- pyrimidin-4-ylamino]-benzenesulfonamide;
/V-methyl-3-(6-(2-methylbenzo[d]thiazol-5-ylamino)pyrimidin-4-ylamino)-4- (methylsulfonyl)benzenesulfonamide;
A/-methyl-4-(methylsulfonyl)-3-[(6-{[4-(1 H-1 ,2,4-triazol-1 -ylmethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3- [6-(1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-4-methanesulfonyl-/V-methyl- benzenesulfonamide;
4- methanesulfonyl-/V-methyl-3-[6-(2-methyl-4-oxo-4H-chromen-7-ylamino)-pyrimidin^ 4-ylamino]-benzenesulfonamide;
5- ({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-2-fluoro-/\/- methylbenzenesulfonamide;
5-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-2-fluoro-/\/-methyl-4-(1 , 1 , 1 - trifluoropropan-2-yloxy)benzenesulfonamide;
1-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 /-/-indole-6- sulfonamide;
3-[(6-{[3,4-bis(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-({6-[(3,4-dichlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(3,4-dimethylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide; /V-methyl-3-[(6-{[3-(1-methylethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[3-(1 , 1-dimethylethyl)phenyl]amino}-4-pyrimidinyl)amino]-A/- methylbenzenesulfonamide;
3-[(6-{[3-(ethyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-({6-[(4-fluorophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonamide;
A/-methyl-3-[(6-{[3-(1 -pyrrolidinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[3-(4-methyl-1 -piperazinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3,5-dichlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-2,3-dihydro-1 H-indol-5-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-2,3-dihydro-1 ,3-benzoxazol-6-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-2,3-dihydro-1 /-/-benzimidazol-5-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-({6-[(2-oxo-1 ,2,3,4-tetrahydro-7-quinolinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(3-bromo-5-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
/V-methyl-3-{[6-({4-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
A/-methyl-3-[(6-{[3-(1 -pyrrolidinylmethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-({6-[(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
3-({6-[(4-{[2-(dimethylamino)ethyl]oxy}phenyl)amino^
methylbenzenesulfonamide;
/V-methyl-3-{[6-({3-[(4-methyl-1 -piperazinyl)methyl]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide; A/-methyl-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[4-(1-methylethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-{[6-({4-[(1 -methylethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-{[6-({4-[(difluoromethyl)oxy]phenyl}amino)-4-pyrimidinyl]amino}-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(2-oxo-1-pyrrolidinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[3-chloro-4-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-({6-[(4-cyclopropylphenyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(1 H-pyrazol-1 -yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[4-(3,5-dimethyl-1 H-pyrazol-1 -yl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
3-[(6-{[4-chloro-3-(methyloxy)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(2-thienyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-[(6-{[4-(2-methyl-1 H-imidazol-1 -yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-[(6-{[4-(1-methylpropyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-{[6-(6-quinolinylamino)-4-pyrimidinyl]amino}benzenesulfon
/V-methyl-3-{[6-({4-[(trifluoromethyl)thio]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-({6-[(4-bromophenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfon
A/-methyl-3-[(6-{[4-(methylthio)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-{[6-({4-[(trifluoromethyl)oxy]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(dimethylamin methylbenzenesulfonamide; 4-(dimethylamino)-/\/-methyl-3-({6-[(3-methylphenyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-1-(6-{[4-(trifluoromethyl)phenyl]amino}-4-pyrimidinyl)-2,3-dihydro-1 H- indole-6-sulfonamide;
1-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/V-methyl-1 /-/-benzimidazole-6- sulfonamide ;
3-({6-[(5-bromo-6-methyl-2-pyridinyl)amino]-4-pyn
trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(1 - methylethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-(4- morpholinyl)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methyloxy)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-[ethyl(methyl)amino]-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-hydroxy-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-fluoro-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylthio)benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2R)-2- (trifluoromethyl)-1 -pyrrolidinyl]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-4-(3,3-difluoro-1-pyrrolidinyl)-/V^ methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4-(1 ,3-oxazol-5-yl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-({6-[(3-methylphenyl)amino]-4-pyrimidinyl}amino)-4-(4- morpholinyl)benzenesulfonamide;
/V-methyl-4-(methyloxy)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-4-(methylthio)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide; 3-({6-[(3-bromo-5-methylphenyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4- (methyloxy)benzenesulfonamide;
1-{6-[(3-bromo-5-methylphenyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 /-/- indole-6-sulfonamide;
/V-methyl-3-{[6-({4-[(2,2,2-trifluoroethyl)oxy]phenyl}amino)-4-pyrimidinyl]amin [(2,2,2-trifluoroethyl)thio]benzenesulfonamide;
3-({6-[(3,4-difluorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide;
/V-methyl-3-{[6-(4-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-{[6-(3-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
A/-methyl-3-({6-[(5-methyl-3-pyridinyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
/V-methyl-3-{[6-(2-pyridinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-5-{[6-({3-[(methylamino)sulfonyl]phenyl}a
pyridinesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
/V-methyl-3-{[6-(1 ,3-thiazol-2-ylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-({6-[(5-methyl-1 ,3-thiazol-2-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-{[6-(1 ,3,4-thiadiazol-2-ylamino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-{[6-(3-isoquinolinylamino)-4-pyrimidinyl]amino}-/V-methylbenzenesulfonam
/V-methyl-3-{[6-(2-quinolinylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-{[6-(1 ,3-oxazol-2-ylamino)-4-pyrimidinyl]amino}benzenesulfonamide;
/V-methyl-3-[(6-{[4-(trifluoromethyl)-1 ,3-thiazol-2-yl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
methyl (2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3- thiazol-4-yl)acetate ;
A/-methyl-3-[(6-{[4-(1-methylethyl)-1 ,3-thiazol-2-yl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-3-({6-[(4-methyl-1 ,3-oxazol-2-yl)amino]-4- pyrimidinyl}amino)benzenesulfonamide; /V-methyl-4-(methyloxy)-3-{[6-(2-pyridinylamino)-4- pyrimidinyl]amino}benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methyloxy)benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-3-{[6-(2-pyridinylamino)-4-pyrimidinyl]amino}-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylthio)benzenesulfonamide;
1-{6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}-/V-methyl-2,3-dihydro-1 H-indole-6 sulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]am pyrimidinyl)amino]benzenesulfonamide;
/V-methyl-3-{[6-(4-pyridinylamino)-4-pyrimidinyl]amino}-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(3-fluoro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-cyano-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-3-{[6-(4-pyrimidinylamino)-4-pyrimidinyl]amino}-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-3-fluoro-2-pyridinyl)amino]-4- trifluoroethyl)oxy]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-3-[(6-{[6-(trifluoromethyl)-3-pyridinyl]ami pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(5-chloro-4-methyl-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-meth trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(4,5-dichloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2 trifluoroethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-6-methyl-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-meth trifluoroethyl)oxy]benzenesulfonamide;
3-(6-(5-isopropylpyridin-2-ylamino)pyrimidin-4-ylamino)-/V-methyl-4-(2,2,2- trifluoroethoxy)benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-4-fluoro-/\/- methylbenzenesulfonamide; 4-fluoro-/V-methyl-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
4-chloro-3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/- methylbenzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
/V-methyl-4-(methylsulfonyl)-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
A/-methyl-4-(methylsulfonyl)-3-{[6-(6-quinolinylamino)-4- pyrimidinyl]amino}benzenesulfonamide;
3- ({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}^
1-methylethyl)oxy]benzenesulfonamide;
/V-methyl-4-[(2,2,2-trifluoro-1 -methylethyl)oxy]-3-[(6-{[5-(trifluoromethyl)-2- pyridinyl]amino}-4-pyrimidinyl)amino]benzenesulfonamide;
4- (fert-butylsulfonyl)-/V-methyl-3-(6-(5-(trifluoromethyl)pyridin-2-ylamino)pyrim^ ylamino)benzenesulfonamide;
4- (fert-butylsulfonyl)-3-(6-(5-chloropyridin-2-ylamino)pyrimidin-4-ylamino)-/\/- methylbenzenesulfonamide;
/V-methyl-4-(propane-2-sulfonyl)-3-[6-(5-trifluoro
4-ylamino]-benzenesulfonamide;
3-[6-(5-chloro-pyridin-2-ylamino)-pyrimidin-4-ylamino]-/\/-methyl-4-(propane-2- sulfonyl)-benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- [(trifluoromethyl)oxy]benzenesulfonamide;
1- [6-(5-chloro-pyridin-2-ylamino)-pyrimidin-4-yl]-3,3-dimethyl-2,3-dihydro-1 /-/-indole- 6-sulfonic acid methylamide;
5- (6-(5-chloropyridin-2-ylamino)pyrimidin-4-ylamino)-2-fluoro-/V-methyl-4-(1 , 1 , 1- trifluoropropan-2-yloxy)benzenesulfonamide;
5-[6-(5-chloro-pyridin-2-ylamino)-pyrimidin-4-ylamm^
methyl-benzenesulfonamide;
5-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-2-fluoro-/V-methyl-4-[(2,2 trifluoroethyl)oxy]benzenesulfonamide;
2- fluoro-/V-methyl-4-[(2,2,2-trifluoroethyl)oxy]-5-[(6-{[5-(trifluoromethyl)-2- pyridinyl]amino}-4-pyrimidinyl)amino]benzenesulfonamide;
3- ({6-[(5-fluoro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4-[(2,2,2- trifluoroethyl)oxy]benzenesulfonamide; 3- ({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimi
methylbenzenesulfonamide;
4- (ethylsulfonyl)-/V-methyl-3-[(6-{[5-(trifluoromethyl)-2-pyridinyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(5-cyano-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide;
3-({6-[(5-cyano-2-pyridinyl)amino]-4-pyrimidinyl}amino)-/V-methyl-4-[(2,2,2-trifl 1 -methylethyl)oxy]benzenesulfonamide;
2- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3-thi carboxylic acid;
(2-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-1 ,3-thiazo yl)acetic acid ;
1-{6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/V-methyl-1 H-indole-6-sulfonamide;
3- {6-[(4-chlorophenyl)amino]-4-pyrimidinyl}-/\/-methyl-2-oxo-2,3-dihydro-1 /-/- benzimidazole-5-sulfonamide;
3-{[6-({3-[6-(dimethylamino)-3-pyridinyl]phenyl}amm^
methylbenzenesulfonamide;
A/-methyl-3-({6-[(5-methyl-3-biphenylyl)amino]-4- pyrimidinyl}amino)benzenesulfonamide;
A/-methyl-3-[(6-{[3-methyl-5-(3-pyridinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-[(6-{[3'-(dimethylamino)-3-biphenylyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
A/-methyl-3-[(6-{[4'-(4-morpholinyl)-3-biphenylyl]amino}-4-pyrimidinyl)amino]- benzenesulfonamide;
A/-methyl-3-{[6-({3-[6-(methyloxy)-3-pyridinyl]phenyl}amino)-4-pyrimidinyl]amino}- benzenesulfonamide;
3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-4- biphenylcarboxamide;
A/-methyl-3-{[6-({3-[5-(methyloxy)-3-pyridinyl]phenyl}amino)-4-pyrimidinyl]amino}- benzenesulfonamide;
3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-3- biphenylcarboxamide;
A/-methyl-3-{[6-({3'-[(methylsulfonyl)amino]-3-biphenylyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide; 3-[(6-{[4'-(dimethylamino)-3-biphenylyl]amino}-4-pyrimidinyl)amino]-A/- methylbenzenesulfonamide;
/V-methyl-3-{[6-({3-[4-(methyloxy)-3-pyridinyl]phenyl}am
benzenesulfonamide;
/V-(3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-4- biphenylyl)acetamide;
/V-methyl-3-{[6-({4'-[(methylsulfonyl)amino]-3-biphenylyl}amino)-4-pyrimidinyl]am benzenesulfonamide;
/V-(3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-3- biphenylyl)acetamide;
/V-methyl-3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-4- biphenylsulfonamide;
/V-methyl-3'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-3- biphenylsulfonamide;
3-[(6-{[4-chloro-3-(3-pyridinyl)phenyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
2'-chloro-5'-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-3- biphenylcarboxamide;
3- [(6-{[6-chloro-3'-(4-morpholinyl)-3-biphenylyl]amino}-4-pyrimidinyl)amino]-/\/- methylbenzenesulfonamide;
4- {[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}benzoic acid; [(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)oxy]acetic acid;
/V,/V-dimethyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
/V,/V-dimethyl-2-[(3-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)oxy]acetamide;
A/-(2-hydroxyethyl)-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
A/-methyl-3-{[6-({4-[(4-methyl-1 -piperazinyl)carbonyl]phenyl}amino)-4- pyrimidinyl]amino}benzenesulfonamide;
4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/V-(1 -methyl-4- piperidinyl)benzamide;
A/-methyl-3-[(6-{[4-(1 -piperazinylcarbonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide; /V-methyl-3-[(6-{[4-({4-[2-(methyloxy)ethyl]-1-pipera^
pyrimidinyl)amino]benzenesulfonamide;
4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/-[2- (methyloxy)ethyl]benzamide;
4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4-pyrimidinyl]amino}-/\/-[3- (methyloxy)propyl]benzamide;
/V-[2-(dimethylamino)ethyl]-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
/\/,/\/-diethyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}benzamide;
A/-methyl-3-[(6-{[4-(1 -pyrrolidinylcarbonyl)phenyl]amino}- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-{[(3S)-3-(dimethylamino)-1 -pyrrolidinyl]carbonyl}phenyl)amino]-4- pyrimidinyl}amino)-/\/-methylbenzenesulfonamide;
A/-methyl-3-{[6-({4-[(4-methylhexahydro-1 H-1 ,4-diazepin-1 - yl)carbonyl]phenyl}amino)-4-pyrimidinyl]amino}benzenesulfonamide;
A/-methyl-3-[(6-{[4-(4-thiomorpholinylcarbonyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-{[6-({4-[(4,4-difluoro-1 -piperidinyl)carbonyl]phenyl}amino)-4-pyrimidinyl]amin methylbenzenesulfonamide;
3-({6-[(4-{[(3R)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl}phenyl)amino]-4- pyrimidinyl}amino)-/\/-methylbenzenesulfonamide;
/V-[2-(dimethylamino)ethyl]-/V-methyl-4-{[6-({3-[(methylamino)sulfonyl]phenyl}am 4-pyrimidinyl]amino}benzamide;
/V-[2-(dimethylamino)ethyl]-/V-methyl-4-[(6-{[5-[(methylamino)sulfonyl]-2- (methylthio)phenyl]amino}-4-pyrimidinyl)amino]benzamide;
/\/-[(4-{[6-({3-[(methylamino)sulfonyl]phenyl}amino)-4- pyrimidinyl]amino}phenyl)carbonyl]glycine;
A/-methyl-3-[(6-{[3-(6-oxo-1 ,6-dihydro-3-pyridinyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(3-hydroxyphenyl)amino]-4-pyrimidinyl}amino)-/V-methylbenzenesulfonami
/V-methyl-4-(methylsulfonyl)-3-[(6-{[4-(trifluoromethyl)phenyl]amino}-4- pyrimidinyl)amino]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/\/-methyl-4- (methylsulfonyl)benzenesulfonamide; 3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(isobutylsutf^ methylbenzenesulfonamide;
3-(6-(4-chlorophenylamino)pyrimidin-4-ylamino)-4-(ethylsulfonyl)-/\/- methylbenzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-m
methylethyl)oxy]benzenesulfonamide;
3-({6-[(4-chlorophenyl)amino]-4-pyrimidinyl}amino)-/V-m
methylethyl)oxy]benzenesulfonamide;
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino
1-methylethyl)oxy]benzenesulfonamide; or
3-({6-[(5-chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino
1-methylethyl)oxy]benzenesulfonamide;
or a salt thereof.
12. A pharmaceutical composition comprising the compound or salt according to any one of claims 1-1 1 and one or more pharmaceutically-acceptable excipients.
13. A method for treating congestive heart failure comprising administering to a patient in need thereof an effective amount of the compound or salt according to any one of claims 1 -1 1 .
14. A method for treating congestive heart failure comprising administering to a patient in need thereof the pharmaceutical composition according to claim 12.
PCT/US2011/020798 2010-01-13 2011-01-11 Compounds and methods WO2011088027A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2011205485A AU2011205485B2 (en) 2010-01-13 2011-01-11 Compounds and methods
SG2012049409A SG182351A1 (en) 2010-01-13 2011-01-11 Compounds and methods
MX2012008141A MX2012008141A (en) 2010-01-13 2011-01-11 Compounds and methods.
CA2786999A CA2786999A1 (en) 2010-01-13 2011-01-11 Compounds and methods
EA201290642A EA201290642A1 (en) 2010-01-13 2011-01-11 CONNECTIONS AND METHODS
JP2012549000A JP2013517273A (en) 2010-01-13 2011-01-11 Compounds and methods
EP11733258.5A EP2523559A4 (en) 2010-01-13 2011-01-11 Compounds and methods
CN2011800138247A CN102791131A (en) 2010-01-13 2011-01-11 Compounds and methods
BR112012017277A BR112012017277A2 (en) 2010-01-13 2011-01-11 COMPOUNDS AND METHODS
US13/520,861 US20120329784A1 (en) 2010-01-13 2011-01-11 Compounds and methods
IL220812A IL220812A0 (en) 2010-01-13 2012-07-05 Compounds and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29463710P 2010-01-13 2010-01-13
US61/294,637 2010-01-13

Publications (2)

Publication Number Publication Date
WO2011088027A1 true WO2011088027A1 (en) 2011-07-21
WO2011088027A8 WO2011088027A8 (en) 2012-08-30

Family

ID=44304601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020798 WO2011088027A1 (en) 2010-01-13 2011-01-11 Compounds and methods

Country Status (13)

Country Link
US (1) US20120329784A1 (en)
EP (1) EP2523559A4 (en)
JP (1) JP2013517273A (en)
KR (1) KR20120114355A (en)
CN (1) CN102791131A (en)
AU (1) AU2011205485B2 (en)
BR (1) BR112012017277A2 (en)
CA (1) CA2786999A1 (en)
EA (1) EA201290642A1 (en)
IL (1) IL220812A0 (en)
MX (1) MX2012008141A (en)
SG (1) SG182351A1 (en)
WO (1) WO2011088027A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145331A1 (en) * 2013-03-15 2014-09-18 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
EP4206196A1 (en) * 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
US11891362B1 (en) * 2023-04-14 2024-02-06 King Faisal University N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents
WO2023196714A3 (en) * 2022-02-23 2024-04-11 President And Fellows Of Harvard College Inhibitors of ddr1 and ddr2 for the treatment of arthritis

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6211061B2 (en) * 2012-05-03 2017-10-11 ジェネンテック， インコーポレイテッド Pyrazole aminopyrimidine derivatives as LRRK2 modulators for use in the treatment of Parkinson's disease
MA41179A (en) 2014-12-19 2017-10-24 Cancer Research Tech Ltd PARG INHIBITOR COMPOUNDS
CN104844526B (en) * 2015-04-16 2018-08-31 温州医科大学 A kind of 4,6- pyrimidinediamines class compound and its preparation method and application
CN106008366A (en) * 2016-05-25 2016-10-12 山东大学 Preparation method of rilpivirine
JP6165373B1 (en) * 2017-02-24 2017-07-19 タマ化学工業株式会社 Method for producing pyridine-3-sulfonyl chloride
KR20240016442A (en) * 2017-05-26 2024-02-06 캔써 리서치 테크놀로지 리미티드 Benzimidazolone derived inhibitors of bcl6
CN108864052A (en) * 2018-06-07 2018-11-23 福建医科大学 A kind of synthesis and application of the fluorescence probe for GC33-3-1 antibody with specific recognition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395742B1 (en) * 1996-05-10 2002-05-28 Janssen Pharmaceutica N.V. 2,4-diaminopyrimidine derivatives
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US20080242681A1 (en) * 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139435A1 (en) * 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
BRPI0506839A (en) * 2004-01-16 2007-06-12 Novartis Ag compositions and methods for inducing cardiomyogenesis
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
PL1951684T3 (en) * 2005-11-01 2017-03-31 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CN101370792B (en) * 2005-11-01 2013-03-20 塔格根公司 Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009540013A (en) * 2006-06-15 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2-anilino-4- (heterocyclic) amino-pyrimidine
CN101589036A (en) * 2006-12-19 2009-11-25 沃泰克斯药物股份有限公司 Aminopyrimidines useful as inhibitors of protein kinases
US7947698B2 (en) * 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2014657A1 (en) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidines as modulators for an EP2 receptor
TWI552752B (en) * 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 Heteroaryl compounds and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395742B1 (en) * 1996-05-10 2002-05-28 Janssen Pharmaceutica N.V. 2,4-diaminopyrimidine derivatives
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US20080242681A1 (en) * 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2523559A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2014145331A1 (en) * 2013-03-15 2014-09-18 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
US9732074B2 (en) 2013-03-15 2017-08-15 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
US10301298B2 (en) 2013-03-15 2019-05-28 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP4206196A1 (en) * 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
WO2023196714A3 (en) * 2022-02-23 2024-04-11 President And Fellows Of Harvard College Inhibitors of ddr1 and ddr2 for the treatment of arthritis
US11891362B1 (en) * 2023-04-14 2024-02-06 King Faisal University N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents

Also Published As

Publication number Publication date
MX2012008141A (en) 2012-08-03
KR20120114355A (en) 2012-10-16
AU2011205485A1 (en) 2012-08-02
EA201290642A1 (en) 2013-05-30
EP2523559A4 (en) 2013-11-06
CA2786999A1 (en) 2011-07-21
BR112012017277A2 (en) 2017-10-03
JP2013517273A (en) 2013-05-16
IL220812A0 (en) 2012-08-30
SG182351A1 (en) 2012-08-30
EP2523559A1 (en) 2012-11-21
CN102791131A (en) 2012-11-21
AU2011205485B2 (en) 2014-09-25
WO2011088027A8 (en) 2012-08-30
US20120329784A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
WO2011088027A1 (en) Compounds and methods
JP6117816B2 (en) Aminopyrimidine derivatives as LRRK2 modulators
JP6185925B2 (en) Aminopyrimidine derivatives as LRRK2 modulators
JP6180426B2 (en) 2- (Phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase LRRK2 modulators for the treatment of Parkinson&#39;s disease
ES2579830T3 (en) Diaminopyrimidine derivatives and procedures for their preparation
AU2008229147A1 (en) Chemical compounds
CA2681250A1 (en) Chemical compounds
WO2011120025A1 (en) Indazolyl-pyrimidines as kinase inhibitors
CA2779107A1 (en) Pyrimidine compounds as delta opioid receptor modulators
WO2014029831A1 (en) Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AU2010315361B2 (en) Quinazoline compounds
CN112313207B (en) Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof
WO2011088031A1 (en) Compounds and methods
US20120157482A1 (en) Compounds and methods
JP2023513794A (en) Inhibitors of ULK1/2 and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180013824.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 220812

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 13520861

Country of ref document: US

Ref document number: 2011205485

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2011733258

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2786999

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012549000

Country of ref document: JP

Ref document number: MX/A/2012/008141

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011205485

Country of ref document: AU

Date of ref document: 20110111

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6931/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20127021083

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201290642

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012017277

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112012017277

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, DOCUMENTO DE CESSAO ESPECIFICO PARA A PRIORIDADE US 61/294,637 DE 13/01/2010, UMA VEZ QUE O DOCUMENTO DE CESSAO APRESENTADO NA PETICAO NO 020120064630 DE 12/07/2012 NAO FAZ REFERENCIA A PRIORIDADE REIVINDICADA PELO DEPOSITANTE E SIM AO PROPRIO PEDIDO DO PCT. A CESSAO DEVE CONTER, NO MINIMO, NUMERO ESPECIFICO DA PRIORIDADE A SER CEDIDA, DATA DE DEPOSITO DA PRIORIDADE, ASSINATURA DE TODOS OS INVENTORES E DATA.

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112012017277

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: 112012017277

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012017277

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120712